<SEC-DOCUMENT>0001019056-22-000180.txt : 20220214
<SEC-HEADER>0001019056-22-000180.hdr.sgml : 20220214
<ACCEPTANCE-DATETIME>20220214112918
ACCESSION NUMBER:		0001019056-22-000180
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20220209
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220214
DATE AS OF CHANGE:		20220214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		22627352

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>modular_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:MODD="http://modular-medical.com/20220209">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_MODD_modular%2Dmedical.com_20220209 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20220209_20220209 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20220209.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-02-09to2022-02-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-09</xbrli:startDate>
        <xbrli:endDate>2022-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>UNITED STATES</b></span><br />
<span style="font-size: 14pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></span><br />
<span style="font-size: 12pt"><b>Washington, D.C. 20549</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 20%; margin-right: auto">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>FORM <span id="xdx_900_edei--DocumentType_c20220209__20220209_zKDpzXQvcCDi"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>CURRENT REPORT</b><br />
<b>Pursuant to Section 13 or 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Securities Exchange Act of 1934</b><br />
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%">Date of Report (Date of earliest event reported):&#160;&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; width: 99%; font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_902_edei--DocumentPeriodEndDate_c20220209__20220209_zBSRGdGFvYw5"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 9,
    2022</ix:nonNumeric></span></b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 24pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20220209__20220209_zEm4i4poReXi"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Exact name of registrant as specified in
its chapter)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20220209__20220209_zgmkogpOWzDi"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityFileNumber_c20220209__20220209_z8ma1ERZYw3c"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:EntityFileNumber">000-49671</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20220209__20220209_znb88biK9vOd"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 1pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 1pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction
    <br />
    of incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">(Commission<br />File Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(IRS Employer<br />
    Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 48%; font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20220209__20220209_zlSwxBMkPg5i"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:EntityAddressAddressLine1">16772
    W. Bernardo Drive</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressCityOrTown_c20220209__20220209_z1xJnOF5jZv3"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20220209__20220209_zlZCaDUoEqe9"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 48%; font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20220209__20220209_zYP3vMMPT67l"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip
    Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%">Registrant&#8217;s telephone number, including area code:&#160;&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; width: 99%; font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--CityAreaCode_c20220209__20220209_zOqi9MbjArb9"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:CityAreaCode">(858)</ix:nonNumeric></span> <span id="xdx_905_edei--LocalPhoneNumber_c20220209__20220209_z6ujJBlWxD89"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 1pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Former name or former address, if changed since last report)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Wingdings"><span id="xdx_90E_edei--WrittenCommunications_c20220209__20220209_zaEQvqTL8oq6"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">o</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Written communications pursuant to Rule
    425 under the Securities Act (17 CFR 230.425)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Wingdings"><span id="xdx_90A_edei--SolicitingMaterial_c20220209__20220209_zt4T5xjUJCol"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">o</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12
    under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20220209__20220209_zdhCO6wj056b"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">o</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Pre-commencement communications pursuant
    to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20220209__20220209_zdAZ5fQl2Xaj"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">o</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Pre-commencement communications pursuant
    to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 0; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; margin-left: 0; text-indent: 0"><span style="font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 40%; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: Black 1pt solid; width: 20%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>Trading
    symbol(s)</b></span></td>
    <td style="border-top: Black 1pt solid; width: 40%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20220209__20220209_zZo7WfNGAr8j"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20220209__20220209_z9Rij54acPie"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" name="dei:TradingSymbol">MODD</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20220209__20220209_zti8XwADbLy4"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span> </span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 27.35pt; text-align: right; text-indent: -27.35pt"><span style="font-size: 10pt">&#160;</span>Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20220209__20220209_zGccuZwwffzk"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0in"><span style="font-size: 10pt">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_906_edei--EntityExTransitionPeriod_c20220209__20220209_zcf7W3Mabdn"><ix:nonNumeric contextRef="From2022-02-09to2022-02-09" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">o</ix:nonNumeric></span></span></span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 0pt"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->
<!-- Field: Page; Sequence: 1 -->
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt"><b>Item 1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On February 9,
2022, Modular Medical, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with
Oppenheimer &amp; Co. Inc., who acted as the representative (the &#8220;Representative&#8221;) of the several underwriters (the &#8220;Underwriters&#8221;),
in a firm commitment underwritten public offering (the &#8220;Offering&#8221;) pursuant to which the Company agreed to sell to the Underwriters
an aggregate of 2,500,000 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) and 2,500,000
warrants (&#8220;Warrants&#8221; and, collectively with the Common Stock, the &#8220;Units&#8221;), each to purchase one share of Common Stock. The price to
the public in the Offering is $6.00 per Unit, before underwriting discounts and commissions. The Common Stock and the Warrants
comprising the Units were immediately separable upon issuance and were issued separately. The Warrants are exercisable immediately,
have an exercise price of $6.60 per share and expire five years from the date of issuance. The Common Stock was approved to list on
the Nasdaq Capital Market under the symbol &#8220;MODD&#8221; and began trading there on February 10, 2022. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The offering closed on February 14, 2022. The gross proceeds from the Offering were $15 million, before deducting underwriting discounts and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Units were offered and sold to the public pursuant to the Company&#8217;s registration statement on Form S-1 (File No. 333-260682), initially filed by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) on November 2, 2021 and declared effective by the SEC on February 9, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Representative, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related &#8220;lock-up&#8221; agreements, the Company, each director and executive officer of the Company, and certain stockholders have agreed not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our Common Stock or securities convertible into Common Stock for a period of 180 days after February 9, 2022, the date of the final prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On February 14, 2022, the Company entered into a warrant agency agreement (the &#8220;Warrant Agency Agreement&#8221;) with Colonial Stock Transfer Company, Inc., a New York limited liability trust company (&#8220;Colonial&#8221;), to serve as the Company&#8217;s warrant agent for the Warrants. Upon the closing of the Offering, Colonial issued the Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The foregoing description of the Underwriting Agreement, the Warrants and the Warrant Agency Agreement are not complete and are qualified in their entirety by reference to the full text of the Underwriting Agreement, the Warrant and the Warrant Agency Agreement, which are filed as exhibits to this Current Report on Form 8-K and are incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt"><b>Item 8.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt"><b>Other Events.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On February 10, 2022, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt">Exhibits:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Exhibit No.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex1_1.htm">Underwriting Agreement between Modular Medical, Inc. and Oppenheimer &amp; Co. Inc., dated February 9, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex4_1.htm">Form of Warrant</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex10_1.htm">Warrant Agency Agreement between Modular Medical, Inc. and Colonial Stock Transfer Company, Inc., dated February 14, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="ex99_1.htm">Press Release dated February 10, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
</table>
<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>MODULAR MEDICAL, INC.</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 42%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 47%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Date: February 14, 2022</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">By:&#160;&#160;</span></td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/ Ellen O&#8217;Connor Vos</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Ellen O&#8217;Connor Vos</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
</table>

    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZF22C3XRp0SJWKUXEbbBTCbaZMol/R/KWxhZxGBiG9773hIhFQWvTIcNpWZdwwH7otEeosUVGe8bgyDfbDMKt8WKcZ239+P7AnAKDgUlnUukgjNa7cdhkkKi5lHOlIFlkKoVqJ6KvnpNtTYPWG92Btg1UTAMb9JpfU8JBP8lS/xqrjsjOkM1AzpJJfoNKpII93fWD+OqgLHMRxeNEomC6Dd+am/PUw6rDPnS5Cf1v9AETaklC -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1_1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0 0 0pt; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Exhibit 1.1</B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>MODULAR
MEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>[____] Shares
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>[_____]
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>UNDERWRITING
AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">[_____],
2022</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Oppenheimer &amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">as Representative
of the several</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Underwriters
named in Schedule I hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">85 Broad Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">New York, New York 10004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Modular
Medical, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), proposes, subject to the terms and conditions contained herein,
to sell to you and the other underwriters (the &ldquo;Underwriters&rdquo;) named on Schedule I to this Underwriting Agreement
(the &ldquo;Agreement&rdquo;), for whom you are acting as Representative (the &ldquo;Representative&rdquo;), an aggregate of (i)
[________] shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;Common
Stock&rdquo;) and (ii) warrants, each warrant exercisable for one share of Common Stock at an exercise price of $[_____] per share
with a term of five years (the &ldquo;Warrants&rdquo;). The respective amounts of the Shares and Warrants to be purchased by each
of the several Underwriters are set forth opposite their names on Schedule I hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">The
shares of Common Stock issuable upon exercise of the Warrants are referred to herein as the &ldquo;Warrant Shares.&rdquo; The
Shares, the Warrants and the Warrant Shares are collectively called the &ldquo;Securities.&rdquo; The Warrants shall be issued
pursuant to, and shall have the rights and privileges set forth in, a warrant agency agreement, dated on or before the Closing
Date, substantially in the form attached hereto as Exhibit B (the &ldquo;Warrant Agreement&rdquo;) between the Company and [_____],
as warrant agent (or any successor, the &ldquo;Warrant Agent&rdquo;). The Shares and Warrants will be issued separately but will
be purchased together in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">The
Company has prepared and filed in conformity with the requirements of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and the published rules and regulations thereunder (the &ldquo;Rules&rdquo;) adopted by the Securities and Exchange
Commission (the &ldquo;Commission&rdquo;), a Registration Statement (as hereinafter defined) on Form S-1 (No. 333-260682), including
a preliminary prospectus, and such amendments thereof as may have been required to the date of this Agreement. Copies of such
Registration Statement (including all amendments thereof) and of the related Preliminary Prospectus (as hereinafter defined) have
heretofore been delivered by the Company or are otherwise available to you. The term &ldquo;Preliminary Prospectus&rdquo; means
any preliminary prospectus included at any time as a part of the Registration Statement or filed with the Commission by the Company
pursuant to Rule 424(a) of the Rules. The term &ldquo;Registration Statement&rdquo; as used in this Agreement means the initial
registration statement (including all exhibits and financial schedules and all documents and information deemed to be part of
the Registration Statement by incorporation by reference or otherwise), as amended at the time and on the date it becomes effective
(the &ldquo;Effective Date&rdquo;), including the information (if any) contained in the form of final prospectus filed with the
Commission pursuant to Rule 424(b) of the Rules and deemed to be part thereof at the time of effectiveness pursuant to Rule 430A
of the Rules. If the Company has filed an abbreviated registration statement to register additional Securities pursuant to Rule
462(b) under the Rules (the &ldquo;462(b) Registration Statement&rdquo;), then any reference herein to the Registration Statement
shall also be deemed to include such 462(b) Registration Statement. The term &ldquo;Prospectus&rdquo; as used in this Agreement
means the prospectus in the form included in the Registration Statement at the time of effectiveness or, if Rule 430A of the Rules
is relied on, the term Prospectus shall also include the final prospectus filed with the Commission pursuant to and within the
time limits described in Rule 424(b) of the Rules.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">The
Company understands that the Underwriters propose to make a public offering of the Securities, as set forth in and pursuant to
the Statutory Prospectus (as hereinafter defined) and the Prospectus, as soon after the Effective Date and the date of this Agreement
as the Representative deems advisable. The Company hereby confirms that the Underwriters and dealers have been authorized to distribute
or cause to be distributed each Preliminary Prospectus, and, if applicable, each Issuer Free Writing Prospectus (as hereinafter
defined) and are authorized to distribute the Prospectus (as from time to time amended or supplemented if the Company furnishes
amendments or supplements thereto to the Underwriters).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale, Purchase, Delivery and Payment for the Securities</U>. On the basis of the representations, warranties and agreements
contained in, and subject to the terms and conditions of, this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly,
to purchase from the Company, the number of Shares and Warrants set forth opposite the name of such Underwriter under the column
&ldquo;Number of Shares and Warrants to be Purchased&rdquo; on Schedule I to this Agreement. The combined purchase price for
one Share and one Warrant to purchase one Warrant Share shall be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , which shall be allocated as $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Share and $0.01 per Warrant.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
of the purchase price for, and delivery of certificates for, the Securities shall be made at the offices of Oppenheimer &amp;
Co. Inc., 85 Broad Street, New York, New York 10004, at 10:00 a.m., New York City time, on the second business day following the
date of this Agreement or at such time on such other date, not later than ten (10) business days after the date of this Agreement,
as shall be agreed upon by the Company and the Representative (such time and date of delivery and payment are called the &ldquo;Closing
Date&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
for the Securities shall be made to the Company by wire transfer of immediately available funds or by certified or official bank
check or checks payable in New York Clearing House (same day) funds drawn to the order of the Company, against delivery to the
Representative for the respective accounts of the Underwriters of certificates for the Shares and/or Warrants to be purchased
by them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Securities shall be registered in such names and shall be in such denominations as the Representative shall request before the
Closing Date and shall be delivered by or on behalf of the Company to the Representative through the facilities of the Depository
Trust Company (&ldquo;DTC&rdquo;) for the account of such Representative.</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter as of the
date hereof and as of the Closing Date, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the Effective Date, the Registration Statement complied, and on the date of the Prospectus, the date any post-effective amendment
to the Registration Statement becomes effective, the date any supplement or amendment to the Prospectus is filed with the Commission,
the Registration Statement and the Prospectus (and any amendment thereof or supplement thereto) will comply, in all material respects,
with the requirements of the Securities Act and the Rules and the Securities and Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and the rules and regulations of the Commission thereunder. Neither the Registration Statement nor any amendments
thereto as of the times they became effective, contained any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements therein not misleading; and on the Effective Date
and the other dates referred to above neither the Registration Statement nor the Prospectus, nor any amendment or supplement of
either of the foregoing, will contain any untrue statement of a material fact or will omit to state any material fact required
to be stated therein or necessary in order to make the statements therein not misleading. When any Preliminary Prospectus was
first filed with the Commission (whether filed as part of the Registration Statement or any amendment thereto or pursuant to Rule
424(a) of the Rules) and when any amendment thereof or supplement thereto was first filed with the Commission, such Preliminary
Prospectus as amended or supplemented complied in all material respects with the applicable provisions of the Securities Act and
the Rules and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein not misleading. If applicable, each Preliminary Prospectus and the
Prospectus delivered to the Underwriters for use in connection with this offering was identical to the electronically transmitted
copies thereof filed with the Commission pursuant to the Commission&rsquo;s Electronic Data Gathering, Analysis and Retrieval
system (&ldquo;EDGAR&rdquo;), except to the extent permitted by Regulation S-T. Notwithstanding the foregoing, none of the representations
and warranties in this paragraph 2(a) shall apply to statements in, or omissions from, the Registration Statement, any Preliminary
Prospectus or the Prospectus made in reliance upon, and in conformity with, information herein or otherwise furnished in writing
by the Representative on behalf of the several Underwriters specifically for use in the Registration Statement, any Preliminary
Prospectus or the Prospectus, as the case may be. With respect to the preceding sentence, the Company acknowledges that the only
information furnished in writing by the Representative on behalf of the several Underwriters for use in the Registration Statement,
any Preliminary Prospectus or the Prospectus is the statements contained in the _____ and _______ paragraphs under the caption
&ldquo;Underwriting&rdquo; in the Prospectus (collectively, the &ldquo;Underwriter Information&rdquo;).</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Applicable Time (as hereinafter defined), none of (i) the price to the public and the number of Securities offered
and sold, as indicated on the cover page of the Prospectus<B><I> </I></B>and the Statutory Prospectus (as hereinafter defined),
all considered together (collectively, the &ldquo;General Disclosure Package&rdquo;), (ii)&nbsp;any individual Issuer Free Writing
Prospectus when considered together with the General Disclosure Package, and (iii) any individual Written Testing-the Waters Communication
(as defined herein), when considered together with the General Disclosure Package, included, includes or will include any untrue
statement of a material fact or omitted, omits or will omit to state any material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided,
however, that this representation and warranty shall not apply to statements in or omissions in the General Disclosure Package
made in reliance upon and in conformity with the Underwriter Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Each
Issuer Free Writing Prospectus (as hereinafter defined), including any electronic road show (including without limitation any
&ldquo;bona fide electronic road show&rdquo; as defined in Rule 433(h)(5) under the Securities Act) (each, a &ldquo;Road Show&rdquo;)
(i) is identified in Schedule III hereto and (ii) complied when issued, and complies, in all material respects with the requirements
of the Securities Act and the Rules and the Exchange Act and the rules and regulations of the Commission thereunder. The Company
has made at least one version of the Road Show available without restriction by means of graphic communication to any person,
including any potential investor in the Securities (and if there is more than one version of a Road Show for the offering that
is a written communication, the version available without restriction was made available no later than the other versions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in"><FONT STYLE="font-size: 10pt">As used in this Section
and elsewhere in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;Applicable
Time&rdquo; means [ ]:00&nbsp;[a.m.]/[p.m.] (Eastern time) on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;Statutory
Prospectus&rdquo; as of any time means the Preliminary Prospectus relating to the Securities that is included in the Registration
Statement immediately prior to the Applicable Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;Issuer
Free Writing Prospectus&rdquo; means each &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the Rules) prepared
by or on behalf of the Company or used or referred to by the Company in connection with the offering of the Securities, including,
without limitation, each Road Show.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness
of the Registration Statement or suspending or preventing the use of any Preliminary Prospectus, the Prospectus or any &ldquo;free
writing prospectus&rdquo;, as defined in Rule 405 under the Rules, has been issued by the Commission and no proceedings for that
purpose have been instituted or are threatened under the Securities Act. Any required filing of any Preliminary Prospectus and/or
the Prospectus and any supplement thereto pursuant to Rule 424(b) of the Rules has been or will be made in the manner and within
the time period required by such Rule 424(b). Any material required to be filed by the Company pursuant to Rule 433(d) or Rule
163(b)(2) of the Rules has been or will be made in the manner and within the time period required by such Rules.</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Issuer Free Writing Prospectus, if any, as of its issue date and at all subsequent times through the completion of the public
offer and sale of the Securities or until any earlier date that the Company notified or notifies the Representative as described
in the next sentence, did not, does not and will not include any information that conflicted, conflicts or will conflict with
the information contained in the Registration Statement, the Statutory Prospectus or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">If
at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result
of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement,
the Statutory Prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or would
omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances prevailing at the subsequent time, not misleading, the Company has promptly notified or will promptly notify
the Representative and has promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing
Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements of the Company (including all notes and schedules thereto) included in the Registration Statement, the
Statutory Prospectus and Prospectus present a true and fair view of the financial position of the Company and its consolidated
subsidiaries at the dates indicated and the statement of operations, stockholders&rsquo; equity and cash flows of the Company
and its consolidated subsidiaries for the periods specified; and such financial statements and related schedules and notes thereto,
and the unaudited financial information filed with the Commission as part of the Registration Statement, have been prepared in
conformity with generally accepted accounting principles, consistently applied throughout the periods involved. The summary and
selected financial data included in the Statutory Prospectus and Prospectus present a true and fair view of the information shown
therein as of the respective dates and for the respective periods specified and have been presented on a basis consistent with
the consolidated financial statements set forth in the Prospectus. The pro forma financial statements and the related notes thereto
included in the Registration Statement, the Statutory Prospectus and the Prospectus present fairly the information shown therein,
have been prepared in accordance with the Commission&rsquo;s rules and guidelines with respect to pro forma financial statements
and have been properly compiled on the bases described therein, and the assumptions used in the preparation thereof are reasonable
and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Farber Hass Hurley LLP (the &ldquo;Auditor&rdquo;), whose reports are filed with the Commission as a part of the Registration
Statement, are and, during the periods covered by their reports, were independent public accountants as required by the Securities
Act and the Rules.</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and each of its subsidiaries, including each entity (corporation, partnership, joint venture, association or other
business organization) controlled directly or indirectly by the Company (each, a &ldquo;subsidiary&rdquo;), (i) is duly organized,
validly existing and in good standing under the laws of their respective jurisdictions of incorporation or organization and each
such entity has all requisite power and authority to carry on its business as is currently being conducted as described in the
Statutory Prospectus and the Prospectus, and to own, lease and operate its properties and to enter into and perform its obligations
pursuant to the public offer and sale of Securities and this Agreement, and (ii) has duly authorized, executed and delivered this
Agreement and the other agreements to be entered into by it in connection with the public offer and sale of Securities, and each
of them, assuming due authorization, execution and delivery by the other parties hereto or thereto, constitutes legal, valid and
binding obligations enforceable against it in accordance with their respective terms. All of the issued shares of capital stock
of, or other ownership interests in, each subsidiary have been duly and validly authorized and issued and are fully paid and non-assessable
and are owned, directly or indirectly, by the Company, free and clear of any lien, charge, mortgage, pledge, security interest,
claim, limitation on voting rights, equity, trust or other encumbrance, preferential arrangement, defect or restriction of any
kind whatsoever. The Company and each of its subsidiaries is duly qualified to do business and is in good standing as a foreign
corporation in each jurisdiction in which the nature of the business conducted by it or location of the assets or properties owned,
leased or licensed by it requires such qualification, except for such jurisdictions where the failure to so qualify individually
or in the aggregate would not have a material adverse effect on the assets, properties, condition, financial or otherwise, or
in the results of operations, business affairs or business prospects of the Company and its subsidiaries considered as a whole
or in the context of the public offer and sale of Securities or underwriting of the Securities (a &ldquo;Material Adverse Effect&rdquo;);
and to the Company&rsquo;s knowledge, no proceeding has been instituted or is threatened in any such jurisdiction revoking, limiting
or curtailing, or seeking to revoke, limit or curtail, such power and authority or qualification or taken against it for its winding-up,
liquidation or dissolution or for any similar or analogous proceeding in any jurisdiction, or for it to enter into any arrangement
or composition for the benefit of creditors, or for the appointment of a receiver, administrative receiver, trustee or similar
officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) At the time of filing the Registration Statement and (ii) on the date hereof, the Company was not and is not an &ldquo;ineligible
issuer,&rdquo; as defined in Rule&nbsp;405 of the Rules, including (but not limited to) the Company or any other subsidiary in
the preceding three (3) years not having been convicted of a felony or misdemeanor or having been made the subject of a judicial
or administrative decree or order as described in Rule&nbsp;405 of the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and each of its subsidiaries (i) owns or possesses legally enforceable rights to use all patents, patent rights, inventions,
trademarks, trademark applications, trade names, service marks, copyrights, copyright applications, licenses, know-how (including
trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems, processes or procedures)
and other similar rights and proprietary knowledge (in each case, whether registered or not and including applications for registration)
(collectively, &ldquo;Intangibles&rdquo;) necessary for the conduct of its business. Neither the Company nor any of its subsidiaries
has received any notice of, or is not aware of, any infringement of or conflict with asserted rights of others with respect to
any Intangibles and neither the Company nor any of its subsidiaries has knowledge of any infringement of or conflict with asserted
rights of others or of any infringement of, or conflict with the Company and its subsidiaries&rsquo; rights with respect to any
Intangibles, (ii) the Company and each of its subsidiaries processes employed and the products and services dealt in by the Company
or any of its subsidiaries do not, to its knowledge, infringe Intangibles of a third party and neither of the Company nor any
of its subsidiaries has received any notice of infringement of or conflict with, and neither of the Company nor any of its subsidiaries
has knowledge of any infringement of or conflict with, asserted rights of a third party with respect to any Intangibles, except
for or in respect of any such infringements or conflicts that would not, individually or in the aggregate, have a Material Adverse
Effect, (iii) except as described in the Statutory Prospectus and the Prospectus, neither the Company nor any of its subsidiaries
is obligated to pay a royalty, grant a license or provide other consideration to any third party in connection with its Intangibles,
and the public offer and sale of Securities will not trigger such payment, except for any such obligations that would not, individually
or in the aggregate, have a Material Adverse Effect.</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as described in the Statutory Prospectus and the Prospectus, the Company and each of its subsidiaries has good and marketable
title in fee simple to all real property, and good and marketable title to all other property owned by it, in each case free and
clear of all liens, encumbrances, claims, security interests and defects, except such as do not materially affect the value of
such property and do not materially interfere with the use made or proposed to be made of such property by the Company and its
subsidiaries. All property held under lease by the Company and its subsidiaries is held by them under valid, existing and enforceable
leases, free and clear of all liens, encumbrances, claims, security interests and defects, except such as are not material and
do not materially interfere with the use made or proposed to be made of such property by the Company and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under
the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the
date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus, being collectively
referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of such time of
filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC
Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and
none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements
and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during
the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and
the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments. The selected financial data set forth under the caption &ldquo;Selected Financial Data&rdquo;
in the SEC Reports and &ldquo;Summary of Financial Data&rdquo; in the Registration Statement, General Disclosure Package, and
Prospectus fairly present, on the basis stated in such SEC Reports, Registration Statement, General Disclosure Package, and Prospectus,
each as applicable, the information included therein. The agreements and documents described in the Registration Statement, the
Preliminary Prospectus, the General Disclosure Package, the Prospectus, and the SEC Reports conform in all material aspects to
the descriptions thereof contained therein and there are no agreements or other documents required by the Securities Act and the
rules and regulations thereunder to be described in the Registration Statement, the Preliminary Prospectus, the General Disclosure
Package, the Prospectus or the SEC Reports or to be filed with the Commission as exhibits to the Registration Statement, that
have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company
is a party or by which it is or may be bound or affected and (i) that is referred to in the Registration Statement, the General
Disclosure Package, the Prospectus or the SEC Reports, or (ii) is material to the Company&rsquo;s business, has been duly authorized
and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company
and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance with its terms, except (x) as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z) that the
remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and
to the discretion of the court before which any proceeding therefore may be brought. None of such agreements or instruments has
been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any other party is in default thereunder
and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would
constitute a default thereunder. To the Company&rsquo;s knowledge, performance by the Company of the material provisions of such
agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or
decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or
businesses, including, without limitation, those relating to environmental laws and regulations, except in each case, as would
not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
to the respective dates as of which information is given in the Registration Statement, the Statutory Prospectus and the Prospectus,
(i) there has not been any event which could have a Material Adverse Effect; (ii) neither the Company nor any of its subsidiaries
has sustained any loss or interference with its assets, businesses or properties (whether owned or leased) from fire, explosion,
earthquake, flood or other calamity, whether or not covered by insurance, or from any labor dispute or any court or legislative
or other governmental action, order or decree which would have a Material Adverse Effect; and (iii) except as described in the
Statutory Prospectus and the Prospectus, since the date of the latest balance sheet included in the Registration Statement and
the Prospectus, neither the Company nor its subsidiaries has (A) issued any securities or incurred any liability or obligation,
direct or contingent, for borrowed money, except such liabilities or obligations incurred in the ordinary course of business,
(B) entered into any transaction not in the ordinary course of business or (C) declared or paid any dividend or made any distribution
on any shares of its stock or redeemed, purchased or otherwise acquired or agreed to redeem, purchase or otherwise acquire any
shares of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no document, contract or other agreement required to be described in the Registration Statement, the Statutory
Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which is not described or filed as required
by the Securities Act or Rules. Each description of a contract, document or other agreement in the Registration Statement, the
Statutory Prospectus or the Prospectus accurately reflects in all respects the terms of the underlying contract, document or other
agreement. Each contract, document or other agreement described in the Registration Statement, the Statutory Prospectus or the
Prospectus or listed in the exhibits to the Registration Statement is in full force and effect and is valid and enforceable by
and against the Company or its subsidiary, as the case may be, in accordance with its terms. Neither the Company nor any of its
subsidiaries, if a subsidiary is a party, nor to the Company&rsquo;s knowledge, any other party, is in default in the observance
or performance of any term or obligation to be performed by it under any such agreement, and no event has occurred which with
notice or lapse of time or both would constitute such a default, in any such case which default or event, individually or in the
aggregate, would have a Material Adverse Effect. No default exists, and no event has occurred which with notice or lapse of time
or both would constitute a default, in the due performance and observance of any term, covenant or condition, by the Company or
its subsidiary, if a subsidiary is a party thereto, of any other agreement or instrument to which the Company or any of its subsidiaries
is a party or by which Company or its properties or business or a subsidiary or its properties or business may be bound or affected
which default or event, individually or in the aggregate, would have a Material Adverse Effect.</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The statistical and market related data included in the Registration Statement, the Statutory Prospectus or the Prospectus
are based on or derived from sources that the Company believes to be reliable and accurate.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; font-weight: normal">(o)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-weight: normal">Neither
the Company nor any subsidiary (i) is in violation of its certificate or articles of incorporation, bylaws, certificate of formation,
limited liability company agreement, partnership agreement or other organizational documents, (ii) is in default under, and no
event has occurred which, with notice or lapse of time, or both, would constitute a default under, or result in the creation or
imposition of any lien, charge, mortgage, pledge, security interest, claim, limitation on voting rights, equity, trust or other
encumbrance, preferential arrangement, defect or restriction of any kind whatsoever, upon, any property or assets of the Company
or any subsidiary pursuant to, any bond, debenture, note, indenture, mortgage, deed of trust, loan agreement or other agreement
or instrument to which it is a party or by which it is bound or to which any of its properties or assets is subject, or (iii)
is in violation of any statute, law, rule, regulation, ordinance, directive, judgment, decree or order of any judicial, regulatory
or other legal or governmental agency or body, foreign or domestic. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has full right, power and authority to execute and deliver this Agreement, the Warrants and the Warrant Agreement,
and to perform its obligations hereunder and thereunder; and all action required to be taken for the due and proper authorization,
execution and delivery by it of this Agreement, the Warrants and the Warrant Agreement, and the consummation by it of the transactions
contemplated hereby and thereby has been duly and validly taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement, the Warrants and the Warrant Agreement have been duly authorized, executed and delivered by the Company and each,
assuming the due authorization, execution and delivery by the other parties hereto, constitutes a valid and legally binding agreement
of the Company, enforceable in accordance with its terms, except as (i) the enforcement hereof may be limited by bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors
or by general equitable principles (whether considered in a proceeding at law or in equity) relating to enforceability and (ii)
rights to indemnification and contribution hereunder may be limited by applicable law and public policy considerations.</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the execution, delivery and performance of this Agreement by the Company nor the consummation of any of the transactions
contemplated hereby (including, without limitation, the issuance and sale by the Company of the Securities) will give rise to
a right to terminate or accelerate the due date of any payment due under, or conflict with or result in the breach of any term
or provision of, or constitute a default (or an event which with notice or lapse of time or both would constitute a default) under,
or require any consent or waiver under, or result in the execution or imposition of any lien, charge or encumbrance upon any properties
or assets of the Company or its subsidiaries pursuant to the terms of, any indenture, mortgage, deed of trust or other agreement
or instrument to which the Company or any of its subsidiaries is a party or by which either the Company or its subsidiaries or
any of their properties or businesses is bound, or any franchise, license, permit, judgment, decree, order, statute, rule or regulation
applicable to the Company or any of its subsidiaries or violate any provision of the charter or bylaws or other organizational
documents of the Company or any of its subsidiaries, except for such consents or waivers which have already been obtained and
are in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company has authorized and outstanding capital stock as set forth under the caption &ldquo;Capitalization&rdquo; in the Statutory
Prospectus and the Prospectus. All of the issued and outstanding shares of capital stock of the Company have been duly and validly
issued and are fully paid and nonassessable and have been issued in compliance with all federal, state and local. There are no
statutory preemptive or other similar rights to subscribe for or to purchase or acquire any shares of capital stock of the Company
or any of its subsidiaries, or any such rights pursuant to its charter, articles of incorporation or bylaws or any other applicable
organizational documents or any agreement or instrument to or by which the Company or any of its subsidiaries is a party or bound.
The Securities have been duly authorized for issuance and sale pursuant to this Agreement and, in the case of the Warrants, the
Warrant Agreement. When issued and sold pursuant to this Agreement, the Shares will be duly and validly issued, fully paid and
nonassessable and none of them will be issued in violation of any preemptive or other similar right. When paid for and issued
in accordance with the Warrants and the Warrant Agreement, the Warrant Shares will be validly issued, fully paid and non-assessable
and none of them will be issued in violation of any preemptive or other similar right. Except as disclosed in the Registration
Statement, the Statutory Prospectus and the Prospectus, there is no outstanding option, warrant or other right calling for the
issuance of, and there is no commitment, plan or arrangement to issue, any share of capital stock of the Company or any of its
subsidiaries or any security convertible into, or exercisable or exchangeable for, such shares. The exercise price of each option
to acquire Common Stock (each, a &ldquo;Company Stock Option&rdquo;) is no less than the fair market value of a share of Common
Stock as determined on the date of grant of such Company Stock Option. All grants of Company Stock Options were validly issued
and properly approved by the Board of Directors of the Company (and, if required, but a committee of the Board of Directors of
the Company and/or the shareholders of the Company) in material compliance with all applicable laws and the terms of the plans
under which such Company Stock Options were issued and were recorded on the Company Financial Statements, in accordance with generally
accepted accounting principles, and no such grants involved any &ldquo;back dating&rdquo;, &ldquo;forward dating,&rdquo; &ldquo;spring
loading&rdquo; or similar practices with respect to the effective date of grant. The Securities conform in all material respects
to all statements in relation thereto contained in the Registration Statement and the Statutory Prospectus and the Prospectus.</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times from its
duly authorized capital stock, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue Warrant Shares issuable upon exercise of outstanding Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
holder of any security of the Company has any right, which has not been waived, to have any security owned by such holder included
in the Registration Statement or to demand registration of any security owned by such holder for a period of one hundred and eighty
(180) days after the date of this Agreement. Each director and executive officer of the Company and each stockholder of the Company
listed on Schedule II hereto has delivered to the Representative his enforceable written lock-up agreement in the form attached
to this Agreement as Exhibit A hereto (&ldquo;Lock-Up Agreement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no legal or governmental proceedings pending to which the Company or any of its subsidiaries is a party or of which any property
of the Company or any of its subsidiaries is the subject which, if determined adversely to the Company or any of its subsidiaries
could individually or in the aggregate have a Material Adverse Effect; and, to the knowledge of the Company, no such proceedings
are threatened or contemplated by governmental authorities or threatened by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
necessary corporate action has been duly and validly taken by the Company to authorize the execution, delivery and performance
of this Agreement, the Warrants and the Warrant Agreement and the issuance and sale of the Securities by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Company nor any of its subsidiaries is involved in any labor dispute nor, to the knowledge of the Company, is any such dispute
threatened, which dispute would have a Material Adverse Effect. The Company is not aware of any existing or imminent labor disturbance
by the employees of any of its principal suppliers or contractors which would have a Material Adverse Effect. The Company is not
aware of any threatened or pending litigation between the Company or its subsidiaries and any of its executive officers which,
if adversely determined, could have a Material Adverse Effect and has no reason to believe that such executive officers will not
remain in the employment of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
transaction has occurred between or among the Company and any of its officers or directors, shareholders or any affiliate or affiliates
of any such officer or director or shareholder that is required to be described in and is not described in the Registration Statement,
the Statutory Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has not taken, nor will it take, directly or indirectly, any action designed to, or which might reasonably be expected
to cause or result in, or which has constituted or which might reasonably be expected to constitute, the stabilization or manipulation
of the price of the Common Stock or any security of the Company to facilitate the sale or resale of any of the Securities.</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and each of its subsidiaries has duly paid all national, regional and local taxes of any kind (including but not limited
to, income taxes, capital gain taxes, withholding taxes, sales and transfer taxes, energy and real estate taxes, labor market
and social contribution taxes, customs duties, VAT, registration fees and similar levies, duties, charges, stamps and imposts
of whatever nature as well as any penalty, fine, surcharge or interest relating thereto) which have become due and payable with
regard to the period up to and including the of this Agreement (other than tax deficiencies which the Company or any of its subsidiaries
is contesting in good faith and for which the Company or any of its subsidiaries have provided adequate provisions if required
by generally accepted accounting principles), except for such failures that would not, individually or in the aggregate, have
a Material Adverse Effect. The Company and each of its subsidiaries has filed all federal, state, local and foreign tax returns
which are required to be filed through the date hereof, which returns are true and correct in all material respects or has received
timely extensions thereof, and has paid all taxes shown on such returns and all assessments received by it to the extent that
the same are material and have become due. There are no tax audits or investigations pending, which if adversely determined would
have a Material Adverse Effect; nor are there any material proposed additional tax assessments against the Company or any of its
subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Securities have been duly authorized for quotation on the National Association of Securities Dealers Automated Quotation (&ldquo;Nasdaq&rdquo;)
Capital Market System, subject to official Notice of Issuance. A registration statement has been filed on Form 8-A pursuant to
Section 12 of the Exchange Act, which registration statement complies in all material respects with the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has taken no action designed to, or likely to have the effect of, terminating the registration of theSecurities under
the Exchange Act or the quotation of the Common Stock or the Warrants on the Nasdaq Capital Market, nor has the Company received
any notification that the Commission or the Nasdaq Capital Market is contemplating terminating such registration or quotation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(dd)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The books, records and accounts of the Company and its subsidiaries accurately and fairly reflect the transactions in, and
dispositions of, the assets of, and the results of operations of, the Company and its subsidiaries. The Company and each of its
subsidiaries maintains a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary
to permit preparation of financial statements in accordance with generally accepted accounting principles and to maintain asset
accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization
and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has established and maintains disclosure controls and procedures (as such term is defined in Rule 13a-15 under the Exchange
Act), which: (i) are designed to ensure that material information relating to the Company is made known to the Company&rsquo;s
principal executive officer and its principal financial officer by others within the Company, particularly during the periods
in which the periodic reports required under the Exchange Act are required to be prepared; (ii) provide for the periodic evaluation
of the effectiveness of such disclosure controls and procedures at the end of the periods in which the periodic reports are required
to be prepared; and (iii) are effective in all material respects to perform the functions for which they were established.</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the evaluation of its disclosure controls and procedures, the Company is not aware of (i) any material weakness or significant
deficiency in the design or operation of internal controls which could adversely affect the Company&rsquo;s ability to record,
process, summarize and report financial data or any material weaknesses in internal controls; or (ii) any fraud, whether or not
material, that involves management or other employees who have a role in the Company&rsquo;s internal controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Except as described in the Statutory Prospectus and the Prospectus and as preapproved in accordance with the requirements set
forth in Section 10A of the Exchange Act, the Auditor has not been engaged by the Company to perform any &ldquo;prohibited activities&rdquo;
(as defined in Section 10A of the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as described in the Statutory Prospectus and the Prospectus, there are no material off-balance sheet arrangements (as defined
in Item 303 of Regulation S-K) that have or are reasonably likely to have a material current or future effect on the Company&rsquo;s
financial condition, revenues or expenses, changes in financial condition, results of operations, liquidity, capital expenditures
or capital resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company&rsquo;s Board of Directors has validly appointed an audit committee whose composition satisfies the requirements of Rule
5605 of the Nasdaq Stock Market and the Board of Directors and/or the audit committee has adopted a charter that satisfies the
requirements of Rule 5605 of the Nasdaq Stock Market. The audit committee has reviewed the adequacy of its charter within the
past twelve (12) months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is in compliance with all other applicable provisions of the Sarbanes-Oxley Act of 2002, as amended (the &ldquo;Sarbanes-Oxley
Act&rdquo;), any related rules and regulations promulgated by the Commission and corporate governance requirements under applicable
Nasdaq regulations upon the effectiveness of such provisions and has no reason to believe that it will not be able to comply with
such provisions at the time of effectiveness. There is and has been no failure on the part of the Company or any of its directors
or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act, including, without limitation,
Section 402 related to loans and Sections 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are customary in the businesses in which they are engaged or propose to engage after giving effect to the transactions
described in the Statutory Prospectus and the Prospectus; all policies of insurance and fidelity or surety bonds insuring the
Company or any of its subsidiaries or the Company&rsquo;s or its subsidiaries&rsquo; respective businesses, assets, employees,
officers and directors are in full force and effect; the Company and each of its subsidiaries are in compliance with the terms
of such policies and instruments in all material respects; and neither the Company nor any subsidiary of the Company has any reason
to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business at a cost that is not materially greater than the
current cost. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for
which it has applied.</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
approval, consent, order, authorization, designation, declaration or filing of, by or with any regulatory, administrative or other
governmental body necessary in connection with the execution and delivery by the Company of this Agreement, the Warrants and the
Warrant Agreement and the consummation of the transactions herein and therein contemplated required to be obtained or performed
by the Company has been obtained or performed, except for (i) such additional steps as may be required by the Financial Industry
Regulatory Authority (&ldquo;FINRA&rdquo;); (ii) as may be necessary to qualify the Securities for public offering by the Underwriters
under the state securities or Blue Sky laws; and (iii) the approval by the Nasdaq Capital Market for the listing of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no affiliations with FINRA among the Company&rsquo;s officers, directors or, to the best of the knowledge of the Company,
any five percent or greater stockholder of the Company, except as set forth in the Registration Statement or otherwise disclosed
in writing to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)
Each of the Company and each of its subsidiaries is in compliance in all material respects with all rules, laws and regulation
relating to the use, treatment, storage and disposal of toxic substances and protection of health or the environment (each such
law, an &ldquo;Environmental Law&rdquo;) which are applicable to its business; (ii) neither the Company nor its subsidiaries has
received any notice from any governmental authority or third party of an asserted claim under Environmental Laws; (iii) each of
the Company and each of its subsidiaries has received all permits, licenses or other approvals required of it under applicable
Environmental Laws to conduct its business and is in compliance with all terms and conditions of any such permit, license or approval;
(iv) to the Company&rsquo;s knowledge, no facts currently exist that will require the Company or any of its subsidiaries to make
future material capital expenditures to comply with Environmental Laws; and (v) no property which is or has been owned, leased
or occupied by the Company or its subsidiaries has been designated as a Superfund site pursuant to the Comprehensive Environmental
Response, Compensation of Liability Act of 1980, as amended (42 U.S.C. Section 9601, et. seq.) (&ldquo;CERCLA 1980&rdquo;) or
otherwise designated as a contaminated site under other Environmental Laws. Neither the Company nor any of its subsidiaries has
been named as a &ldquo;potentially responsible party&rdquo; under CERCLA 1980.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the ordinary course of its business, the Company periodically reviews the effect of Environmental Laws on the business, operations
and properties of the Company and its subsidiaries, in the course of which the Company identifies and evaluates associated costs
and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties
or compliance with Environmental Laws, or any permit, license or approval, any related constraints on operating activities and
any potential liabilities to third parties). On the basis of such review, the Company has reasonably concluded that such associated
costs and liabilities would not, singly or in the aggregate, have a Material Adverse Effect.</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is not and, after giving effect to the offering and sale of the Securities and the application of proceeds thereof as
described in the Statutory Prospectus and the Prospectus, will not be an &ldquo;investment company&rdquo; within the meaning of
the Investment Company Act of 1940, as amended (the &ldquo;Investment Company Act&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company or any other person associated with or acting on behalf of the Company including, without limitation, any director, officer,
agent or employee of the Company or its subsidiaries, has not, directly or indirectly, while acting on behalf of the Company or
its subsidiaries (i) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating
to political activity; (ii)&nbsp;made any direct or indirect unlawful payment or unlawful benefit to foreign or domestic government
officials or employees or to foreign or domestic political parties or campaigns from corporate funds; (iii) violated or is in
violation of, or engaged in any activity or conduct which would constitute an offense under, any provision of the Foreign Corrupt
Practices Act of 1977, as amended, or any provision of any applicable non-U.S. anti-bribery or anti-corruption law or regulation
(&ldquo;Anti-Corruption Laws&rdquo;); or (iv) made any other unlawful payment. Neither the Company nor its subsidiaries will directly
or indirectly use the proceeds of the public offer and sale of Securities or lend, contribute or otherwise make available such
proceeds to any subsidiary, affiliate, joint venture partner or any other person or entity for the purpose of financing or facilitating
any activity in violation of applicable Anti-Corruption Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;Money Laundering Laws&rdquo;)
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending, or to the best knowledge of the Company,
threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate
of the Company or any of its subsidiaries, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;OFAC&rdquo;); and the Company will not directly or indirectly use the proceeds
of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered
by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as described in the Registration Statement, the Statutory Prospectus and the Prospectus, the Company has not sold or issued any
shares of capital stock during the six-month period preceding the date of the Prospectus, including any sales pursuant to Rule
144A under, or Regulations D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified
stock options plans or other employee compensation plans or pursuant to outstanding options, rights or warrants.</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(uu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has fulfilled its obligations, if any, under the minimum funding standards of Section 302 of the U.S. Employee Retirement
Income Security Act of 1974 (&ldquo;ERISA&rdquo;) and the regulations and published interpretations thereunder with respect to
each &ldquo;plan&rdquo; as defined in Section 3(3) of ERISA and such regulations and published interpretations in which its employees
are eligible to participate and each such plan is in compliance in all material respects with the presently applicable provisions
of ERISA and such regulations and published interpretations. No &ldquo;Reportable Event&rdquo; (as defined in 12 ERISA) has occurred
with respect to any &ldquo;Pension Plan&rdquo; (as defined in ERISA) for which the Company could have any liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the Company, its directors or its officers has distributed nor will distribute prior to the later of (i) the Closing Date and
(ii) completion of the distribution of the Securities, any offering material in connection with the offering and sale of the Securities
other than any Preliminary Prospectus, the Prospectus, the Registration Statement and other materials, if any, permitted by the
Securities Act and consistent with the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
the date of the preliminary prospectus included in the Registration Statement filed with the Commission on [_________] (or, if
earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any Testing-the-Waters
Communication (as defined herein)) through the date hereof, the Company has been and is an &ldquo;emerging growth company,&rdquo;
as defined in Section 2(a) of the Securities Act (an &ldquo;Emerging Growth Company&rdquo;). &ldquo;Testing-the-Waters Communication&rdquo;
means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company (a) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the
consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A under the
Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act, and (b)
has not authorized anyone other than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms
that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company
has not distributed any Written Testing-the-Waters Communications (as defined herein) other than those listed on Schedule IV hereto.
&ldquo;Written Testing-the-Waters Communication&rdquo; means any Testing-the-Waters Communication that is a written communication
within the meaning of Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(yy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has the power to submit, and pursuant to Section 9 of this Agreement, has legally, validly, effectively and irrevocably
submitted, to the personal jurisdiction of each United States federal court and New York state court located in the Borough of
Manhattan, in the City of New York, New York, U.S.A. (each, a &ldquo;New York Court&rdquo;), and the Company has the power to
designate, appoint and authorize, and pursuant to Section 9 of this Agreement, has legally, validly, effectively and irrevocably
designated, appointed and authorized an agent for service of process in any action arising out of or relating to this Agreement
in any New York Court, and service of process effected on such authorized agent will be effective to confer valid personal jurisdiction
over the Company as provided in Section 9 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(zz)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and each of its subsidiaries has all requisite corporate power and authority, and all necessary authorizations, approvals,
consents, orders, licenses, certificates and permits of and from all governmental or regulatory bodies or any other person or
entity (collectively, the &ldquo;Permits&rdquo;), to own, lease and license its assets and properties and conduct its business,
all of which are valid and in full force and effect, except where the lack of such Permits, individually or in the aggregate,
would not have a Material Adverse Effect. The Company and each of its subsidiaries has fulfilled and performed in all material
respects all of its obligations with respect to such Permits and no event has occurred that allows, or after notice or lapse of
time would allow, revocation or termination thereof or results in any other material impairment of the rights of the Company thereunder.
Except as may be required under the Securities Act and state and foreign Blue Sky laws, no other Permits are required to enter
into, deliver and perform this Agreement and to issue and sell the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
transaction, stamp or other issuance or transfer taxes or duties, and no capital gain, income transfer, withholder or other tax
or duty is payable on behalf of the Underwriters to any taxing authority or therein in connection with (i) the issuance, sale
and delivery of the Securities by the Company; (ii) the purchase from the Company, and the initial sale and delivery by the Underwriters
of the Securities to purchasers thereof; (iii) the holding or transfer of the Securities; or (iv) the execution and delivery of
this Agreement or any other document to be furnished hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(bbb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any certificate signed by an officer or board member of the Company and delivered to the Underwriters or to counsel for the Underwriters
pursuant to the terms of this Agreement shall be deemed a representation and warranty by the Company, as appropriate, to the Underwriters
as to matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ccc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the Company&rsquo;s representation and warranty under (a) above, all forward-looking statements, forecasts, estimates,
targets and predictions and expressions of opinion, belief, intention and expectation made by the Company expressed in or included
in the Registration Statement and in the General Disclosure Package, are truly and honestly held, are not misleading and have
been made on reasonable grounds after due and careful consideration of such relevant circumstances and assumptions reasonable
deemed relevant and there are no facts which have not been disclosed which by their omission make any such estimates materially
misleading or which are material for disclosure. Each of the assumptions used in the preparation of the forward-looking statements,
forecasts, estimates, targets and predictions are reasonable and, to the Company&rsquo;s knowledge, there are no other material
assumptions that should reasonably be taken into account in the preparation of such information and the adjustments used therein
are appropriate to give effect to the transactions and circumstances referred to therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ddd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) No outstanding indebtedness of the Company or any of its subsidiaries has become repayable before its stated maturity, nor
has any security in respect of such indebtedness become enforceable by reason of default by the Company or any of its subsidiaries,
and no event has occurred or is, the Company&rsquo;s knowledge, impending which, with the lapse of time or the fulfilment of any
condition or the giving of notice or the compliance with any other formality, may reasonably be expected to result in any such
indebtedness becoming so repayable or any such security becoming enforceable and neither the Company nor any of its subsidiaries
has received notice from any person to whom any indebtedness of the Company or any of its subsidiaries which is repayable on demand
is owed, demanding or, to the Company&rsquo;s knowledge, threatening to demand repayment of, or to take any steps to enforce any
security for, the same; (ii) the amounts borrowed by the Company or any of its subsidiaries do not exceed any limitation (A) on
borrowing contained in its constitutional documents, any debenture or other deed or document binding upon them, and neither the
Company nor any of its subsidiaries has outstanding any loan capital, or is or has engaged in a financing of a type which would
not be required to be shown or reflected in its audited accounts, except in any such case as would not, individually or in the
aggregate, have a Material Adverse Effect; and (B) all borrowing facilities of each of the Company and each of its subsidiaries
have been duly executed by such Group company and are in full force and effect and are in compliance with all covenants and undertakings
contained therein, except as may terminate in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(eee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and its subsidiaries have no pending insolvency, bankruptcy, composition or similar proceedings pending against them and
have no reason to believe that any such proceeding may be brought and are not in liquidation or receivership.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(fff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) All the information and communications technologies required for use in the business of the Company and its subsidiaries,
including, without limitation, hardware, proprietary and third party software, networks, peripherals and associated documentation
and any IT systems currently being implemented by the Company (&ldquo;<B>IT Systems</B>&rdquo;) used or planned to be used in
connection with the businesses of the Company and its subsidiaries: (A) are owned by, or properly licensed or leased to, the Company
or its subsidiaries, as applicable, for the foreseeable future following the offering of the Securities, and are not dependent
on any facilities or systems which are not under the ownership or control of the Company and its subsidiaries and the Company
and its subsidiaries do not share any user rights with any other person; and (B) are all the IT Systems required for the present
needs of the business of the Company and its subsidiaries and the anticipated requirements of the Company and its subsidiaries
and the Company has, for the foreseeable future following the offer of Securities, taken reasonable steps to ensure system capacity
and ability to process current peak volumes and anticipated volumes in a timely manner; (ii) in relation to the IT Systems, there
has not been any act or default by the Company or any of its subsidiaries or their sub-lessees, sub-licensees, sub-contractors
nor any other person, and there is no breach of any lease, license, support, maintenance service agreement, understanding or other
arrangement (together, &ldquo;<B>IT Contracts</B>&rdquo;) granted or provided by a third party in favor of the Company or any
of its subsidiaries which may in any way, in the reasonable opinion of the Company, result in any IT Contract being terminated.
There is no reason to believe that any IT Contract granted or provided by a third party will not be renewed when it expires on
the same or substantially the same terms (including as regards pricing and any other commercial details); (iii) there are no circumstances
in which the ownership, benefit or right to use the IT Systems may be lost or rendered liable to termination, by virtue of the
making of the public offer and sale of Securities as contemplated by this Agreement (and the Registration Statement and the General
Disclosure Package), the entry into and performance of this Agreement and each agreement referred to in it, or the offering and
sale of the Securities, except for any such losses or terminations that would not, individually or in the aggregate, have a Material
Adverse Effect or otherwise be material in the context of the offering of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ggg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries comply in all material respects with all applicable data protection laws, guidelines and industry
standards and of any privacy policies of its own. Neither the Company nor any of its subsidiaries has received any notice from
a competent authority (including any information or enforcement notice, or any transfer prohibition notice) alleging that the
Company or any of its subsidiaries has not complied with applicable data protection laws, guidelines and industry standards. None
of the Company or any of its subsidiaries has received any material unresolved written claim from an individual for compensation
for breaches of applicable data protection laws or for loss or unauthorized disclosure of personal data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(hhh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its subsidiaries has engaged in price exchange, price fixing or other comparable anti-competitive
practices. Neither the Company nor any of its subsidiaries is a party to any agreement, arrangement or concerted practice or is
carrying on any practice which in whole or in part contravenes or is invalidated by any anti-trust, anti-monopoly, competition,
fair trading, consumer protection or similar legislation in any jurisdiction of the Company or any of its subsidiaries is established
or operating or in respect of which any filing, registration or notification is required or is advisable pursuant to such legislation
(whether or not the same has in fact been made), except for any such contraventions or invalidations, or any such failures to
make a filing, registration or notification, that would not, individually or in the aggregate, have a Material Adverse Effect
or otherwise be material in the context of the public offer and sale of Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions of the Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters under this Agreement are several
and not joint. The respective obligations of the Underwriters to purchase the Securities are subject to each of the following
terms and conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notification
that the Registration Statement has become effective shall have been received by the Representative and the Prospectus shall have
been timely filed with the Commission in accordance with Section 4(a) of this Agreement and any material required to be filed
by the Company pursuant to Rule 433(d) of the Rules shall have been timely filed with the Commission in accordance with such rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No order preventing or suspending the use of any Preliminary Prospectus, the Prospectus or any &ldquo;free writing prospectus&rdquo;
(as defined in Rule 405 of the Rules), shall have been or shall be in effect and no order suspending the effectiveness of the
Registration Statement shall be in effect and no proceedings for such purpose shall be pending before or threatened by the Commission,
and any requests for additional information on the part of the Commission (to be included in the Registration Statement or the
Prospectus or otherwise) shall have been complied with to the satisfaction of the Commission and the Representative. If the Company
has elected to rely upon Rule 430A, Rule 430A information previously omitted from the effective Registration Statement pursuant
to Rule 430A shall have been transmitted to the Commission for filing pursuant to Rule 424(b) within the prescribed time period
and the Company shall have provided evidence satisfactory to the Underwriters of such timely filing, or a post-effective amendment
providing such information shall have been promptly filed and declared effective in accordance with the requirements of Rule 430A.</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
representations and warranties of the Company contained in this Agreement and in the certificates delivered pursuant to Section
3(d) shall be true and correct when made and on and as of each Closing Date as if made on such date. The Company shall have performed
all covenants and agreements and satisfied all the conditions contained in this Agreement required to be performed or satisfied
by it at or before such Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Representative shall have received on the Closing Date a certificate, addressed to the Representative and dated the Closing Date,
of the chief executive or chief operating officer and the chief financial officer or chief accounting officer of the Company to
the effect that: (i) the representations, warranties and agreements of the Company in this Agreement were true and correct when
made and are true and correct as of the Closing Date; (ii) the Company has performed all covenants and agreements and satisfied
all conditions contained herein; (iii) they have carefully examined the Registration Statement, the Prospectus, the General Disclosure
Package, and any individual Issuer Free Writing Prospectus and, in their opinion (A) as of the Effective Date the Registration
Statement and Prospectus did not include, and as of the Applicable Time, neither (i)&nbsp;the General Disclosure Package, nor
(ii)&nbsp;any individual Issuer Free Writing Prospectus, when considered together with the General Disclosure Package, included
any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they were made, not misleading, and (B) since the Effective
Date, no event has occurred which should have been set forth in a supplement or otherwise required an amendment to the Registration
Statement, the Statutory Prospectus or the Prospectus; (iv) no stop order suspending the effectiveness of the Registration Statement
has been issued and, to their knowledge, no proceedings for that purpose have been instituted or are pending under the Securities
Act and (v) there has not occurred any Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Representative shall have received: (i) simultaneously with the execution of this Agreement, a signed letter from the Auditor
addressed to the Representative and dated the date of this Agreement, in form and substance reasonably satisfactory to the Representative,
containing statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters
with respect to the financial statements and certain financial information contained in the Registration Statement and the General
Disclosure Package, and (ii) on the Closing Date, a signed letter from the Auditor addressed to the Representative and dated the
date of the Closing Date, in form and substance reasonably satisfactory to the Representative containing statements and information
of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to the financial
statements and certain financial information contained in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Representative shall have received on the Closing Date from Lucosky Brookman LLP, counsel for the Company, an opinion and negative
assurance statement, addressed to the Representative and dated the Closing Date, in form and substance reasonably satisfactory
to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
<FONT STYLE="background-color: white">Representative shall have received on the Closing Date from Schmeiser, Olsen &amp; Watts
LLP, intellectual property counsel for the Company, an opinion and written negative assurances statement, addressed to the
Representative and dated the Closing Date, in form and substance satisfactory to the Representative. </FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Representative shall have received on the Closing Date from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the
Representative, a negative assurance statement, addressed to the Representative and dated as of the Closing Date, with respect
to such matters as the Representative may reasonably require, and the Company shall have furnished or provided access to such
counsel of such documents as they request for enabling them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
proceedings taken in connection with the sale of the Securities as herein contemplated shall be reasonably satisfactory in form
and substance to the Representative and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(j) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Representative shall have received copies of the Lock-up Agreements executed by each entity or person listed on Schedule II hereto.
In the event that Oppenheimer &amp; Co. Inc., in its sole discretion, agrees to release or waive any restriction set forth in
a Lock-Up Agreement for an officer or director of the Company, and provides the Company with notice of the impending release or
waiver at least three (3) Business Days before the effective date of such release or waiver (which release or waiver shall be
substantially in the Form found at Exhibit A-1 attached hereto), the Company agrees to announce the impending release or waiver
by a press release substantially in the form of Exhibit A-2 attached hereto through a major news service at least two (2) Business
Days before the effective date of the release or waiver<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Securities shall have been approved for listing and quotation on the Nasdaq Capital Market, subject only to official notice of
issuance, and the Company has taken no action designed to, or likely to have the effect of, delisting the Securities, nor has
the Company received any notification that the Nasdaq Capital Market is contemplating terminating such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Representative shall be reasonably satisfied that since the respective dates as of which information is given in the Registration
Statement, the Statutory Prospectus, the General Disclosure Package and the Prospectus, (i) there shall not have been any material
change in the capital stock of the Company or any material change in the indebtedness (other than in the ordinary course of business)
of the Company, (ii) except as set forth or contemplated by the Registration Statement, the Statutory Prospectus, the General
Disclosure Package or the Prospectus, no material oral or written agreement or other transaction shall have been entered into
by the Company that is not in the ordinary course of business or that could reasonably be expected to result in a material reduction
in the future earnings of the Company, (iii) no loss or damage (whether or not insured) to the property of the Company shall have
been sustained that had or could reasonably be expected to have a Material Adverse Effect, (iv) no legal or governmental action,
suit or proceeding affecting the Company or any of its properties that is material to the Company or that affects or could reasonably
be expected to affect the transactions contemplated by this Agreement shall have been instituted or threatened and (v) there shall
not have been any material change in the assets, properties, condition (financial or otherwise), or in the results of operations,
business affairs or business prospects of the Company or its subsidiaries considered as a whole that makes it impractical or inadvisable
in the Representative&rsquo;s judgment to proceed with the purchase or offering of the Securities as contemplated hereby.</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="color: blue"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(<FONT STYLE="font-size: 10pt">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINRA
shall have confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting
terms and agreements in connection with the offering of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall have furnished or caused to be furnished to the Representative such further certificates or documents as the Representative
shall have reasonably requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agreement, duly executed by each of the Company and the Warrant Agent, substantially in the form of Exhibit B hereto,
shall have been delivered to the Representative on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.
<U>Covenants and other Agreements of the Company and the Underwriters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)
The Company covenants and agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will use its best efforts to cause the Registration Statement, if not effective at the time of execution of this Agreement,
and any amendments thereto, to become effective as promptly as possible. The Company shall prepare the Prospectus in a form approved
by the Representative and file such Prospectus pursuant to Rule 424(b) under the Securities Act not later than the Commission&rsquo;s
close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier
time as may be required by the Rules. The Company will file with the Commission all Issuer Free Writing Prospectuses in the time
and manner required under Rules 433(d) or 163(b)(2), as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall promptly advise the Representative in writing (A) when any post-effective amendment to the Registration Statement
shall have become effective or any supplement to the Prospectus shall have been filed, (B) of any request by the Commission for
any amendment of the Registration Statement or the Prospectus or for any additional information, (C) of the issuance by the Commission
of any stop order suspending the effectiveness of the Registration Statement or of any order preventing or suspending the use
of any preliminary prospectus or any &ldquo;free writing prospectus&rdquo;, as defined in Rule 405 of the Rules, or the institution
or threatening of any proceeding for that purpose and (D) of the receipt by the Company of any notification with respect to the
suspension of the qualification of the Securities for sale in any jurisdiction or the initiation or threatening of any proceeding
for such purpose. The Company shall not file any amendment of the Registration Statement or supplement to the Prospectus or any
Issuer Free Writing Prospectus unless the Company has furnished the Representative a copy for its review and obtained the Representative&rsquo;s
consent (not to be reasonably withheld) prior to filing and shall not file any such proposed amendment or supplement to which
the Representative reasonably objects. The Company shall use its best efforts to prevent the issuance of any such stop order and,
if issued, to obtain as soon as possible the withdrawal thereof.</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any time when a prospectus relating to the Securities (or, in lieu thereof, the notice referred to in Rule 173(a) of the Rules)
is required to be delivered under the Securities Act, any event occurs as a result of which the Prospectus as then amended or
supplemented would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements
therein in the light of the circumstances under which they were made not misleading, or if it shall be necessary to amend or supplement
the Prospectus to comply with the Securities Act or the Rules, the Company promptly shall prepare and file with the Commission,
subject to the second sentence of paragraph (ii) of this Section 4(a), an amendment or supplement which shall correct such statement
or omission or an amendment which shall effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any time following issuance of an Issuer Free Writing Prospectus there occurs an event or development as a result of which
such Issuer Free Writing Prospectus would conflict with the information contained in the Registration Statement or would include
an untrue statement of a material fact or would omit to state a material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances prevailing at the subsequent time, not misleading, the Company
will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus
to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall make generally available to its security holders and to the Representative as soon as practicable, but not later
than forty-five (45) days after the end of the 12-month period beginning at the end of the fiscal quarter of the Company during
which the Effective Date occurs (or ninety (90) days if such 12-month period coincides with the Company&rsquo;s fiscal year),
an earning statement (which need not be audited) of the Company, covering such 12-month period, which shall satisfy the provisions
of Section 11(a) of the Securities Act or Rule 158 of the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall furnish to the Representative and counsel for the Underwriters, without charge, signed copies of the Registration
Statement (including all exhibits thereto and amendments thereof) and to each other Underwriter a copy of the Registration Statement
(without exhibits thereto) and all amendments thereof and, so long as delivery of a prospectus by an Underwriter or dealer may
be required by the Securities Act or the Rules, as many copies of any Preliminary Prospectus, any Issuer Free Writing Prospectus
and the Prospectus and any amendments thereof and supplements thereto as the Representative may reasonably request. If applicable,
the copies of the Registration Statement, Preliminary Prospectus, any Issuer Free Writing Prospectus and Prospectus and each amendment
and supplement thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed
with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall cooperate with the Representative and its counsel in endeavoring to qualify the Securities for offer and sale in
connection with the offering under the laws of such jurisdictions as the Representative may designate and shall maintain such
qualifications in effect so long as required for the distribution of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company, during the period when the Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules) is required
to be delivered under the Securities Act and the Rules or the Exchange Act, will file all reports and other documents required
to be filed with the Commission pursuant to Section 13, 14 or 15 of the Exchange Act within the time periods required by the Exchange
Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
the prior written consent of Oppenheimer &amp; Co. Inc., for a period of one hundred and eighty (180) days after the date of this
Agreement, the Company shall not issue, sell or register with the Commission (other than on Form S-8 or on any successor form),
or otherwise dispose of, directly or indirectly, any equity securities of the Company (or any securities convertible into, exercisable
for or exchangeable for equity securities of the Company), except for the issuance of the Securities pursuant to the Registration
Statement and the issuance of securities pursuant to the Company&rsquo;s existing stock option plan or bonus plan as described
in the Registration Statement and the Prospectus<FONT STYLE="color: #FFC000">. </FONT><FONT STYLE="color: #F79646"> </FONT>In
the event that during this period, (A) any shares are issued pursuant to the Company&rsquo;s existing stock option plan or bonus
plan that are exercisable during such 180-day period or (B) any registration is effected on Form S-8 or on any successor form
relating to shares that are exercisable during such 180-day period, the Company shall obtain the written agreement of such grantee
or purchaser or holder of such registered securities that, for a period of one hundred and eighty (180) days after the date of
this Agreement, such person will not, without the prior written consent of Oppenheimer &amp; Co. Inc., offer for sale, sell, distribute,
grant any option for the sale of, or otherwise dispose of, directly or indirectly, or exercise any registration rights with respect
to, any securities owned by such person. Notwithstanding the foregoing, the Company represents and warrants that each such grantee
or purchaser or holder of such registered securities shall be subject to similar lockup restrictions as set forth on Exhibit A
attached hereto and the Company shall enforce such rights and impose stop-transfer restrictions on any such sale or other transfer
or disposition of such shares until the end of the applicable period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or before completion of this offering, the Company shall make all filings required under applicable securities laws and by the
Nasdaq Capital Market (including any required registration under the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Closing Date, the Company will issue no press release or other communications directly or indirectly and hold no press
conference with respect to the Company, the condition, financial or otherwise, or the earnings, business affairs or business prospects
of any of them, or the offering of the Securities without the prior written consent of the Representative unless in the judgment
of the Company and its counsel, and after notification to the Representative, such press release or communication is required
by law.</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 1.25in; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will apply the net proceeds from the offering of the Securities in the manner set forth under &ldquo;Use of Proceeds&rdquo;
in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will promptly notify the Representative if the Company ceases to be an Emerging Growth Company at any time prior to the
later of (a)&nbsp;completion of the distribution of the Securities within the meaning of the Securities Act and (b)&nbsp;completion
of the 180-day restricted period referred to in Section 4(a)(ix) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development
as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material
fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly
amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement
or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to pay, or reimburse if paid by the Representative, whether or not the transactions contemplated hereby
are consummated or this Agreement is terminated, all costs and expenses incident to the public offering of the Securities and
the performance of the obligations of the Company under this Agreement including those relating to: (i) the preparation, printing,
reproduction filing and distribution of the Registration Statement, including all exhibits thereto, each Preliminary Prospectus,
the Prospectus, any Issuer Free Writing Prospectus, all amendments and supplements thereto, and the printing, filing and distribution
of this Agreement; (ii) the preparation and delivery of certificates for the Securities to the Underwriters, if applicable; (iii)
the registration or qualification of the Securities for offer and sale under the securities or Blue Sky laws of the various jurisdictions
referred to in Section 4(a)(vii), including the reasonable fees and disbursements of counsel for the Underwriters in connection
with such registration and qualification and the preparation, printing, distribution and shipment of preliminary and supplementary
Blue Sky memoranda; (iv) the furnishing (including costs of shipping and mailing) to the Representative and to the Underwriters
of copies of each Preliminary Prospectus, the Prospectus and all amendments or supplements to the Prospectus, any Issuer Free
Writing Prospectus, and of the several documents required by this Section to be so furnished, as may be reasonably requested for
use in connection with the offering and sale of the Securities by the Underwriters or by dealers to whom Securities may be sold;
(v) the filing fees of FINRA in connection with its review of the terms of the public offering and reasonable fees and disbursements
of counsel for the Underwriters in connection with such review; (vi) inclusion of the Securities for quotation on the Nasdaq Capital
Market; (vii) all transfer taxes, if any, with respect to the sale and delivery of the Securities by the Company to the Underwriters;
and (viii) all costs and expenses incident to the offering and the performance of the obligations of the Company under this Agreement,
and all reasonable out-of-pocket costs and expenses incident to the performance of the obligations of the Representative under
this Agreement (including, without limitation, the fees and expenses of Underwriters&rsquo; outside attorneys), provided that
any such out-of-pocket costs and expenses shall not exceed (without the prior consent of the Company which shall not be unreasonably
withheld, conditioned or delayed) $150,000 and; provided, further, that, for purposes of clarity, expenses in excess of an aggregate
of $200,000 will not be reimbursed to the Underwriters. In addition to the payments set forth in this Section, the Company agrees
that, the Company grants to the Representative, for a period of twelve (12) months from the date of this Agreement, the right
of first refusal to act as lead bookrunning underwriter, lead initial purchaser, lead placement agent, or lead selling agent,
as the case may be, on any financing for the Company. In the event the Company advises the Representative that it desires to effect
any such financing, the Representative shall have five (5) business days from such notice to notify the Company that it intends
to exercise its right of first refusal, and the Company and the Representative will negotiate in good faith the terms of the Representative&rsquo;s
engagement in a separate agreement, which agreement would set forth, among other matters, compensation for the Representative
based upon customary fees for the services provided.The Representative&rsquo;s participation in any such financing will be subject
to the approval of the Representative&rsquo;s internal committees and other conditions customary for such an undertaking.</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges and agrees that each of the Underwriters has acted and is acting solely in the capacity of a principal in
an arm&rsquo;s length transaction between the Company, on the one hand, and the Underwriters, on the other hand, with respect
to the offering of Securities contemplated hereby (including in connection with determining the terms of the offering) and not
as a financial advisor, agent or fiduciary to the Company or any other person, and that the Underwriters may have interests that
differ from those of the Company. Additionally, the Company acknowledges and agrees that the Underwriters have not and will not
advise the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction.
The Company has consulted with its own advisors concerning such matters and shall be responsible for making its own independent
investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall have no responsibility or liability
to the Company or any other person with respect thereto, whether arising prior to or after the date hereof. Any review by the
Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions have been and
will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. The Company agrees that
it will not claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary
duty to the company or any other person in connection with any such transaction or the process leading thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 27pt"><FONT STYLE="font-size: 10pt">(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company represents and agrees that, unless it obtains the prior consent of the Representative, and each Underwriter represents
and agrees that, unless it obtains the prior consent of the Company and the Representative, it has not made and will not make
any offer relating to the Securities that would constitute an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433,
or that would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule&nbsp;405, required to be filed
with the Commission. The Company has complied and will comply with the requirements of Rule 433 under the Securities Act applicable
to any Issuer Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping.
The Company represents that it has satisfied and agrees that it will satisfy the conditions set forth in Rule 433 of the Rules
to avoid a requirement to file with the Commission any Road Show.</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 27pt"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall ensure that: (i) the qualifications of the persons serving as board members and the overall composition of the Board
of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and with the listing requirements
of the Trading Market and (ii) if applicable, at least one member of the Board of Directors qualifies as a &ldquo;financial expert&rdquo;
as such term is defined under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company agrees to indemnify and hold harmless each Underwriter, its officers and employees and each person, if any, who controls
any Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all losses,
claims, damages and liabilities, joint or several (including any reasonable investigation, legal and other expenses incurred in
connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted), to which they, or
any of them, may become subject under the Securities Act, the Exchange Act or other federal or state law or regulation, at common
law or otherwise, insofar as such losses, claims, damages or liabilities arise, directly or indirectly, in connection with, out
of or are based upon i) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus,
the Registration Statement, the Statutory Prospectus, the Prospectus, any Issuer Free Writing Prospectus<B> </B>or any &ldquo;issuer-information&rdquo;
filed or required to be filed pursuant to Rule 433(d) of the Rules, any amendment thereof or supplement thereto, any Written Testing-the-Waters
Communication, or in any Blue Sky application or other information or other documents executed by the Company filed in any state
or other jurisdiction to qualify any or all of the Securities under the securities laws thereof (any such application, document
or information being hereinafter referred to as a &ldquo;Blue Sky Application&rdquo;), ii) any omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or iii)
any actual or alleged breach by the Company of any of its obligations, or of any of its representations, warranties and undertakings,
set out in this Agreement; provided, however, that such indemnity shall not inure to the benefit of any Underwriter (or any person
controlling such Underwriter) on account of any losses, claims, damages or liabilities arising from the sale of the Securities
to any person by such Underwriter if such untrue statement or omission or alleged untrue statement or omission was made in such
preliminary prospectus, the Registration Statement, the Prospectus, the Statutory Prospectus, any Issuer Free Writing Prospectus
or such amendment or supplement thereto, any Written Testing-the-Waters Communication, or in any Blue Sky Application in reliance
upon and in conformity with the Underwriter Information, or if any such losses, claims, damages or liabilities have arisen from
(i) the fraud, gross negligence, willful misconduct or bad faith of, or material breach of the Agreement by the person entitled
to indemnification to the extent finally judicially determined by a court of competent jurisdiction or by a regulatory authority
(as appropriate) or (ii) a breach of the duties owed by an person to indemnification under relevant regulatory rules to the extent
finally judicially determined by a court of competent jurisdiction or by a regulatory authority (as appropriate). This indemnity
agreement will be in addition to any liability which the Company may otherwise have.</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, and each person, if any, who controls
the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, each director of the Company,
and each officer of the Company who signs the Registration Statement, against any losses, claims, damages or liabilities to which
such party may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact
contained in any preliminary prospectus, the Registration Statement or the Prospectus, or any amendment or supplement thereto,
or arise, directly or indirectly, in connection with, out of or are based upon the omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the
extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made
in any Preliminary Prospectus, the Registration Statement, the Statutory Prospectus or the Prospectus or any such amendment or
supplement in reliance upon and in conformity with the Underwriter Information; provided, however, that the obligation of each
Underwriter to indemnify the Company (including any controlling person, director or officer thereof) shall be limited to the amount
of the underwriting discount and commissions applicable to the Securities to be purchased by such Underwriter hereunder, and that
that such indemnity shall not inure to the benefit of the Company (or any person controlling such Company) on account of any losses,
claims, damages or liabilities arising from (i) the fraud, gross negligence, willful misconduct or bad faith of, or material breach
of the Agreement by the person entitled to indemnification to the extent finally judicially determined by a court of competent
jurisdiction or by a regulatory authority (as appropriate) or (ii) a breach of the duties owed by an person to indemnification
under relevant regulatory rules to the extent finally judicially determined by a court of competent jurisdiction or by a regulatory
authority (as appropriate).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 27pt"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
party that proposes to assert the right to be indemnified under this Section will, promptly after receipt of notice of commencement
of any action, suit or proceeding against such party in respect of which a claim is to be made against an indemnifying party or
parties under this Section, notify each such indemnifying party of the commencement of such action, suit or proceeding, enclosing
a copy of all papers served. No indemnification provided for in Section 5(a) or 5(b) shall be available to any party who shall
fail to give notice as provided in this Section 5(c) if the party to whom notice was not given was unaware of the proceeding to
which such notice would have related and was prejudiced by the failure to give such notice but the omission so to notify such
indemnifying party of any such action, suit or proceeding shall not relieve it from any liability that it may have to any indemnified
party for contribution or otherwise than under this Section. In case any such action, suit or proceeding shall be brought against
any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be
entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified,
to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying
party to such indemnified party of its election so to assume the defense thereof and the approval by the indemnified party of
such counsel, the indemnifying party shall not be liable to such indemnified party for any legal or other expenses, except as
provided below and except for the reasonable costs of investigation subsequently incurred by such indemnified party in connection
with the defense thereof. The indemnified party shall have the right to employ its counsel in any such action, but the fees and
expenses of such counsel shall be at the expense of such indemnified party unless (i) the employment of counsel by such indemnified
party has been authorized in writing by the indemnifying parties, (ii) the indemnified party shall have been advised by counsel
that there may be one or more legal defenses available to it which are different from or in addition to those available to the
indemnifying party (in which case the indemnifying parties shall not have the right to direct the defense of such action on behalf
of the indemnified party) or (iii) the indemnifying parties shall not have employed counsel to assume the defense of such action
within a reasonable time after notice of the commencement thereof, in each of which cases the fees and expenses of counsel shall
be at the expense of the indemnifying parties. An indemnifying party shall not be liable for any settlement of any action, suit,
and proceeding or claim effected without its written consent, which consent shall not be unreasonably withheld or delayed. No
indemnifying party shall settle any action, suit or proceeding for which indemnification or contribution is or would have been
available hereunder to an indemnified person that was or could have been made party thereto without obtaining a release in favor
of each such indemnified person from all claims brought in or arising from such action, suit or proceeding.</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in Section
5(a) or 5(b) is due in accordance with its terms but for any reason is unavailable to or insufficient to hold harmless an indemnified
party in respect to any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall
contribute to the aggregate losses, liabilities, claims, damages and expenses (including any investigation, legal and other expenses
reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claims asserted,
but after deducting any contribution received by any person entitled hereunder to contribution from any person who may be liable
for contribution) incurred by such indemnified party, as incurred, in such proportion as is appropriate to reflect the relative
benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the Securities pursuant
to this Agreement or, if such allocation is not permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to above but also the relative fault of the Company on the one hand and the Underwriters on
the other hand in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses,
as well as any other relevant equitable considerations. The Company and the Underwriters agree that it would not be just and equitable
if contribution pursuant to this Section 6 were determined by pro rata allocation (even if the Underwriters were treated as one
entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred
to above. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred
to above shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.
Notwithstanding the provisions of this Section 6, no Underwriter (except as may be provided in the Agreement Among Underwriters)
shall be required to contribute any amount in excess of the underwriting discounts and commissions applicable to the Securities
purchased by such Underwriter. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of
this Section 6, each person, if any, who controls an Underwriter within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, including
any person who, with his or her consent, is named in the Registration Statement as about to become a director of the Company,
each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the
meaning of the Section 15 of the Securities Act or Section 20 of the Exchange Act, shall have the same rights to contribution
as the Company. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit
or proceeding against such party in respect of which a claim for contribution may be made against another party or parties under
this Section 6, notify such party or parties from whom contribution may be sought, but the omission so to notify such party or
parties from whom contribution may be sought shall not relieve the party or parties from whom contribution may be sought from
any other obligation it or they may have hereunder or otherwise than under this Section 6. No party shall be liable for contribution
with respect to any action, suit, proceeding or claim settled without its written consent. The Underwriters&rsquo; obligations
to contribute pursuant to this Section 6 are several in proportion to their respective underwriting commitments and not joint.</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement may be terminated with respect to the Securities to be purchased on the Closing Date by the Representative by notifying
the Company at any time at or before the Closing Date in the absolute discretion of the Representative if: (i) there has occurred
any material adverse change in the securities markets or any event, act or occurrence that has materially disrupted, or in the
opinion of the Representative, will in the future materially disrupt, the securities markets or there shall be such a material
adverse change in general financial, political or economic conditions or the effect of international conditions on the financial
markets in the United States is such as to make it, in the judgment of the Representative, inadvisable or impracticable to market
the Securities or enforce contracts for the sale of the Securities; (ii) there has occurred any outbreak or material escalation
of hostilities or acts of terrorism or other calamity or crisis the effect of which on the financial markets of the United States
is such as to make it, in the judgment of the Representative, inadvisable or impracticable to market the Securities or enforce
contracts for the sale of the Securities; (iii) trading in the Securities or any securities of the Company has been suspended
or materially limited by the Commission or trading generally on the New York Stock Exchange, Inc. or the Nasdaq Stock Market has
been suspended or materially limited, or minimum or maximum ranges for prices for securities shall have been fixed, or maximum
ranges for prices for securities have been required, by any of said exchanges or by such system or by order of the Commission,
FINRA, or any other governmental or regulatory authority; (iv) a banking moratorium has been declared by any state or federal
authority; (v) in the judgment of the Representative, there has been, since the time of execution of this Agreement or since the
respective dates as of which information is given in the Prospectus, any material adverse change in the assets, properties, condition,
financial or otherwise, or in the results of operations, business affairs or business prospects of the Company and its subsidiaries
considered as a whole, whether or not arising in the ordinary course of business; (vi) the representations and warranties given
by the Company in this Agreement have ceased to be true and accurate in all material respects; or (vii) there has been a material
breach by the Company of any of the covenants contained in this Agreement.</FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Agreement is terminated pursuant to any of its provisions, the Company shall not be under any liability to any Underwriter,
and no Underwriter shall be under any liability to the Company, except that (y) if this Agreement is terminated by the Representative
or the Underwriters because of any failure, refusal or inability on the part of the Company to comply with the terms or to fulfill
any of the conditions of this Agreement, the Company will reimburse the Underwriters for all out-of-pocket expenses (including
the reasonable fees and disbursements of their counsel) incurred by them in connection with the proposed purchase and sale of
the Securities or in contemplation of performing their obligations hereunder and (z) no Underwriter who shall have failed or refused
to purchase the Securities agreed to be purchased by it under this Agreement, without some reason sufficient hereunder to justify
cancellation or termination of its obligations under this Agreement, shall be relieved of liability to the Company or to the other
Underwriters for damages occasioned by its failure or refusal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Substitution
of Underwriters</U>. If any Underwriter shall default in its obligation to purchase on the Closing Date the Securities agreed
to be purchased hereunder on the Closing Date, the Representative shall have the right, within thirty-six (36) hours thereafter,
to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase such Securities
on the terms contained herein. If, however, the Representative shall not have completed such arrangements within such 36-hour
period, then the Company shall be entitled to a further period of thirty-six (36) hours within which to procure another party
or other parties satisfactory to the Underwriters to purchase such Securities on such terms. If, after giving effect to any arrangements
for the purchase of the Securities of a defaulting Underwriter or Underwriters by the Representative and the Company as provided
above, the aggregate number of Securities which remains unpurchased on the Closing Date does not exceed one-eleventh (1/11) of
the aggregate number of all the Securities that all the Underwriters are obligated to purchase on such date, then the Company
shall have the right to require each non-defaulting Underwriter to purchase the number of Securities which such Underwriter agreed
to purchase hereunder at such date and, in addition, to require each non-defaulting Underwriter to purchase its pro rata share
(based on the number of Securities which such Underwriter agreed to purchase hereunder) of the Securities of such defaulting Underwriter
or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from
liability for its default. In any such case, either the Representative or the Company shall have the right to postpone the Closing
Date for a period of not more than seven (7) days in order to effect any necessary changes and arrangements (including any necessary
amendments or supplements to the Registration Statement or Prospectus or any other documents), and the Company agrees to file
promptly any amendments to the Registration Statement or the Prospectus which in the opinion of the Company and the Underwriters
and their counsel may thereby be made necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">If,
after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the
Representative and the Company as provided above, the aggregate number of such Securities which remains unpurchased exceeds 10%
of the aggregate number of all the Securities to be purchased at such date, then this Agreement shall terminate, without liability
on the part of any non-defaulting Underwriter to the Company, and without liability on the part of the Company, except as provided
in Sections 4(b), 5, 6 and 7. The provisions of this Section 8 shall not in any way affect the liability of any defaulting Underwriter
to the Company or the nondefaulting Underwriters arising out of such default. The term &ldquo;Underwriter&rdquo; as used in this
Agreement shall include any person substituted under this Section 8 with like effect as if such person had originally been a party
to this Agreement with respect to such Securities.</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">9.
<U>Miscellaneous</U>. The respective agreements, representations, warranties, indemnities and other statements of the Company
and the several Underwriters, as set forth in this Agreement or made by or on behalf of them pursuant to this Agreement, shall
remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf
of any Underwriter or the Company or any of their respective officers, directors or controlling persons referred to in Sections
5 and 6 hereof, and shall survive delivery of and payment for the Securities. In addition, the provisions of Sections 4(b), 5,
6 and 7 shall survive the termination or cancellation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">This
Agreement has been and is made for the benefit of the Underwriters, the Company, and their respective successors and assigns,
and, to the extent expressed herein, for the benefit of persons controlling any of the Underwriters, or the Company, and directors
and officers of the Company, and their respective successors and assigns, and no other person shall acquire or have any right
under or by virtue of this Agreement. The term &ldquo;successors and assigns&rdquo; shall not include any purchaser of Securities
from any Underwriter merely because of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">All
notices and communications hereunder shall be in writing and mailed or delivered or by telephone or facsimile if subsequently
confirmed in writing, (a) if to the Representative, c/o Oppenheimer &amp; Co. Inc., 85 Broad Street, New York, New York 10004
Attention: Equity Capital Markets, with a copy to Oppenheimer &amp; Co. Inc., 85 Broad Street, New York, New York 10004 Attention:
General Counsel, and to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 666 Third Avenue, New York, New York 10017, Attention:
Ivan K. Blumenthal, Esq., Facsimile: 212-983-3115,<I> </I>and (b) if to the Company, to its agent for service as such agent&rsquo;s
address appears on the cover page of the Registration Statement, with a copy to Lucosky Brookman LLP, 101 Wood Avenue South, Woodbridge,
New Jersey 08830, Attention: Lawrence Metelitsa, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>This
Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements
made and to be performed in such state. </B> Any legal suit, action or proceeding arising out of or based upon this Agreement
or the transactions contemplated hereby (&ldquo;Related Proceedings&rdquo;) may be instituted in the federal courts of the United
States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case
located in the Borough of Manhattan in the City of New York (collectively, the &ldquo;Specified Courts&rdquo;), and each party
irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment
of any such court (a &ldquo;Related Judgment&rdquo;), as to which such jurisdiction is non-exclusive) of such courts in any such
suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&rsquo;s address set forth
above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably
and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts
and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other
proceeding brought in any such court has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">With
respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity
(whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment)
and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each
party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim
or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without
limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
obligations of the Company pursuant to this Agreement in respect of any sum due to the Underwriters shall, notwithstanding any
judgment in a currency other than United States dollars, not be discharged until the first business day, following receipt by
the Underwriters of any sum adjudged to be so due in such other currency, on which the Underwriters may in accordance with normal
banking procedures purchase United States dollars with such other currency. If the United States dollars so purchased are less
than the sum originally due to the Underwriters in United States dollars hereunder, the Company agrees as a separate obligation
and notwithstanding any such judgment, to indemnify the Underwriters against such loss. If the United States dollars so purchased
are greater than the sum originally due to the Underwriters hereunder, the Underwriters agree to pay to the Company an amount
equal to the excess of the dollars so purchased over the sum originally due to the Underwriters hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">All
payments made or deemed to be made by the Company under this Agreement, if any, will be made without withholding or deduction
for or on account of any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes
on net income) imposed or levied by any jurisdiction from or through which payment is made, or, in each case, any political subdivision
or any taxing authority thereof or therein unless the Company is or becomes required by law to withhold or deduct such taxes,
duties, assessments or other governmental charges. In such event, the Company will pay such additional amounts as will result,
after such withholding or deduction, in the receipt by each Underwriter, its officers and employees, and each person controlling
any Underwriter, as the case may be, of the amounts that would otherwise have been receivable in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>[Remainder
of Page Intentionally Left Blank. Signature Page Follows.]</I></FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">This
Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Please
confirm that the foregoing correctly sets forth the agreement among us.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 50%">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font:10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">MODULAR MEDICAL, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>

</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Confirmed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">OPPENHEIMER &amp; CO. INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">___________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Acting severally on behalf of itself</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">and as representative of the several</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Underwriters named in Schedule I
annexed</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>[Signature
Page to Underwriting Agreement]</I></FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt">SCHEDULE
I</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 79%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 19%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 2%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt"><U>Name</U></FONT></td>
    <TD STYLE="vertical-align: bottom; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt">Number
of</FONT><BR>
<FONT STYLE="font-size: 10pt">Shares and </FONT><BR>
<FONT STYLE="font-size: 10pt">Warrants to</FONT><BR>
<FONT STYLE="font-size: 10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Be Purchased&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P></td>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Oppenheimer
                                         &amp; Co. Inc.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Lake Street Capital Markets,
        LLC</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">The Benchmark Company, LLC</FONT></P></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">Total</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">SCHEDULE II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">Lock-up Signatories</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Paul DiPerna</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Ellen O&rsquo;Connor Vos</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Liam Burns</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">William J. Febbo</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Morgan C. Frank</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Carmen Volkart</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">James Besser</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">JEB Partners, L.P.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Manchester Explorer, L.P.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Manchester Management LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">SCHEDULE III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">Issuer Free Writing
Prospectuses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">[None]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">SCHEDULE IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">Testing-the-Waters
Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">[TO COME]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Exhibit
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">[Form of Lock-Up
Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5in; text-align: right; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Exhibit
A-1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>[Form
of Waiver of Lock-up]</B><BR>
<BR>
<B>[Oppenheimer Letterhead]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt">[corporation]<BR>
Public Offering of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt 3.75in; text-align: right; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">[
], 20[ ]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-size: 10pt">[Name and Address of<BR>
Officer or Director<BR>
Requesting Waiver]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-size: 10pt">Dear Mr./Ms. [Name]:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">This
letter is being delivered to you in connection with the offering by [Corporation] (the &ldquo;Company&rdquo;) of [ ] shares of
common stock, $0.001 par value (the &ldquo;Common Stock&rdquo;) of the Company, and the lock-up agreement dated [ ], 2021 (the
&ldquo;Lock-up Agreement&rdquo;), executed by you in connection with such offering, and your request for a [waiver] [release]
dated [ ], 20[ ], with respect to [ ] shares of Common Stock (the &ldquo;Securities&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Oppenheimer
&amp; Co. Inc. hereby agrees to [waive] [release] the transfer restrictions set forth in the Lock-up Letter, but only with respect
to the Securities, effective [ ], 20[ ][date to be 3 business days from date of letter]; <U>provided</U>, <U>however</U>, that
such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release] by press release through a major
news service at least two (2) business days before effectiveness of such [waiver] [release]. This letter will serve as notice
to the Company of the impending [waiver] [release].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Except
as expressly [waived] [released] hereby, the Lock-up Letter shall remain in full force and effect.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 50%">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Yours very truly,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font:10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">OPPENHEIMER &amp; CO.
INC.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>

</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">cc: [Company
contact]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5in; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5in; text-align: right; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Exhibit
A-2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>[Form
of Lock Up Waiver/Release Company Press Release]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>[Company]</B><BR>
<B>[Date]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">(&ldquo;[Company]&rdquo;)
announced today that Oppenheimer &amp; Co. Inc., the [lead book-running] manager in the Company&rsquo;s recent public sale of
[ ] shares of common stock, is [waiving] [releasing] a lock-up restriction with respect to [ ] shares of the Company&rsquo;s common
stock held by [ ], an [officer/director] of the Company. The [waiver] [release] will take effect on [ ], 20[ ], and the related
shares may be sold on or after such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>This press release is not an offer
for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities
may not be offered or sold in the United States absent registration or an exemption from registration under the United States
Securities Act of 1933, as amended. </B></FONT></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Exhibit
B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Form of Warrant Agreement</FONT></P>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex4_1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML STYLE="font: 10pt Times New Roman, Times, Serif">
<HEAD STYLE="font: 10pt Times New Roman, Times, Serif">
     <TITLE STYLE="font: 10pt Times New Roman, Times, Serif"></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MODULAR
MEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANT
TO PURCHASE COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Warrant No.: ____________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Number of Shares of Common Stock: ____________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Date of Issuance: [___], 2022 (&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Issuance
Date</B></FONT>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Modular
Medical, Inc., a company organized under the laws of Nevada (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Company</B></FONT>&rdquo;),
hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ____________,
the registered holder hereof or its permitted assigns (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Holder</B></FONT>&rdquo;),
is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect,
at any time or times on or after [___] (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Initial Exercisability
Date</B></FONT>&rdquo;), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ____________ (____________)
fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Warrant
Shares</B></FONT>&rdquo;). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including
any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Warrant</B></FONT>&rdquo;),
shall have the meanings set forth in Section 17. This Warrant shall initially be issued and maintained in the form of a security held
in book-entry form and the Depository Trust Company or its nominee (&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DTC</B></FONT>&rdquo;)
shall initially be the sole registered holder of this Warrant, subject to a Beneficial Owner&rsquo;s right to elect to receive a Warrant
in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply. The Company
and the Warrant Agent may deem and treat the registered Holder of this Warrant, or, if the Warrant is held in book-entry form, the Beneficial
Owner, as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes,
absent actual notice to the contrary. This Warrant is one of the Warrants to Purchase Common Stock (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Warrants</B></FONT>&rdquo;)
issued pursuant to (i) that certain Underwriting Agreement, dated as of [___], 2022 (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Subscription
Date</B></FONT>&rdquo;) by and between the Company and Oppenheimer &amp; Co. Inc., as representative of the several underwriters named
therein, (ii) the Company&rsquo;s Registration Statement on Form S-1 (File number 333-260682) (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
Statement</B></FONT>&rdquo;) and (iii) the Company&rsquo;s prospectus dated as of [___], 2022.</FONT></P>
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>EXERCISE OF WARRANT</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Mechanics of Exercise</U></FONT>. Subject to the terms and conditions hereof
(including, without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by the Holder at any time or
times on or after the Initial Exercisability Date, in whole or in part, by delivery (whether via facsimile, electronic mail or otherwise)
of a written notice, in the form attached hereto as <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exhibit A</U></FONT>
(the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exercise Notice</B></FONT>&rdquo;), of the Holder&rsquo;s election
to exercise this Warrant. Within one (1) Trading Day following the delivery of the Exercise Notice, the Holder shall make payment to
the Company of an amount equal to the Exercise Price in effect on the date of such exercise multiplied by the number of Warrant Shares
as to which this Warrant is being exercised (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Aggregate Exercise
Price</B></FONT>&rdquo;) in cash by wire transfer of immediately available funds or, if the provisions of Section 1(d) are applicable,
by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)). The Holder
shall not be required to deliver the original Warrant in order to effect an exercise hereunder, nor shall any ink-original signature
or medallion guarantee (or other type of guarantee or notarization) with respect to any Exercise Notice be required. Execution and delivery
of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original
Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares and the Holder shall not
be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder
and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within
five (5) Trading Days of the date on which the final Exercise Notice is delivered to the Company. On or before the first (1st) Trading
Day following the date on which the Holder has delivered the applicable Exercise Notice, the Company shall transmit by facsimile or electronic
mail an acknowledgment of confirmation of receipt of the Exercise Notice, in the form attached to the Exercise Notice, to the Holder
and the Transfer Agent. So long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise, if applicable)
on or prior to the first (1st) Trading Day following the date on which the Exercise Notice has been delivered to the Company, then on
or prior to the earlier of (i) the second (2<FONT STYLE="font-family: Times New Roman, Times, Serif">nd</FONT>) Trading Day and (ii)
the number of Trading Days comprising the Standard Settlement Period, in each case following the date on which the Exercise Notice has
been delivered to the Company, or, if the Holder does not deliver the Aggregate Exercise Price (or notice of a Cashless Exercise, if
applicable) on or prior to the first (1st) Trading Day following the date on which the Exercise Notice has been delivered to the Company,
then on or prior to the first (1st) Trading Day following the date on which the Aggregate Exercise Price (or notice of a Cashless Exercise)
is delivered (such earlier date, or if later, the earliest day on which the Company is required to deliver Warrant Shares pursuant to
this Section 1(a), the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share Delivery Date</B></FONT>&rdquo;), the
Company shall (X) provided that the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program (&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FAST</B></FONT>&rdquo;),
credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder&rsquo;s or its
designee&rsquo;s balance account with DTC through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating
in FAST, issue and dispatch by overnight courier to the physical address or email address as specified in the Exercise Notice, a certificate
or evidence of a credit of book-entry shares, registered in the name of the Holder or its designee, for the number of Warrant Shares
to which the Holder is entitled pursuant to such exercise. The Company shall be responsible for all fees and expenses of the Transfer
Agent and all fees and expenses with respect to the issuance of Warrant Shares via DTC, if any, including without limitation for same
day processing. Upon delivery of the Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder
of record and beneficial owner of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date
such Warrant Shares are credited to the Holder&rsquo;s DTC account or the date of delivery of the certificates evidencing such Warrant
Shares, as the case may be. If this Warrant is physically delivered to the Company in connection with any exercise pursuant to this Section
1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares
being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three (3) Trading Days after
any exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section 7(d))
representing the right to purchase the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less
the number of Warrant Shares with respect to which this Warrant is exercised. No fractional Warrant Shares are to be issued upon the
exercise of this Warrant, but rather the number of Warrant Shares to be issued shall be rounded down to the nearest whole number. The
Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and
expenses of the Transfer Agent) which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this
Warrant. The Company&rsquo;s obligations to issue and deliver Warrant Shares in accordance with the terms and subject to the conditions
hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent
with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff,
counterclaim, recoupment, limitation or termination; <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided, however</U></FONT>,
that the Company shall not be required to deliver Warrant Shares with respect to an exercise prior to the Holder&rsquo;s delivery of
the Aggregate Exercise Price (or notice of a Cashless Exercise) with respect to such exercise. Notwithstanding the foregoing, a Beneficial
Owner shall effect exercises made pursuant to this Section 1(a) by delivering to DTC (or such other clearing corporation, as applicable)
the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other
clearing corporation, as applicable), subject to such Beneficial Owner&rsquo;s right to elect to receive a Warrant in certificated form
pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exercise Price</U></FONT>. For purposes of this Warrant, &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exercise
Price</B></FONT>&rdquo; means $[____] per share, subject to adjustment as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Company&rsquo;s Failure to Timely Deliver Securities</U></FONT>. If either
(I) the Company shall fail for any reason or for no reason to issue to the Holder on or prior to the applicable Share Delivery Date,
if (x) the Transfer Agent is not participating in FAST, a certificate or evidence of a book-entry credit for the number of shares of
Common Stock to which the Holder is entitled and register such Common Stock on the Company&rsquo;s share register or (y) the Transfer
Agent is participating in FAST, to credit the Holder&rsquo;s balance account with DTC, for such number of shares of Common Stock to which
the Holder is entitled upon the Holder&rsquo;s exercise of this Warrant or (II) a registration statement (which may be the Registration
Statement) covering the issuance or resale of the Warrant Shares that are the subject of the Exercise Notice (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exercise
Notice Warrant Share</B></FONT>s&rdquo;) is not available for the issuance or resale, as applicable, of such Exercise Notice Warrant
Shares and (x) the Company fails to promptly, but in no event later than one (1) Business Day after such registration statement becomes
unavailable, to so notify the Holder and (y) the Company is unable to deliver the Exercise Notice Warrant Shares electronically without
any restrictive legend by crediting such aggregate number of Exercise Notice Warrant Shares to the Holder&rsquo;s or its designee&rsquo;s
balance account with DTC through its Deposit / Withdrawal At Custodian system (the event described in the immediately foregoing clause
(II) is hereinafter referred as a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Notice Failure</B></FONT>&rdquo;
and together with the event described in clause (I) above, an &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exercise
Failure</B></FONT>&rdquo;), then, in addition to all other remedies available to the Holder, if on or prior to the applicable Share Delivery
Date either (I) if the Transfer Agent is not participating in FAST, the Company shall fail to issue and deliver a certificate or evidence
of a book-entry credit to the Holder and register such shares of Common Stock on the Company&rsquo;s share register or, if the Transfer
Agent is participating in FAST, credit the Holder&rsquo;s balance account with DTC for the number of shares of Common Stock to which
the Holder is entitled upon the Holder&rsquo;s exercise hereunder or pursuant to the Company&rsquo;s obligation pursuant to clause (ii)
below or (II) if a Notice Failure occurs, and if after such date the Holder is required by its broker to purchase (in an open market
transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Buy-In</B></FONT>&rdquo;),
then the Company shall, within three (3) Trading Days after the Holder&rsquo;s request, (A) pay in cash to the Holder the amount, if
any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so
purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to
the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)
of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. The Company&rsquo;s current
transfer agent participates in FAST. In the event that the Company changes transfer agents while this Warrant is outstanding, the Company
shall select a transfer agent that participates in FAST. While this Warrant is outstanding, the Company shall cause its transfer agent
to participate in FAST with respect to this Warrant. In addition to the foregoing rights, (i) if the Company fails to deliver the applicable
number of Warrant Shares upon an exercise pursuant to Section 1 by the applicable Share Delivery Date, then the Holder shall have the
right to rescind such exercise in whole or in part and retain and/or have the Company return, as the case may be, any portion of this
Warrant that has not been exercised pursuant to such Exercise Notice; provided that the rescission of an exercise shall not affect the
Company&rsquo;s obligation to make any payments that have accrued prior to the date of such notice pursuant to this Section 1(c) or otherwise,
and (ii) if a registration statement (which may be the Registration Statement) covering the issuance or resale of the Warrant Shares
that are subject to an Exercise Notice is not available for the issuance or resale, as applicable, of such Exercise Notice Warrant Shares
and the Holder has submitted an Exercise Notice prior to receiving notice of the non-availability of such registration statement and
the Company has not already delivered the Warrant Shares underlying such Exercise Notice electronically without any restrictive legend
by crediting such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder&rsquo;s
or its designee&rsquo;s balance account with DTC through its Deposit / Withdrawal At Custodian system, the Holder shall have the option,
by delivery of notice to the Company, to (x) rescind such Exercise Notice in whole or in part and retain or have returned, as the case
may be, any portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that the rescission of an
Exercise Notice shall not affect the Company&rsquo;s obligation to make any payments that have accrued prior to the date of such notice
pursuant to this Section 1(c) or otherwise, and/or (y) switch some or all of such Exercise Notice from a cash exercise to a Cashless
Exercise. In addition to the foregoing, if the Company fails for any reason to deliver to the Holder the Warrant Shares subject to an
Exercise Notice by the second Trading Day following the Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the Weighted Average Price of the
Common Stock on the date of the applicable Exercise Notice), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading
Day after the Share Delivery Date) for each Trading Day after the second Trading Day following such Share Delivery Date until such Warrant
Shares are delivered or Holder rescinds such exercise.</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Cashless Exercise</U></FONT>. Notwithstanding anything contained herein to
the contrary, if a registration statement (which may be the Registration Statement) covering the issuance or resale of the Exercise Notice
Warrant Shares is not available for the issuance or resale, as applicable, of such Exercise Notice Warrant Shares, the Holder may, in
its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made
to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the &ldquo;Net
Number&rdquo; of shares of Common Stock determined according to the following formula (a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cashless
Exercise</B></FONT>&rdquo;):</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1pt 1.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1.75pt 1.25pt; text-align: right"><FONT STYLE="font-size: 10pt">Net
    Number =</FONT>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1.75pt 1.25pt; text-align: center"><FONT STYLE="font-size: 10pt">(A
    x B) - (A x C)</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1pt 1.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1pt 1.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1pt 1.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1pt 1.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 2pt 1.25pt 1.75pt; text-align: center"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1pt 1.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 1pt 1.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.25pt; padding-left: 1.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.25pt; padding-left: 1.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.25pt; padding-left: 1.25pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.25pt; padding-left: 1.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.25pt; padding-left: 1.25pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">For
purposes of the foregoing formula:</FONT></P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-left: 17.3pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A = the total number of shares with respect to which this Warrant is then being exercised.</FONT> <FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;
</FONT></P>

<P STYLE="margin-left: 17.3pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">B = as applicable: (i) the Weighted Average Price of the Common Stock on the Trading Day immediately preceding the date of the applicable Exercise Notice if such Exercise Notice is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the Weighted Average Price on the Trading Day immediately preceding the date of the applicable Exercise Notice or (z) the Bid Price of the Common Stock as of the time of the Holder&rsquo;s execution of the applicable Exercise Notice if such Exercise Notice is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 1(a) hereof or (iii) the Weighted Average Price of the Common Stock on the date of the applicable Exercise Notice if the date of such Exercise Notice is a Trading Day and such Exercise Notice is both executed and delivered pursuant to Section 1(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day.</FONT> <FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;
</FONT></P>

<P STYLE="margin-left: 17.3pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">C = the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the Company acknowledges and agrees that in accordance with Section 3(a)(9) of
the Securities Act of 1933, as amended, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised,
and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees
not to take any position contrary to this Section 1(d). Without limiting the rights of a Holder to receive Warrant Shares on a &ldquo;cashless
exercise,&rdquo; and to receive the cash payments contemplated pursuant to Sections 1(c) and 4(b), in no event will the Company be required
to net cash settle a Warrant exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Disputes</U></FONT>. In the case of a dispute as to the determination of
the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of
Warrant Shares that are not disputed and resolve such dispute in accordance with Section 11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f) <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Beneficial
Ownership</U></FONT>. Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of
any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the
terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent
that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would
beneficially own in excess of 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) (the
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Maximum Percentage</B></FONT>&rdquo;) of the number
of shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing
sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties
shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of
shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (A) exercise of the
remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and
(B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including,
without limitation, any convertible notes or convertible preferred stock or warrants, including the other Warrants)
beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise
analogous to the limitation contained in this Section 1(f). For purposes of this Section 1(f), beneficial ownership shall be
calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1934
Act</B></FONT>&rdquo;). For purposes of this Warrant, in determining the number of outstanding shares of Common Stock the
Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the
number of outstanding shares of Common Stock as reflected in (x) the Company&rsquo;s most recent Annual Report on Form 10-K,
Quarterly Report on Form 10-Q and Current Reports on Form 8-K or other public filing with the Securities and Exchange
Commission (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SEC</B></FONT>&rdquo;), as the case may
be, (y) a more recent public announcement by the Company or (z) any other written notice by the Company or the Transfer Agent
setting forth the number of shares of Common Stock outstanding (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Reported
Outstanding Share Number</B></FONT>&rdquo;). If the Company receives an Exercise Notice from the Holder at a time when the
actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i)
notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise
Notice would otherwise cause the Holder&rsquo;s beneficial ownership, as determined pursuant to this Section 1(f), to exceed
the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to
such Exercise Notice (the number of shares by which such purchase is reduced, the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Reduction
Shares</B></FONT>&rdquo;) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise
price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of the
Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail to the Holder the
number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the
event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other
Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of
outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by
which the Holder&rsquo;s and the other Attribution Parties&rsquo; aggregate beneficial ownership exceeds the Maximum
Percentage (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Excess Shares</B></FONT>&rdquo;) shall be
deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the
Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the
Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a
written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other
percentage not in excess of 9.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage
will not be effective until the sixty-first (61<FONT STYLE="font-family: Times New Roman, Times, Serif">st</FONT>) day after
such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the other
Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of
clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall
not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule
16a-1(a)(1) of the 1934 Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on
the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the
terms of this Section 1(f) to the extent necessary to correct this paragraph or any portion of this paragraph which may be
defective or inconsistent with the intended beneficial ownership limitation contained in this Section 1(f) or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph
may not be waived and shall apply to a successor holder of this Warrant.</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Required Reserve Amount</U></FONT>. So long as this Warrant remains outstanding,
the Company shall at all times keep reserved for issuance under this Warrant a number of shares of Common Stock at least equal to 100%
of the maximum number of shares of Common Stock as shall be necessary to satisfy the Company&rsquo;s obligation to issue shares of Common
Stock under the Warrants then outstanding (without regard to any limitations on exercise) (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Required
Reserve Amount</B></FONT>&rdquo;); <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided</U></FONT> that at no time shall
the number of shares of Common Stock reserved pursuant to this Section 1(g) be reduced other than in connection with any exercise of
Warrants or such other event covered by Section 2(c) below. The Required Reserve Amount (including, without limitation, each increase
in the number of shares so reserved) shall be allocated pro rata among the holders of the Warrants based on the number of shares of Common
Stock issuable upon exercise of Warrants held by each holder thereof on the Issuance Date (without regard to any limitations on exercise)
(the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Authorized Share Allocation</B></FONT>&rdquo;). In the event
that a holder shall sell or otherwise transfer any of such holder&rsquo;s Warrants, each transferee shall be allocated a pro rata portion
of such holder&rsquo;s Authorized Share Allocation. Any shares of Common Stock reserved and allocated to any Person which ceases to hold
any Warrants shall be allocated to the remaining holders of Warrants, pro rata based on the number of shares of Common Stock issuable
upon exercise of the Warrants then held by such holders thereof (without regard to any limitations on exercise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Insufficient Authorized Shares</U></FONT>. If at any time while this Warrant
remains outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its
obligation to reserve for issuance the Required Reserve Amount (an &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Authorized
Share Failure</B></FONT>&rdquo;), then the Company shall promptly take all action reasonably necessary to increase the Company&rsquo;s
authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant
then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence
of an Authorized Share Failure, but in no event later than ninety (90) days after the occurrence of such Authorized Share Failure, the
Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock.
In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its reasonable best
efforts to solicit its stockholders&rsquo; approval of such increase in authorized shares of Common Stock and to cause its board of directors
to recommend to the stockholders that they approve such proposal. Notwithstanding the foregoing, if at any such time of an Authorized
Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding shares of
Common Stock to approve the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining
such consent and submitting for filing with the SEC an Information Statement on Schedule 14C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES</U></FONT>. The
Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Intentionally omitted</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Voluntary Adjustment By Company</U></FONT>. The Company may at any time during
the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board
of Directors of the Company.</FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Adjustment Upon Subdivision or Combination of Common Stock</U></FONT>. If
the Company at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, recapitalization or otherwise)
one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately
prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the
Company at any time on or after the Subscription Date combines (by combination, reverse stock split or otherwise) one or more classes
of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination
will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section
2(c) shall become effective at the close of business on the date the subdivision or combination becomes effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>RIGHTS UPON DISTRIBUTION OF ASSETS</U></FONT>. In addition to any adjustments
pursuant to Section 2 above, if, on or after the Subscription Date and on or prior to the Expiration Date, the Company shall declare
or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way
of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property, options,
evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement
or other similar transaction) (a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Distribution</B></FONT>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without
limitation, the Maximum Percentage) immediately before the date on which a record is taken for such Distribution, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(provided, however, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution
to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and
beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage,
at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution
or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).</FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>PURCHASE RIGHTS; FUNDAMENTAL TRANSACTION</U></FONT><U>S</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Purchase Right</U></FONT><U>s</U>. In addition to any adjustments
pursuant to Section 2 above, if at any time on or after the Subscription Date and on or prior to the Expiration Date the Company
grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of Common Stock (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Purchase
Rights</B></FONT>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the
aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including
without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or
sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be
determined for the grant, issuance or sale of such Purchase Rights (<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided,
however</U></FONT>, that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in
the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such Common Stock as a result of such
Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall be held in abeyance for
the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution
Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right
granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance) to
the same extent as if there had been no such limitation).</FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Fundamental Transaction</U></FONT>. The Company shall not enter into or be
party to a Fundamental Transaction unless the Successor Entity assumes in writing all of the obligations of the Company under this Warrant
in accordance with the provisions of this Section 4(b), including agreements to deliver to the Holder in exchange for this Warrant a
security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including,
without limitation, which is exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock
acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to
such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but
taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares
of capital stock, such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the consummation of each
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of
the applicable Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation
of each Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise
of this Warrant at any time after the consummation of the applicable Fundamental Transaction, in lieu of the shares of Common Stock (or
other securities, cash, assets or other property (except such items still issuable under Sections 3 and 4(a) above, which shall continue
to be receivable thereafter)) issuable upon the exercise of this Warrant prior to the applicable Fundamental Transaction, such shares
of common stock (or its equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to
receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable
Fundamental Transaction (without regard to any limitations on the exercise of this Warrant), as adjusted in accordance with the provisions
of this Warrant. Notwithstanding the foregoing, and without limiting Section 1(f) hereof, the Holder may elect, at its sole option, by
delivery of written notice to the Company to waive this Section 4(b) to permit the Fundamental Transaction without the assumption of
this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of each Fundamental Transaction
pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange
for shares of Common Stock (a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate Event</B></FONT>&rdquo;),
the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of
this Warrant at any time after the consummation of the applicable Fundamental Transaction but prior to the Expiration Date, in lieu of
the shares of the Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections
3 and 4(a) above, which shall continue to be receivable thereafter)) issuable upon the exercise of the Warrant prior to such Fundamental
Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or
subscription rights) (collectively, the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate Event Consideration</B></FONT>&rdquo;)
which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been
exercised immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant).
The provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Requisite Holders.
The provisions of this Section 4(b) shall apply similarly and equally to successive Fundamental Transactions and Corporate Events. Notwithstanding
the foregoing, in the event of a Change of Control, at the request of the Holder delivered before the 30th day after such Change of Control,
the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Business Days
after such request (or, if later, on the effective date of the Change of Control), an amount equal to the Black Scholes Value of the
remaining unexercised portion of this Warrant on the effective date of such Change of Control, payable in cash; provided, however, that,
if the Change of Control is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors,
Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Change of Control,
the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant,
that is being offered and paid to the holders of Common Stock of the Company in connection with the Change of Control, whether that consideration
be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from
among alternative forms of consideration in connection with the Change of Control; provided, further, that if holders of Common Stock
are not offered or paid any consideration in such Change of Control, such holders of Common Stock will be deemed to have received common
stock of the Successor Entity (which entity may be the Company following such Change of Control) in such Change of Control.</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>NONCIRCUMVENTION</U></FONT>. The Company hereby covenants and agrees that
the Company will not, by amendment of its Certificate of Incorporation or Bylaws, or through any reorganization, transfer of assets,
consolidation, merger, scheme of arrangement, dissolution, issuance or sale of securities, or any other voluntary action, avoid or seek
to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all of the
provisions of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality
of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this
Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii)
shall, so long as any of the Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized
and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the Warrants, the number of shares of Common
Stock as shall from time to time be necessary to effect the exercise of the Warrants then outstanding (without regard to any limitations
on exercise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>WARRANT HOLDER NOT DEEMED A STOCKHOLDER</U></FONT>. Except as otherwise specifically
provided herein, the Holder, solely in such Person&rsquo;s capacity as a holder of this Warrant, shall not be entitled to vote or receive
dividends or be deemed the holder of capital stock of the Company for any purpose, nor shall anything contained in this Warrant be construed
to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder of this Warrant, any of the rights of a stockholder of
the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification
of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise,
prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this
Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any
securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by
the Company or by creditors of the Company. Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same
notices and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>REISSUANCE OF WARRANTS</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Transfer of Warrant</U></FONT>. If this Warrant is to be transferred, the
Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder
a new Warrant (in accordance with Section 7(d)), registered as the Holder may request, representing the right to purchase the number
of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is
being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant
Shares not being transferred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Lost, Stolen or Mutilated Warrant</U></FONT>. Upon receipt by the Company
of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of
loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form (but without the obligation
to post a bond) and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver
to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying this
Warrant.</FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exchangeable for Multiple Warrants</U></FONT>. This Warrant is exchangeable,
upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section
7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new
Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Issuance of New Warrants</U></FONT>. Whenever the Company is required to
issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall
represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in
the case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when
added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed
the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant
which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>NOTICES</U></FONT>. Whenever notice is required to be given under this Warrant,
including, without limitation, an Exercise Notice, unless otherwise provided herein, such notice shall be given in writing, (i) if delivered
(a) from within the domestic United States, by first-class registered or certified airmail, or nationally recognized overnight express
courier, postage prepaid, electronic mail or by facsimile or (b) from outside the United States, by International Federal Express, electronic
mail or facsimile, and (ii) will be deemed given (A) if delivered by first-class registered or certified mail domestic, three (3) Business
Days after so mailed, (B) if delivered by nationally recognized overnight carrier, one (1) Business Day after so mailed, (C) if delivered
by International Federal Express, two (2) Business Days after so mailed and (D) at the time of transmission, if delivered by electronic
mail to each of the email addresses specified in this Section 8 prior to 5:00 p.m. (New York time) on a Trading Day and (E) the next
Trading Day after the date of transmission, if delivered by electronic mail to each of the email addresses specified in this Section
8 on a day that is not a Trading Day or later than 5:00 p.m. (New York time) on any Trading Day, and will be delivered and addressed
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in; border-left-width: 0in; border-left-color: Black"><FONT STYLE="font-size: 10pt">(i)
if to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.45in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">Modular Medical,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1.45in; text-align: left"><FONT STYLE="font-size: 10pt">16772 W. Bernardo
Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1.45in; text-align: left"><FONT STYLE="font-size: 10pt">San Diego, CA,
92127</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1.45in; text-align: left"><FONT STYLE="font-size: 10pt">Attention: <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: yellow">[
]</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 1.45in; text-align: left"><FONT STYLE="font-size: 10pt">Email: <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: yellow">[
]</FONT></FONT></P>



<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in; border-left-width: 0in; border-left-color: Black"><FONT STYLE="font-size: 10pt">(ii)
if to the Holder, at such address or other contact information delivered by the Holder to the Company or as is on the books and records
of the Company<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail
a description of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written
notice to the Holder (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the
calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a
record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or
sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares
of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation; provided
in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the
Holder. It is expressly understood and agreed that the time of exercise specified by the Holder in each Exercise Notice shall be definitive
and may not be disputed or challenged by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>AMENDMENT AND WAIVER</U></FONT>. Except as otherwise provided herein or as
permitted by the Warrant Agency Agreement, the provisions of this Warrant may be amended or waived and the Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent
of the Holder or Beneficial Owner, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>GOVERNING LAW; JURISDICTION; JURY TRIAL</U></FONT>. This Warrant shall be
governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and
performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of
law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
The Company hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to the Company at the address set forth in Section 8(i) above or such other address as the Company subsequently
delivers to the Holder and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein
shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction
to collect on the Company&rsquo;s obligations to the Holder, to realize on any collateral or any other security for such obligations,
or to enforce a judgment or other court ruling in favor of the Holder. If either party shall commence an action, suit or proceeding to
enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party
for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding. <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT
OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B></FONT></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">11.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>DISPUTE RESOLUTION</U></FONT>. In the case of a dispute as to the determination
of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic
calculations via facsimile or electronic mail within two (2) Business Days of receipt of the Exercise Notice or other event giving rise
to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or calculation
of the Exercise Price or the Warrant Shares within three (3) Business Days of such disputed determination or arithmetic calculation being
submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile or electronic mail (a) the disputed
determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or
(b) the disputed arithmetic calculation of the Warrant Shares to the Company&rsquo;s independent, outside accountant. The Company shall
cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify
the Company and the Holder of the results no later than ten (10) Business Days from the time it receives the disputed determinations
or calculations. Such investment bank&rsquo;s or accountant&rsquo;s determination or calculation, as the case may be, shall be binding
upon all parties absent demonstrable error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">12.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</U></FONT>. The
remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and any other
Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein
shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.
The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy
at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach,
the Holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without
the necessity of showing economic loss and without any bond or other security being required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>TRANSFER</U></FONT>. This Warrant and the Warrant Shares may be offered for
sale, sold, transferred, pledged or assigned without the consent of the Company.</FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">14.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>SEVERABILITY; CONSTRUCTION; HEADINGS</U></FONT>. If any provision of this
Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision
that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be
valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions
of this Warrant so long as this Warrant as so modified continues to express, without material change, the original intentions of the
parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does
not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits
that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid
or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid
or unenforceable provision(s). This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed
against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or
affect the interpretation of, this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">15.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>DISCLOSURE</U></FONT>. Upon receipt or delivery by the Company of any notice
in accordance with the terms of this Warrant, unless the Company has in good faith determined that the matters relating to such notice
do not constitute material, nonpublic information relating to the Company or its subsidiaries, the Company shall contemporaneously with
any such receipt or delivery publicly disclose such material, nonpublic information on a Current Report on Form 8-K or otherwise. In
the event that the Company believes that a notice contains material, nonpublic information relating to the Company or its subsidiaries,
the Company so shall indicate to such Holder contemporaneously with delivery of such notice, and in the absence of any such indication,
the Holder shall be allowed to presume that all matters relating to such notice do not constitute material, nonpublic information relating
to the Company or its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>WARRANT AGENCY AGREEMENT</U></FONT>. If this Warrant is held in global form
through DTC (or any successor depositary), this Warrant is issued subject to the Warrant Agency Agreement. To the extent any provision
of this Warrant conflicts with the express provisions of the Warrant Agency Agreement, the provisions of this Warrant shall govern and
be controlling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>CERTAIN
DEFINITIONS</U></FONT>. For purposes of this Warrant, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Affiliate</B></FONT>&rdquo; means, with respect to any Person, any
other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood
for purposes of this definition that &ldquo;control&rdquo; of a Person means the power directly or indirectly either to vote 10% or more
of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management
and policies of such Person whether by contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Attribution Parties</B></FONT>&rdquo; means, collectively, the following
Persons and entities: (i) any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to
time after the Subscription Date, directly or indirectly managed or advised by the Holder&rsquo;s investment manager or any of its Affiliates
or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be
deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial ownership
of the Company&rsquo;s Common Stock would or could be aggregated with the Holder&rsquo;s and the other Attribution Parties for purposes
of Section 13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution
Parties to the Maximum Percentage.</FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Beneficial Owner</B></FONT>&rdquo; means a Person whose interest in
this Warrant is a beneficial interest in certificate(s) representing this Warrant held in book-entry form through DTC (or another established
clearing corporation performing similar functions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Bid Price</B></FONT>&rdquo; means, for any security as of the particular
time of determination, the bid price for such security on the Principal Market as reported by Bloomberg as of such time of determination,
or, if the Principal Market is not the principal securities exchange or trading market for such security, the bid price of such security
on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg as of such time
of determination, or if the foregoing does not apply, the bid price of such security in the over-the-counter market on the electronic
bulletin board for such security as reported by Bloomberg as of such time of determination, or, if no bid price is reported for such
security by Bloomberg as of such time of determination, the average of the bid prices of any market makers for such security as reported
in the OTC Link or the Pink Open Market as of such time of determination. If the Bid Price cannot be calculated for a security as of
the particular time of determination on any of the foregoing bases, the Bid Price of such security as of such time of determination shall
be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon
the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section 11. All such
determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during
such period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
<FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Black Scholes Value</B>&rdquo;</FONT> means the value of this
Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as
of the day immediately following the first public announcement of the applicable Change of Control, or, if the Change of Control
is not publicly announced, the date the Change of Control is consummated, for pricing purposes and reflecting (i) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date
of request, (ii) an expected volatility equal to 100% (iii) the underlying price per share used in such calculation shall be the
greater of (a) the highest Weighted Average Price during the five (5) Trading Days prior to the closing of the Change of Control
and (b) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being
offered in such Change of Control, (iv) a zero cost of borrow and (v) a 360 day annualization factor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Bloomberg</B></FONT>&rdquo; means Bloomberg Financial Markets.</FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Business Day</B></FONT>&rdquo; means any day other than Saturday,
Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Change of Control</B></FONT>&rdquo; means any Fundamental
Transaction other than (i) any reorganization, recapitalization or reclassification of the Common Stock in which holders of
the Company&rsquo;s voting power immediately prior to such reorganization, recapitalization or reclassification continue
after such reorganization, recapitalization or reclassification to hold publicly traded securities and, directly or
indirectly, are, in all material respect, the holders of the voting power of the surviving entity (or entities with the
authority or voting power to elect the members of the board of directors (or their equivalent if other than a corporation) of
such entity or entities) after such reorganization, recapitalization or reclassification, (ii) pursuant to a migratory merger
effected solely for the purpose of changing the jurisdiction of incorporation of the Company or (iii) a merger in connection
with a bona fide acquisition by the Company of any Person in which (x) the gross consideration paid, directly or indirectly,
by the Company in such acquisition is not greater than 20% of the Company&rsquo;s market capitalization as calculated on the
date of the consummation of such merger and (y) such merger does not contemplate a change to the identity of a majority of
the board of directors of the Company. Notwithstanding anything herein to the contrary, any transaction or series of
transaction that, directly or indirectly, results in the Company or the Successor Entity not having Common Stock or common
stock, as applicable, registered under the 1934 Act and listed on an Eligible Market shall be deemed a Change of
Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Closing Bid Price</B></FONT>&rdquo; means, for any security as of
any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported
by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or
the closing trade price, as the case may be, then the last bid price or the last trade price, respectively, of such security prior to
4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading
market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities
exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last
closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board
for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security
by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the
OTC Link or the Pink Open Market. If the Closing Bid Price cannot be calculated for a security on a particular date on any of the foregoing
bases, the Closing Bid Price of such security on such date shall be the fair market value as mutually determined by the Company and the
Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved
pursuant to Section 11. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination,
reclassification or other similar transaction during the applicable calculation period.</FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common Stock</B></FONT>&rdquo; means (i) the Company&rsquo;s Common
Stock, par value $0.001 per share, and (ii) any capital stock into which such Common Stock shall have been changed or any capital stock
resulting from a reclassification of such Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Convertible Securities</B></FONT>&rdquo; means any stock or securities
(other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Eligible Market</B></FONT>&rdquo; means The Nasdaq Capital Market,
the NYSE American LLC, The Nasdaq Global Select Market, The Nasdaq Global Market or The New York Stock Exchange, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Expiration Date</B></FONT>&rdquo; means the date sixty (60) months
after the Initial Exercisability Date or, if such date falls on a day other than a Business Day or on which trading does not take place
on the Principal Market (a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Holiday</B></FONT>&rdquo;), the next day
that is not a Holiday.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Fundamental Transaction</B></FONT>&rdquo; means (A) that the Company
shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i) consolidate
or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or (ii) sell, assign, transfer,
convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its &ldquo;significant subsidiaries&rdquo;
(as defined in Rule 1-02 of Regulation S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities to
make, or allow the Company to be subject to or have its shares of Common Stock be subject to or party to one or more Subject Entities
making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of
Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities
making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding;
or (z) such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity
making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under
the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or more Subject
Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x) at least 50% of the outstanding shares
of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the
Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase agreement or other
business combination were not outstanding; or (z) such number of shares of Common Stock such that the Subject Entities become collectively
the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (v)
reorganize, recapitalize or reclassify its shares of Common Stock, (B) that the Company shall, directly or indirectly, including through
subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities
in the aggregate to be or become the &ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly,
whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common
Stock, merger, consolidation, business combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization,
recapitalization or reclassification or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary voting
power represented by issued and outstanding shares of Common Stock, (y) at least 50% of the aggregate ordinary voting power represented
by issued and outstanding shares of Common Stock not held by all such Subject Entities as of the Subscription Date calculated as if any
shares of Common Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power
represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject
Entities to effect a statutory short form merger or other transaction requiring other stockholders of the Company to surrender their
Common Stock without approval of the stockholders of the Company or (C) directly or indirectly, including through subsidiaries, Affiliates
or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured
in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition
or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument or transaction.</FONT></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Group</B></FONT>&rdquo; means a &ldquo;group&rdquo; as that term is
used in Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Options</B></FONT>&rdquo; means any rights, warrants or
options to subscribe for or purchase shares of Common Stock or Convertible Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(q)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Parent Entity</B></FONT>&rdquo; of a Person means an entity that,
directly or indirectly, controls the applicable Person, including such entity whose common stock or equivalent equity security is quoted
or listed on an Eligible Market (or, if so elected by the Holder, any other market, exchange or quotation system), or, if there is more
than one such Person or such entity, the Person or such entity designated by the Holder or in the absence of such designation, such Person
or entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction or Change of Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(r)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Person</B></FONT>&rdquo; means an individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or
any department or agency thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(s)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Principal Market</B></FONT>&rdquo; means The Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(t)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Requisite Holders</B></FONT>&rdquo; means the holders of the Warrants
representing a majority of the shares of Common Stock underlying the Warrants then outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(u)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Standard Settlement Period</B></FONT>&rdquo; means the standard settlement
period, expressed in a number of Trading Days, for the Company&rsquo;s primary trading market or quotation system with respect to the
Common Stock that is in effect on the date of receipt of an applicable Exercise Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(v)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Subject Entity</B></FONT>&rdquo; means any Person, Persons or Group
or any Affiliate or associate of any such Person, Persons or Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(w)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Successor Entity</B></FONT>&rdquo; means one or more Person or Persons
(or, if so elected by the Holder, the Company or Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or
Change of Control or one or more Person or Persons (or, if so elected by the Holder, the Company or the Parent Entity) with which such
Fundamental Transaction or Change of Control shall have been entered into.</FONT></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(x)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Trading Day</B></FONT>&rdquo; means any day on which the Common Stock
is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the
principal securities exchange or securities market on which the Common Stock is then traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(y)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transaction Documents</B></FONT>&rdquo; means any agreement entered
into by and between the Company and the Holder, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(z)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer Agent</B></FONT>&rdquo; means Colonial Stock Transfer Company,
Inc., the current transfer agent of the Company, with a mailing address of 66 Exchange Place, 1st Floor, Salt Lake City, UT 84111 and
a telephone number of 801-355-5740, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(aa)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Warrant Agency Agreement</B></FONT>&rdquo; means the warrant agency
agreement, dated on or prior to the Initial Exercisability Date, between the Company and the Warrant Agent, pursuant to which the Warrant
Agent shall act as warrant agent for the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(bb)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Warrant Agent</B></FONT>&rdquo; means the Transfer Agent and any successor
warrant agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(cc)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Weighted Average Price</B></FONT>&rdquo; means, for any security as
of any date, the dollar volume-weighted average price for such security on the Principal Market during the period beginning at 9:30:01
a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00
p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by
Bloomberg through its &ldquo;Volume at Price&rdquo; function or, if the foregoing does not apply, the dollar volume-weighted average
price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning
at 9:30:01 a.m., New York time (or such other time as such market publicly announces is the official open of trading), and ending at
4:00:00 p.m., New York time (or such other time as such market publicly announces is the official close of trading), as reported by Bloomberg,
or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest
Closing Bid Price and the lowest closing ask price of any of the market makers for such security as reported in the OTC Link or the Pink
Open Market. If the Weighted Average Price cannot be calculated for a security on a particular date on any of the foregoing bases, the
Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.
If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant
to Section 11 with the term &ldquo;Weighted Average Price&rdquo; being substituted for the term &ldquo;Exercise Price.&rdquo; All such
determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or other similar
transaction during the applicable calculation period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Signature
Page Follows]</B></FONT></P>
<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>IN
WITNESS WHEREO</B>F, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; background-color: white"><B>Modular Medical, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Ellen O&rsquo;Connor Vos</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">[Signature Page to Warrant
to Purchase Common Stock]</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EXERCISE
NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>TO
BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>WARRANT
TO PURCHASE COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>MODULAR
MEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
undersigned holder hereby exercises the right to purchase ______________ shares of Common Stock (&ldquo;<B>Warrant Shares</B>&rdquo;)
of Modular Medical, Inc., a company organized under the laws of Nevada (the &ldquo;<B>Company</B>&rdquo;), evidenced by the attached
Warrant to Purchase Common Stock (the &ldquo;<B>Warrant</B>&rdquo;). Capitalized terms used herein and not otherwise defined shall have
the respective meanings set forth in the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">1. Form of Exercise Price. The holder intends
that payment of the Exercise Price shall be made as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt; background-color: white">______________
a &ldquo;Cash Exercise&rdquo; with respect to ______________ Warrant Shares; and/or ______________ a &ldquo;Cashless Exercise&rdquo;
with respect to ______________ Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">2. Payment of Exercise Price. In the event
that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder
shall pay the Aggregate Exercise Price in the sum of $ _________ to the Company in accordance with the terms of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">3. Delivery of Warrant Shares. The Company
shall deliver to the holder ______________ Warrant Shares in accordance with the terms of the Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Date:
________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name
of Registered Holder</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">By:
_________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Exhibit
A-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>ACKNOWLEDGMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company hereby acknowledges this Exercise Notice and hereby directs Colonial Stock Transfer Company, Inc. to issue the above indicated
number of shares of Common Stock on or prior to the applicable Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Modular Medical, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10_1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML STYLE="font: 10pt Times New Roman, Times, Serif">
<HEAD STYLE="font: 10pt Times New Roman, Times, Serif">
     <TITLE STYLE="font: 10pt Times New Roman, Times, Serif"></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANT
AGENCY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This WARRANT AGENCY
AGREEMENT, dated as of [______], 2022 (&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Agreement</U></FONT>&rdquo;),
between Modular Medical, Inc., a Nevada corporation (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Company</U></FONT>&rdquo;),
and Colonial Stock Transfer Company, Inc., a New York limited liability trust company (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrant
Agent</U></FONT>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>W
I T N E S S E T H</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
pursuant to a registered offering by the Company of shares of common stock, par value $0.001 per share (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Common
Stock</U></FONT>&rdquo;), warrants to purchase shares of Common Stock (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrants</U></FONT>&rdquo;)
pursuant to an effective registration statement on Form S-1 (File No. 333-260682) [and an effective registration statement filed pursuant
to Rule 462(b) under the Securities Act of 1933, as amended] (collectively, the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Registration
Statement</U></FONT>&rdquo;), the Company wishes to issue the Warrants in book-entry form entitling the respective holders of the Warrants
(the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Holders</U></FONT>,&rdquo; which term shall include a Holder&rsquo;s
transferees, successors and assigns and &ldquo;Holder&rdquo; shall include, if the Warrants are held in &ldquo;street name,&rdquo; a
Participant (as defined below) or a designee appointed by such Participant) to purchase an aggregate of up to [_________] shares of Common
Stock upon the terms and subject to the conditions hereinafter set forth (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Offering</U></FONT>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
the shares of Common Stock and the Warrants to be issued in connection with the Offering shall be immediately separable and will be issued
separately, but will be purchased together in the Offering; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
the Company wishes the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing so to act, in connection with
the issuance, registration, transfer, exchange, exercise and replacement of the Warrants and, in the Warrant Agent&rsquo;s capacity as
the Company&rsquo;s transfer agent, the delivery of the Warrant Shares (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW,
THEREFORE, in consideration of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
1. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Certain Definitions</U></FONT>. For purposes of this Agreement, the following
terms have the meanings indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Business Day</U></FONT>&rdquo; means any day other than Saturday,
Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided</U></FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>however</U></FONT>, for clarification, commercial banks shall not be deemed
to be authorized or required by law to remain closed due to &ldquo;stay at home,&rdquo; &ldquo;shelter-in-place,&rdquo; &ldquo;non-essential
employee&rdquo; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental
authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York
generally are open for use by customers on such day.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Close of Business</U></FONT>&rdquo; on any given date means 5:00 p.m.,
New York City time, on such date; <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided</U></FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>however</U></FONT>,
that if such date is not a Business Day it means 5:00 p.m., New York City time, on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Person</U></FONT>&rdquo; means an individual, corporation, association,
partnership, limited liability company, joint venture, trust, unincorporated organization, government or political subdivision thereof
or governmental agency or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrant Certificate</U></FONT>&rdquo; means a certificate in substantially
the form attached as <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exhibit 1</U></FONT> hereto, representing such number
of Warrant Shares as is indicated therein, provided that any reference to the delivery of a Warrant Certificate in this Agreement shall
include delivery of notice from the Depositary or a Participant (each as defined below) of the transfer or exercise of a Warrant in the
form of a Global Warrant (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrant Shares</U></FONT>&rdquo; means the shares of Common Stock
underlying the Warrants and issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.55pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">All
other capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.55pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
2. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Appointment of Warrant Agent</U></FONT>. The Company hereby appoints the
Warrant Agent to act as agent for the Company in accordance with the terms and conditions hereof, and the Warrant Agent hereby accepts
such appointment. The Company may from time to time appoint a Co-Warrant Agent as it may, in its sole discretion, deem necessary or desirable.
The Warrant Agent shall have no duty to supervise, and will in no event be liable for the acts or omissions of, any co-Warrant Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
3. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Global Warrants</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.55pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
The Warrants shall be issuable in book entry form (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Global Warrants</U></FONT>&rdquo;).
All of the Warrants shall initially be represented by one or more Global Warrants deposited with the Warrant Agent and registered in
the name of Cede &amp; Co., a nominee of The Depository Trust Company (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Depositary</U></FONT>&rdquo;),
or as otherwise directed by the Depositary. Ownership of beneficial interests in the Warrants shall be shown on, and the transfer of
such ownership shall be effected through, records maintained by (i) the Depositary or its nominee for each Global Warrant or (ii) institutions
that have accounts with the Depositary (such institution, with respect to a Warrant in its account, a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Participant</U></FONT>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
If the Depositary subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the
Warrant Agent regarding other arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no
longer necessary to have the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depositary
to deliver to the Warrant Agent for cancellation each Global Warrant, and the Company shall instruct the Warrant Agent to deliver to
each Holder a Warrant Certificate.</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
A Holder has the right to elect at any time or from time to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate
Request Notice (as defined below). Upon written notice by a Holder to the Warrant Agent for the exchange of some or all of such Holder&rsquo;s
Global Warrants for a Warrant Certificate evidencing the same number of Warrants, which request shall be in the form attached hereto
as <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Annex A</U></FONT> (a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrant
Certificate Request Notice</U></FONT>&rdquo; and the date of delivery of such Warrant Certificate Request Notice by the Holder, the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrant
Certificate Request Notice Date</U></FONT>&rdquo; and the deemed surrender upon delivery by the Holder of a number of Global Warrants
for the same number of Warrants evidenced by a Warrant Certificate, a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrant
Exchange</U></FONT>&rdquo;), the Warrant Agent shall promptly effect the Warrant Exchange and shall promptly issue and deliver, at the
expense of the Company, to the Holder a Warrant Certificate for such number of Warrants in the name set forth in the Warrant Certificate
Request Notice. Such Warrant Certificate shall be dated the original issue date of the Warrants, shall be executed by manual or facsimile
signature by an authorized signatory of the Company and shall be in the form attached hereto as <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exhibit
1</U></FONT>. In connection with a Warrant Exchange, the Company agrees to deliver, or to direct the Warrant Agent to deliver, the Warrant
Certificate to the Holder within two (2) Business Days of the Warrant Certificate Request Notice pursuant to the delivery instructions
in the Warrant Certificate Request Notice (&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrant Certificate Delivery
Date</U></FONT>&rdquo;). If the Company fails for any reason to deliver to the Holder the Warrant Certificate subject to the Warrant
Certificate Request Notice by the Warrant Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
and not as a penalty, for each $1,000 of Warrant Shares evidenced by such Warrant Certificate (based on the Weighted Average Price (as
defined in the Warrant Certificate) of the Common Stock on the Warrant Certificate Request Notice Date), $10 per Business Day (increasing
to $20 per Business Day on the third Business Day after the Warrant Certificate Delivery Date) for each Business Day after such Warrant
Certificate Delivery Date until such Warrant Certificate is delivered or, prior to delivery of such Warrant Certificate, the Holder rescinds
such Warrant Exchange. The Company covenants and agrees that, upon the date of delivery of the Warrant Certificate Request Notice, the
Holder shall be deemed to be the holder of the Warrant Certificate and, notwithstanding anything to the contrary set forth herein, the
Warrant Certificate shall be deemed for all purposes to contain all of the terms and conditions of the Warrants evidenced by such Warrant
Certificate and the terms of this Agreement, other than Sections 3(c) and 9 herein, shall not apply to the Warrants evidenced by the
Warrant Certificate. In the event a beneficial owner requests a Warrant Exchange, upon issuance of the paper Warrant Certificate, the
Company shall act as warrant agent and the terms of the paper Warrant Certificate so issued shall exclusively govern in respect thereof.
For purposes of clarity, the Company and the Warrant Agent acknowledge and agree that, with respect to the terms of the Warrants, the
Warrant Certificate or Global Warrant shall set forth the terms of the Warrants and, in the event of any conflict between the Warrant
Certificate or the Global Warrant and this Agreement, the Warrant Certificate or the Global Warrants, as the case may be, shall control.
For purposes of Regulation SHO, a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this
Warrant held in book-entry form through DTC shall be deemed to have exercised its interest in this Warrant upon instructing its broker
that is a Participant to exercise its interest in this Warrant, except that, if the date of exercise is a date when the stock transfer
books of the Company are closed, such Person shall be deemed to have become the holder of such shares at the open of business on the
next succeeding date on which the stock transfer books are open.</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
4. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Form of Warrant</U></FONT>. The Warrants, together with the form of election
to purchase Common Stock (the &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exercise Notice</U></FONT>&rdquo;) and
the form of assignment to be printed on the reverse thereof, whether a Warrant Certificate or a Global Warrant, shall be in the form
of <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exhibit 1</U></FONT> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 26.55pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
5. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Countersignature and Registration</U></FONT>. The Warrant Certificates
shall be executed on behalf of the Company by its Chief Executive Officer, Chief Financial Officer or Vice President, either manually
or by electronic signature, and have affixed thereto the Company&rsquo;s seal or a facsimile thereof which shall be attested by the Secretary
or an Assistant Secretary of the Company, either manual or electronic signature. The Warrant Certificates shall be countersigned by the
Warrant Agent by either manual or by facsimile signature and shall not be valid for any purpose unless so countersigned. In case any
officer of the Company who shall have signed any of the Warrant Certificates shall cease to be such officer of the Company before countersignature
by the Warrant Agent and issuance and delivery by the Company, such Warrant Certificates, nevertheless, may be countersigned by the Warrant
Agent, issued and delivered with the same force and effect as though the person who signed such Warrant Certificate had not ceased to
be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company by any person who, at the actual date
of the execution of such Warrant Certificate, shall be a proper officer of the Company to sign such Warrant Certificate, although at
the date of the execution of this Agreement any such person was not such an officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Warrant Agent will keep or cause to be kept, at its office designated for such purpose, books for registration and transfer of the Warrant
Certificates issued hereunder. Such books shall show the names and addresses of the respective Holders of the Warrant Certificates, the
number of warrants evidenced on the face of each of such Warrant Certificate and the date of each of such Warrant Certificate. The Warrant
Agent will create a special account for the issuance of Warrant Certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
6. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Transfer, Split Up, Combination and Exchange of Warrant Certificates;
Mutilated, Destroyed, Lost or Stolen Warrant Certificates</U></FONT>. Subject to the provisions of the Warrant Certificate and the last
sentence of this first paragraph of Section 6 and subject to applicable law, rules or regulations, or any &ldquo;stop transfer&rdquo;
instructions the Company may give to the Warrant Agent, at any time after the closing date of the Offering, and at or prior to the Close
of Business on the Expiration Date (as such term is defined in the Warrant Certificate), any Warrant Certificate or Warrant Certificates
or Global Warrant or Global Warrants may be transferred, split up, combined or exchanged for another Warrant Certificate or Warrant Certificates
or Global Warrant or Global Warrants, entitling the Holder to purchase a like number of shares of Common Stock as the Warrant Certificate
or Warrant Certificates or Global Warrant or Global Warrants surrendered then entitled such Holder to purchase. Any Holder desiring to
transfer, split up, combine or exchange any Warrant Certificate or Global Warrant shall make such request in writing delivered to the
Warrant Agent, and shall surrender the Warrant Certificate or Warrant Certificates to be transferred, split up, combined or exchanged
at the office of the Warrant Agent designated for such purpose, provided that no such surrender is applicable to the Holder of a Global
Warrant. Any requested transfer of Warrants, whether in book-entry form or certificate form, shall be accompanied by evidence of authority
of the party making such request that may be reasonably required by the Warrant Agent. Thereupon the Warrant Agent shall, subject to
the last sentence of this first paragraph of Section 6, countersign and deliver to the Person entitled thereto a Warrant Certificate
or Warrant Certificates, as the case may be, as so requested. The Company may require payment from the Holder of a sum sufficient to
cover any tax or governmental charge that may be imposed in connection with any transfer, split up, combination or exchange of Warrant
Certificates. The Company shall compensate the Warrant Agent per the fee schedule mutually agreed upon by the parties hereto and provided
separately on the date hereof.</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Upon
receipt by the Warrant Agent of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate,
which evidence shall include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining,
and, in case of loss, theft or destruction, of indemnity in customary form and amount, and satisfaction of any other reasonable requirements
established by Section 8-405 of the Uniform Commercial Code as in effect in the State of Nevada, and reimbursement to the Company and
the Warrant Agent of all reasonable expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant
Certificate if mutilated, the Company will make and deliver a new Warrant Certificate of like tenor to the Warrant Agent for delivery
to the Holder in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
7. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exercise of Warrants; Exercise Price; Expiration Date</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
The Warrants shall be exercisable commencing on the Initial Exercisability Date (as such term is defined in the Warrant Certificate).
The Warrants shall cease to be exercisable at the Close of Business on the Expiration Date (as such term is defined in the Warrant Certificate).
Subject to the foregoing and to Section 7(b) below, the Holder of a Warrant may exercise the Warrant in whole or in part upon surrender
of the Warrant Certificate, if required, with the executed Exercise Notice and payment of the Exercise Price (as such term is defined
in the Warrant Certificate) (unless exercised via a cashless exercise) pursuant to Section 1(a) of the Warrant Certificate, to the Warrant
Agent at the office of the Warrant Agent designated for such purpose. In the case of the Holder of a Global Warrant, the Holder shall
deliver the executed Exercise Notice and the payment of the Exercise Price pursuant to Section 1(a) of the Warrant Certificate. Notwithstanding
any other provision in this Agreement, a holder whose interest in a Global Warrant is a beneficial interest in a Global Warrant held
in book-entry form through the Depositary (or another established clearing corporation performing similar functions), shall effect exercises
by delivering to the Depositary (or such other clearing corporation, as applicable) the appropriate instruction form for exercise, complying
with the procedures to effect exercise that are required by the Depositary (or such other clearing corporation, as applicable). The Company
acknowledges that the bank accounts maintained by the Warrant Agent in connection with the services provided under this Agreement will
be in its name and that the Warrant Agent may receive investment earnings in connection with the investment at Warrant Agent risk and
for its benefit of funds held in those accounts from time to time. Neither the Company nor the Holders will receive interest on any deposits
or Exercise Price. No ink-original Exercise Notice shall be required, nor shall any medallion guarantee (or other type of guarantee or
notarization) of any Exercise Notice be required.</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
Upon receipt of an Exercise Notice for a cashless exercise pursuant to Section 1(d) of the Warrant Certificate (each, a &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Cashless
Exercise</U></FONT>&rdquo;), the Warrant Agent shall deliver a copy of the Exercise Notice to the Company and the Company shall promptly
calculate and transmit to the Warrant Agent in writing the number of Warrant Shares issuable in connection with such Cashless Exercise.
The Warrant Agent shall issue such number of Warrant Shares in connection with such Cashless Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
Upon the Warrant Agent&rsquo;s receipt of a Warrant Certificate at or prior to the Close of Business on the Expiration Date set forth
in such Warrant Certificate, with the executed Exercise Notice and payment of the Exercise Price pursuant to Section 1(a) of the Warrant
Certificate, the shares to be purchased (other than in the case of a Cashless Exercise) and an amount equal to any applicable tax, governmental
charge referred to in Section 6 by wire transfer, or by certified check or bank draft payable to the order of the Company (or, in the
case of the Holder of a Global Warrant, the delivery of the executed Exercise Notice and the payment of the Exercise Price pursuant to
Section 1(a) of the Warrant Certificate (other than in the case of a Cashless Exercise) and any other applicable amounts as set forth
herein), the Warrant Agent shall cause the Warrant Shares underlying such Warrant Certificate or Global Warrant to be delivered to or
upon the order of the Holder of such Warrant Certificate or Global Warrant, registered in such name or names as may be designated by
such Holder, no later than the Share Delivery Date (as such term is defined in the Warrant Certificate). If the Company is then a participant
in the DWAC system of the Depositary and either (A) there is an effective registration statement permitting the issuance of the Warrant
Shares to or resale of the Warrant Shares by Holder or (B) the Warrant is being exercised via Cashless Exercise, then the certificates
for Warrant Shares shall be transmitted by the Warrant Agent to the Holder by crediting the account of the Holder&rsquo;s broker with
the Depositary through its DWAC system. For the avoidance of doubt, if the Company becomes obligated to pay any amounts to any Holders
pursuant to Section 1(c) of the Warrant Certificate, such obligation shall be solely that of the Company and not that of the Warrant
Agent. Notwithstanding anything else to the contrary in this Agreement, except in the case of a Cashless Exercise, if any Holder fails
to duly deliver payment to the Warrant Agent of an amount equal to the aggregate Exercise Price of the Warrant Shares to be purchased
upon exercise of such Holder&rsquo;s Warrant as set forth in Section 7(a) hereof, the Warrant Agent will not be obligated to deliver
such Warrant Shares (via DWAC or otherwise) until following receipt of such payment, and the applicable Share Delivery Date shall be
deemed extended by one Business Day for each Business Day (or part thereof) until such payment is delivered to the Warrant Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
The Warrant Agent shall deposit all funds received by it in payment of the Exercise Price for all Warrants in the account of the Company
maintained with the Warrant Agent for such purpose (or to such other account as directed by the Company in writing) and shall advise
the Company via email at the end of each day on which Exercise Notices are received or funds for the exercise of any Warrant are received
of the amount so deposited to its account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
In case the Holder of any Warrant Certificate shall exercise fewer than all Warrants evidenced thereby, upon the request of the Holder,
a new Warrant Certificate evidencing the number of Warrants equivalent to the number of Warrants remaining unexercised may be issued
by the Warrant Agent to the Holder of such Warrant Certificate or to his duly authorized assigns in accordance with Section 1(a) of the
Warrant Certificate, subject to the provisions of Section 6 hereof.</FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
8. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Cancellation and Destruction of Warrant Certificates</U></FONT>. All Warrant
Certificates surrendered for the purpose of exercise, transfer, split up, combination or exchange shall, if surrendered to the Company
or to any of its agents, be delivered to the Warrant Agent for cancellation or in canceled form, or, if surrendered to the Warrant Agent,
shall be canceled by it, and no Warrant Certificates shall be issued in lieu thereof except as expressly permitted by any of the provisions
of this Agreement. The Company shall deliver to the Warrant Agent for cancellation and retirement, and the Warrant Agent shall so cancel
and retire, any other Warrant Certificate purchased or acquired by the Company otherwise than upon the exercise thereof. The Warrant
Agent shall deliver all canceled Warrant Certificates to the Company, or shall, at the written request of the Company, destroy such canceled
Warrant Certificates, and in such case shall deliver a certificate of destruction thereof to the Company, subject to any applicable law,
rule or regulation requiring the Warrant Agent to retain such canceled certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
9. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Certain Representations; Reservation and Availability of Shares of Common
Stock or Cash</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
This Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery
hereof by the Warrant Agent, constitutes a valid and legally binding obligation of the Company enforceable against the Company in accordance
with its terms, and the Warrants have been duly authorized, executed and issued by the Company and, assuming due execution thereof by
the Warrant Agent pursuant hereto and payment therefor by the Holders as provided in the Registration Statement, constitute valid and
legally binding obligations of the Company enforceable against the Company in accordance with their terms and entitled to the benefits
hereof; in each case except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar
laws relating to or affecting creditors&rsquo; rights generally or by general equitable principles (regardless of whether such enforceability
is considered in a proceeding in equity or at law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
As of the date hereof, the authorized capital stock of the Company consists of (i) 50,000,000 shares of Common Stock, of which 6,390,372
shares of Common Stock are issued and outstanding, and [___________] shares of Common Stock are reserved for issuance upon exercise of
the Warrants, and (ii) 5,000,000 shares of preferred stock, of which 0 shares are issued and outstanding. Except for awards granted pursuant
to an equity incentive plan or as otherwise disclosed in the Registration Statement, there are no other outstanding obligations, warrants,
options or other rights to subscribe for or purchase from the Company any class of capital stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
The Company covenants and agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of Common
Stock or its authorized and issued shares of Common Stock held in its treasury, free from preemptive rights, the number of shares of
Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants.</FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
The Warrant Agent will create a special account for the issuance of Common Stock upon the exercise of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
The Company further covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges
which may be payable in respect of the original issuance or delivery of the Warrant Certificates or certificates evidencing Common Stock
upon exercise of the Warrants. The Company shall not, however, be required to pay any tax or governmental charge which may be payable
in respect of any transfer involved in the transfer or delivery of Warrant Certificates or the issuance or delivery of certificates for
Common Stock in a name other than that of the Holder of the Warrant Certificate evidencing Warrants surrendered for exercise or to issue
or deliver any certificate for shares of Common Stock upon the exercise of any Warrants until any such tax or governmental charge shall
have been paid (any such tax or governmental charge being payable by the Holder of such Warrant Certificate at the time of surrender)
or until it has been established to the Company&rsquo;s reasonable satisfaction that no such tax or governmental charge is due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
10. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Common Stock Record Date</U></FONT>. Each Holder shall be deemed to have
become the holder of record for the Warrant Shares pursuant to Section 1(a) of the Warrant Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
11. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Adjustment of Exercise Price, Number of Shares of Common Stock or Number
of the Company Warrants</U></FONT>. The Exercise Price, the number of shares covered by each Warrant and the number of Warrants outstanding
are subject to adjustment from time to time as provided in Section 2 of the Warrant Certificate. In the event that at any time, as a
result of an adjustment made pursuant to Section 2 of the Warrant Certificate, the Holder of any Warrant thereafter exercised shall become
entitled to receive any shares of capital stock of the Company other than shares of Common Stock, thereafter the number of such other
shares so receivable upon exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly
equivalent as practicable to the provisions with respect to the shares contained in Section 2 of the Warrant Certificate, and the provisions
of Sections 7, 9 and 13 of this Agreement with respect to the shares of Common Stock shall apply on like terms to any such other shares.
All Warrants originally issued by the Company subsequent to any adjustment made to the Exercise Price pursuant to the Warrant Certificate
shall evidence the right to purchase, at the adjusted Exercise Price, the number of shares of Common Stock purchasable from time to time
hereunder upon exercise of the Warrants, all subject to further adjustment as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
12. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Certification of Adjusted Exercise Price or Number of Shares of Common
Stock</U></FONT>. Whenever the Exercise Price or the number of shares of Common Stock issuable upon the exercise of each Warrant is adjusted
as provided in Section 11 or 13, the Company shall (a) promptly prepare a certificate setting forth the Exercise Price of each Warrant
as so adjusted, and a brief statement of the facts accounting for such adjustment, (b) promptly file with the Warrant Agent and with
each transfer agent for the Common Stock a copy of such certificate and (c) instruct the Warrant Agent to send a brief summary thereof
to each Holder of a Warrant Certificate.</FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
13. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Fractional Shares of Common Stock</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.55pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
The Company shall not issue fractions of Warrants or distribute Warrant Certificates which evidence fractional Warrants. Whenever any
fractional Warrant would otherwise be required to be issued or distributed, the actual issuance or distribution shall reflect a rounding
of such fraction either up or down to the nearest whole Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
The Company shall not issue fractions of shares of Common Stock upon exercise of Warrants or distribute stock certificates which evidence
fractional shares of Common Stock. Whenever any fraction of a share of Common Stock would otherwise be required to be issued or distributed,
the actual issuance or distribution in respect thereof shall be made in accordance with Section 1(a) of the Warrant Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
14. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Conditions of the Warrant Agent&rsquo;s Obligations</U></FONT>. The Warrant
Agent accepts its obligations herein set forth upon the terms and conditions hereof, including the following to all of which the Company
agrees and to all of which the rights hereunder of the Holders from time to time of the Warrant Certificates shall be subject:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
Compensation and Indemnification. The Company agrees promptly to pay the Warrant Agent the compensation detailed on <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exhibit
2</U></FONT> hereto for all services rendered by the Warrant Agent and to reimburse the Warrant Agent for reasonable out-of-pocket expenses
(including reasonable counsel fees) incurred without gross negligence, bad faith or willful misconduct by the Warrant Agent in connection
with the services rendered hereunder by the Warrant Agent. The Company also agrees to indemnify the Warrant Agent for, and to hold it
harmless against, any loss, liability or expense incurred without gross negligence, bad faith or willful misconduct on the part of the
Warrant Agent, arising out of or in connection with its acting as Warrant Agent hereunder, including the reasonable costs and expenses
of defending against any claim of such liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
Agent for the Company. In acting under this Warrant Agreement and in connection with the Warrant Certificates, the Warrant Agent is acting
solely as agent of the Company and does not assume any obligations or relationship of agency or trust for or with any of the Holders
of Warrant Certificates or beneficial owners of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
Counsel. The Warrant Agent may consult with counsel satisfactory to it, which may include counsel for the Company, and the written advice
of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder
in good faith and in accordance with the advice of such counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
Documents. The Warrant Agent shall be protected and shall incur no liability for or in respect of any action taken or omitted by it in
reliance upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably
believed by it to be genuine and to have been presented or signed by the proper parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
Certain Transactions. The Warrant Agent, and its officers, directors and employees, may become the owner of, or acquire any interest
in, Warrants, with the same rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted
by applicable law, it or they may engage or be interested in any financial or other transaction with the Company and may act on, or as
depositary, trustee or agent for, any committee or body of Holders of Warrants or other obligations of the Company as freely as if it
were not the Warrant Agent hereunder. Nothing in this Warrant Agreement shall be deemed to prevent the Warrant Agent from acting as trustee
under any indenture to which the Company is a party.</FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)
No Liability for Interest. Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any monies
at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant Certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)
No Liability for Invalidity. The Warrant Agent shall have no liability with respect to any invalidity of this Agreement or any of the
Warrant Certificates (except as to the Warrant Agent&rsquo;s countersignature thereon).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)
No Responsibility for Representations. The Warrant Agent shall not be responsible for any of the recitals or representations herein or
in the Warrant Certificates (except as to the Warrant Agent&rsquo;s countersignature thereon), all of which are made solely by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0pt 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)
No Implied Obligations. The Warrant Agent shall be obligated to perform only such duties as are herein and in the Warrant Certificates
specifically set forth and no implied duties or obligations shall be read into this Agreement or the Warrant Certificates against the
Warrant Agent. The Warrant Agent shall not be under any obligation to take any action hereunder which may tend to involve it in any expense
or liability, the payment of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall
not be accountable or under any duty or responsibility for the use by the Company of any of the Warrant Certificates authenticated by
the Warrant Agent and delivered by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds
of the Warrant Certificates. The Warrant Agent shall have no duty or responsibility in case of any default by the Company in the performance
of its covenants or agreements contained herein or in the Warrant Certificates or in the case of the receipt of any written demand from
a Holder of a Warrant Certificate with respect to such default, including, without limiting the generality of the foregoing, any duty
or responsibility to initiate or attempt to initiate any proceedings at law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
15. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Purchase or Consolidation or Change of Name of Warrant Agent</U></FONT>.
Any Person into which the Warrant Agent or any successor Warrant Agent may be merged or with which it may be consolidated, or any Person
resulting from any merger or consolidation to which the Warrant Agent or any successor Warrant Agent shall be party, or any Person succeeding
to the stock transfer or other shareholder services business of the Warrant Agent or any successor Warrant Agent, shall be the successor
to the Warrant Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties
hereto, provided that such Person would be eligible for appointment as a successor Warrant Agent under the provisions of Section 17.
In case at the time such successor Warrant Agent shall succeed to the agency created by this Agreement any of the Warrant Certificates
shall have been countersigned but not delivered, any such successor Warrant Agent may adopt the countersignature of the predecessor Warrant
Agent and deliver such Warrant Certificates so countersigned; and in case at that time any of the Warrant Certificates shall not have
been countersigned, any successor Warrant Agent may countersign such Warrant Certificates either in the name of the predecessor Warrant
Agent or in the name of the successor Warrant Agent; and in all such cases such Warrant Certificates shall have the full force provided
in the Warrant Certificates and in this Agreement.</FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
case at any time the name of the Warrant Agent shall be changed and at such time any of the Warrant Certificates shall have been countersigned
but not delivered, the Warrant Agent may adopt the countersignature under its prior name and deliver Warrant Certificates so countersigned;
and in case at that time any of the Warrant Certificates shall not have been countersigned, the Warrant Agent may countersign such Warrant
Certificates either in its prior name or in its changed name; and in all such cases such Warrant Certificates shall have the full force
provided in the Warrant Certificates and in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
16. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Duties of Warrant Agent</U></FONT>. The Warrant Agent undertakes the
duties and obligations imposed by this Agreement upon the following terms and conditions, by all of which the Company, by its acceptance
hereof, shall be bound:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.55pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
The Warrant Agent may consult with legal counsel reasonably acceptable to the Company (who may be legal counsel for the Company), and
the written advice of such counsel shall be full and complete authorization and protection to the Warrant Agent as to any action taken
or omitted by it in good faith and in accordance with such opinion or advice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or
matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence
in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed
by the Chief Executive Officer, Chief Financial Officer or Vice President of the Company; and such certificate shall be full authorization
and protection to the Warrant Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance
upon such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
Subject to the limitation set forth in Section 14, the Warrant Agent shall be liable hereunder only for its own gross negligence, bad
faith or willful misconduct, or for a breach by it of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)
The Warrant Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in
the Warrant Certificates (except its countersignature thereof) by the Company or be required to verify the same, but all such statements
and recitals are and shall be deemed to have been made by the Company only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)
The Warrant Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof
(except the due execution hereof by the Warrant Agent) or in respect of the validity or execution of any Warrant Certificate (except
its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this
Agreement or in any Warrant Certificate; nor shall it be responsible for the adjustment of the Exercise Price or the making of any change
in the number of shares of Common Stock required under the provisions of Section 11 or 13 or responsible for the manner, method or amount
of any such change or the ascertaining of the existence of facts that would require any such adjustment or change (except with respect
to the exercise of Warrants evidenced by Warrant Certificates after actual notice of any adjustment of the Exercise Price); nor shall
it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common
Stock to be issued pursuant to this Agreement or any Warrant Certificate or as to whether any shares of Common Stock will, when issued,
be duly authorized, validly issued, fully paid and nonassessable.</FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)
Each party hereto agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and
delivered all such further and other acts, instruments and assurances as may reasonably be required by the other party hereto for the
carrying out or performing by any party of the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)
The Warrant Agent is hereby authorized to accept instructions with respect to the performance of its duties hereunder from the Chief
Executive Officer, Chief Financial Officer, Vice President or Controller of the Company, and to apply to such officers for advice or
instructions in connection with its duties, and it shall not be liable and shall be indemnified and held harmless for any action taken
or suffered to be taken by it in good faith in accordance with instructions of any such officer, provided the Warrant Agent carries out
such instructions without gross negligence, bad faith or willful misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)
The Warrant Agent and any shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants
or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract
with or lend money to the Company or otherwise act as fully and freely as though it were not Warrant Agent under this Agreement. Nothing
herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)
The Warrant Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself
or by or through its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or
misconduct of any such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct,
provided reasonable care was exercised in the selection and continued employment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
17. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Change of Warrant Agent</U></FONT>. The Warrant Agent may resign and
be discharged from its duties under this Agreement upon 30 days&rsquo; notice in writing sent to the Company and to each transfer agent
of the Common Stock, and to the Holders of the Warrant Certificates. The Company may remove the Warrant Agent or any successor Warrant
Agent upon 30 days&rsquo; notice in writing, sent to the Warrant Agent or successor Warrant Agent, as the case may be, and to each transfer
agent of the Common Stock, and to the Holders of the Warrant Certificates. If the Warrant Agent shall resign or be removed or shall otherwise
become incapable of acting, the Company shall appoint a successor to the Warrant Agent. If the Company shall fail to make such appointment
within a period of 30 days after such removal or after it has been notified in writing of such resignation or incapacity by the resigning
or incapacitated Warrant Agent or by the Holder of a Warrant Certificate (who shall, with such notice, submit his Warrant Certificate
for inspection by the Company), then the Holder of any Warrant Certificate may apply to any court of competent jurisdiction for the appointment
of a new Warrant Agent, provided that, for purposes of this Agreement, the Company shall be deemed to be the Warrant Agent until a new
warrant agent is appointed. Any successor Warrant Agent, whether appointed by the Company or by such a court, shall be a Person, other
than a natural person, organized and doing business under the laws of the United States or of a state thereof, in good standing, which
is authorized under such laws to exercise stock transfer powers and is subject to supervision or examination by federal or state authority
and which has at the time of its appointment as Warrant Agent a combined capital and surplus of at least $50,000,000. After appointment,
the successor Warrant Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named
as Warrant Agent without further act or deed; but the predecessor Warrant Agent shall deliver and transfer to the successor Warrant Agent
any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the
purpose. Not later than the effective date of any such appointment, the Company shall file notice thereof in writing with the predecessor
Warrant Agent and each transfer agent of the Common Stock, and mail a notice thereof in writing to the Holders of the Warrant Certificates.
However, failure to give any notice provided for in this Section 17, or any defect therein, shall not affect the legality or validity
of the resignation or removal of the Warrant Agent or the appointment of the successor Warrant Agent, as the case may be.</FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
18. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Issuance of New Warrant Certificates</U></FONT>. Notwithstanding any
of the provisions of this Agreement or of the Warrants to the contrary, the Company may, at its option, issue new Warrant Certificates
evidencing Warrants in such form as may be approved by its Board of Directors to reflect any adjustment or change in the Exercise Price
per share and the number or kind or class of shares of stock or other securities or property purchasable under the several Warrant Certificates
made in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
19. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notices</U></FONT>. Notices or demands authorized by this Agreement to
be given or made (i) by the Warrant Agent or by the Holder of any Warrant Certificate to or on the Company, (ii) by the Company or by
the Holder of any Warrant Certificate to or on the Warrant Agent or (iii) by the Company or the Warrant Agent to the Holder of any Warrant
Certificate, shall be deemed given when in writing (a) on the date delivered, if delivered personally, (b) on the first Business Day
following the deposit thereof with Federal Express or another recognized overnight courier, if sent by Federal Express or another recognized
overnight courier, (c) on the fourth Business Day following the mailing thereof with postage prepaid, if mailed by registered or certified
mail (return receipt requested), and (d) the time of transmission, if such notice or communication is delivered via facsimile or email
attachment at or prior to 5:00 p.m. (New York City time) on a Business Day and (e) the next Business Day after the date of transmission,
if such notice or communication is delivered via email attachment on a day that is not a Business Day or later than 5:00 p.m. (New York
City time) on any Business Day, in each case to the parties at the following addresses (or at such other address for a party as shall
be specified by like notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
If to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">Modular
Medical, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">16772
W. Bernardo Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">San
Diego, CA 92127</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">Attention:
[ ]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">Email:
[ ]</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
If to the Warrant Agent, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">Colonial
Stock Transfer Company, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">66
Exchange Place, 1st Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">Salt
Lake City, UT 84111</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">Attention:
[ ]</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in; border-left-width: 0in; border-left-color: Black"><FONT STYLE="font-size: 10pt">With
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.45in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: justify; text-indent: 1.45in; border-left-width: 0in; border-left-color: Black"><FONT STYLE="font-size: 10pt">[
]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">For any notice delivered
by email to be deemed given or made, such notice must be followed by notice sent by overnight courier service to be delivered on the
next Business Day following such email, unless the recipient of such email has acknowledged via return email receipt of such email.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)
If to the Holder of any Warrant Certificate, to the address of such Holder as shown on the registry books of the Company. Any notice
required to be delivered by the Company to the Holder of any Warrant may be given by the Warrant Agent on behalf of the Company. Notwithstanding
any other provision of this Agreement, where this Agreement provides for notice of any event to a Holder of any Warrant, such notice
shall be sufficiently given if given to the Depositary (or its designee) pursuant to the procedures of the Depositary or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.55pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
20. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Supplements and Amendments</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.55pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)
The Company and the Warrant Agent may from time to time supplement or amend this Agreement without the approval of any Holders of Global
Warrants in order (i) to add to the covenants and agreements of the Company for the benefit of the Holders of the Global Warrants, (ii)
to surrender any rights or power reserved to or conferred upon the Company in this Agreement, (iii) to cure any ambiguity, (iv) to correct
or supplement any provision contained herein which may be defective or inconsistent with any other provisions herein, or (v) to make
any other provisions with regard to matters or questions arising hereunder which the Company and the Warrant Agent may deem necessary
or desirable, provided that such addition, correction or surrender shall not adversely affect the interests of the Holders of the Global
Warrants or the Warrant Certificates in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)
In addition to the foregoing, with the consent of Holders of Warrants entitled, upon exercise thereof, to receive not less than a majority
of the shares of Common Stock issuable thereunder, the Company and the Warrant Agent may modify this Agreement for the purpose of adding
any provisions to or changing in any manner or eliminating any of the provisions of this Agreement or modifying in any manner the rights
of the Holders of the Global Warrants; <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided</U></FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>however</U></FONT>,
that no modification of the terms (including but not limited to the adjustments described in Section 11 upon which the Warrants are exercisable
or reducing the percentage required for consent to modification of this Agreement may be made without the consent of the Holder of each
outstanding warrant certificate affected thereby; provided further, however, that no amendment hereunder shall affect any terms of any
Warrant Certificate issued in a Warrant Exchange. As a condition precedent to the Warrant Agent&rsquo;s execution of any amendment, the
Company shall deliver to the Warrant Agent a certificate from a duly authorized officer of the Company that states that the proposed
amendment complies with the terms of this Section 20. No supplement or amendment to this Agreement shall be effective unless duly executed
by the Warrant Agent.</FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
21. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Successors</U></FONT>. All covenants and provisions of this Agreement
by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
22. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Benefits of this Agreement</U></FONT>. Nothing in this Agreement shall
be construed to give any Person other than the Company, the Holders of Warrant Certificates and the Warrant Agent any legal or equitable
right, remedy or claim under this Agreement; but this Agreement shall be for the sole and exclusive benefit of the Company, the Warrant
Agent and the Holders of the Warrant Certificates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
23. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Governing Law; Jurisdiction</U></FONT>. This Agreement and each Warrant
Certificate issued hereunder shall be governed by, and construed in accordance with, the laws of the State of New York without giving
effect to the conflicts of law principles thereof. The Company hereby agrees that any action, proceeding or claim against it arising
out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States
District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive.
The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenience forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
24. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Counterparts</U></FONT>. This Agreement may be executed in any number
of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together
constitute but one and the same instrument. A signature to this Agreement transmitted electronically shall have the same authority, effect
and enforceability as an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
25. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Captions</U></FONT>. The captions of the sections of this Agreement have
been inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
26. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Severability</U></FONT>. Wherever possible, each provision of this Agreement
shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be
prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section
27. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Force Majeure</U></FONT>. Notwithstanding anything to the contrary contained
herein, Warrant Agent shall not be liable for any delays or failures in performance resulting from acts beyond its reasonable control
including, without limitation, acts of God, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunction
of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems,
labor difficulties, war, or civil unrest, it being understood that the Warrant Agent shall use reasonable best efforts which are consistent
with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. Notwithstanding
anything herein to the contrary, this Section 27 shall not affect the Company&rsquo;s obligations to the Holders of the Warrants as provided
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">[<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature
Page Follows</I></FONT>]</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>MODULAR MEDICAL, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Ellen O&rsquo;Connor Vos</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>COLONIAL STOCK TRANSFER COMPANY, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">[Signature Page to Warrant
Agency Agreement]</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex
A: Form of Warrant Certificate Request Notice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">WARRANT CERTIFICATE
REQUEST NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">To: Colonial Stock
Transfer Company, Inc. as Warrant Agent for Modular Medical, Inc. (the &ldquo;Company&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned
Holder of Common Stock Purchase Warrants (&ldquo;Warrants&rdquo;) in the form of Global Warrants issued by the Company hereby elects
to receive a Warrant Certificate evidencing the Warrants held by the Holder as specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">Name of Holder of Warrants in form
    of Global Warrants: _____________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">Name of Holder in Warrant Certificate (if different
    from name of Holder of Warrants in form of Global Warrants): ________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">Number of Warrants in name of Holder in form of
    Global Warrants: _____________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">Number of Warrants for which Warrant Certificate
    shall be issued: _____________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">Number of Warrants in name of Holder in form of
    Global Warrants after issuance of Warrant Certificate, if any: _______________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-size: 10pt">Warrant Certificate shall be delivered to the
    following address:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned hereby
acknowledges and agrees that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed
to have surrendered the number of Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced
by the Warrant Certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">[SIGNATURE OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">Name of Investing Entity:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I></FONT><FONT STYLE="font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">Name of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">Title of Authorized Signatory:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">_________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">_______________________________________________________________</FONT></P>



<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1: Form of Warrant Certificate</B></FONT></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
2: Compensation of Warrant Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Payable at Closing: $[&nbsp;&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">Additional Monthly Fee: $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] (subject
to adjustment from time to time upon mutual agreement of the Company and the Warrant Agent)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>








</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML STYLE="font: 10pt Times New Roman, Times, Serif">
<HEAD STYLE="font: 10pt Times New Roman, Times, Serif">
     <TITLE STYLE="font: 10pt Times New Roman, Times, Serif"></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV STYLE="color:black; margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="color:black; font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="margin: 0pt 0pt 10pt; color: black; font: 10pt Times New Roman, Times, Serif; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>EXHIBIT
99.1</B></FONT></P>

<P STYLE="margin: 0pt 0pt 10pt; font: 10pt Times New Roman, Times, Serif; text-align: right; background-color: white"><IMG SRC="modular001.jpg" ALT="">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Modular
Medical Announces Pricing of $15 Million Public Offering and Uplisting to the Nasdaq Capital Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">SAN
DIEGO, CA, Feb. 10, 2022 (ACCESSWIRE) -- Modular Medical, Inc., (Nasdaq:MODD) (the &ldquo;Company&rdquo; or &ldquo;Modular Medical&rdquo;),
a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce
the burden of diabetes care for clinicians and individuals living with diabetes,&nbsp;announced today the pricing of its underwritten
public offering of 2,500,000 units at a price to the public of $6.00 per unit, for aggregate gross proceeds of $15 million, prior to
deducting underwriting discounts, commissions and other estimated offering expenses. Each unit consists of one share of common stock,
par value $0.001 per share, and one warrant to purchase one share of common stock. The common stock and warrants are immediately separable
from the Units and will be issued separately. The warrants are exercisable immediately, expire five years from the date of issuance and
have an exercise price of $6.60 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0; background-color: white; color:black"><FONT STYLE="font-size: 10pt; color: Black">The
Company intends to use the net proceeds from this offering for general corporate purposes, including working capital, to develop its
initial sales and marketing infrastructure, to fund additional research and development activities, to develop its initial manufacturing
and production capabilities and make related capital expenditures and to repay a promissory note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0; background-color: white; color:black"><FONT STYLE="font-size: 10pt; color: Black">The
Company also announced that, in connection with the offering, its common stock has been approved for listing on the Nasdaq Capital Market
and will begin trading on the Nasdaq Capital Market under the symbol &ldquo;MODD&rdquo; on February 10, 2022. The Company does not intend
to apply for listing of the warrants on any national securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0; background-color: white; color:black"><FONT STYLE="font-size: 10pt; color: Black">Oppenheimer
&amp; Co. Inc. is acting as sole book-running manager for the offering. The Benchmark Company, LLC and Lake Street Capital Markets LLC
are acting as co-lead managers for the offering. The offering is expected to close on February 14, 2022, subject to customary closing
conditions.</FONT></P>

<P STYLE="margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
registration statement on Form S-1 (File No. 333-260682) relating to these securities has been filed with the U.S. Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) and was declared effective by the SEC on February 9, 2022. The offering is being made only by means
of a written prospectus that forms the part of the effective registration statement. Copies of the final prospectus relating to the offering,
when available, may be obtained from Oppenheimer &amp; Co. Inc., Attention: Syndicate Prospectus Department, at 85 Broad Street, 26th
floor, New York, NY 10004, or via email at&nbsp;</FONT><FONT STYLE="font-size: 10pt; color: Black"><U>equityprospectus@opco.com</U> <FONT STYLE="font-family: Times New Roman, Times, Serif">or
telephone at (212) 667-8055. Investors may also obtain these documents at no cost by visiting the SEC&rsquo;s website at&nbsp;https://www.sec.gov.</FONT></FONT></P>
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0; background-color: white; color:black"><FONT STYLE="font-size: 10pt; color: Black">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color:black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>About
Modular Medical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color:black"><FONT STYLE="font-size: 10pt; color: Black">Modular
Medical, Inc. (Nasdaq:MODD) is a development-stage diabetes technology company based in San Diego, CA. Working from an innovative set
of patented technologies, Modular Medical intends to launch the first insulin pump designed to meet the unmet needs of the greater part
of the insulin-requiring diabetes community. The Company seeks to transform the user experience, revolutionize design and streamline
manufacturing, to decisively open access to the new standard in wearable insulin delivery. Modular Medical was founded by Paul DiPerna,
a seasoned medical device professional and world-class microfluidics engineer. Mr. DiPerna was previously the founder (in 2005) of Tandem
Diabetes (TNDM) and invented and designed its t:slim insulin pump. More information is available at&nbsp;https://modular-medical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color:black"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color:black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color:black"><FONT STYLE="font-size: 10pt; color: Black">This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Modular
Medical desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including
this cautionary statement in connection with this safe harbor legislation. The words &ldquo;forecasts&rdquo; &ldquo;believe,&rdquo; &ldquo;may,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;could,&rdquo;
&ldquo;target,&rdquo; &ldquo;potential,&rdquo; &ldquo;is likely,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; and similar expressions, as they
relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements primarily on
its current expectations and projections about future events and financial trends that it believes may affect its financial condition,
results of operations, business strategy, and financial needs. Important factors that could cause actual results to differ from those
in the forward-looking statements, include the Company&rsquo;s expectations with respect to commencement of trading of its common stock
on the Nasdaq Capital Market, the completion of the public offering and the use of proceeds, and the Risk Factors contained within its
filings with the SEC, including its Annual Report on Form 10-K for the year ended March 31, 2021. Any forward-looking statement made
by us herein speaks only as of the date on which it is made. Factors or events that could cause the Company&rsquo;s actual results to
differ may emerge from time to time, and it is not possible for the Company to predict all of them. Modular Medical undertakes no obligation
to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as
may be required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-left: 0; color:black"><FONT STYLE="font-size: 10pt; color: Black">All
trademarks mentioned herein are the property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color:black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color:black"><FONT STYLE="font-size: 10pt; color: Black">Ellen O&rsquo;Connor
Vos</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color:black"><FONT STYLE="font-size: 10pt; color: Black">Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color:black"><FONT STYLE="font-size: 10pt; color: Black">Modular Medical,
Inc.<BR STYLE="font: 10pt Times New Roman, Times, Serif">
+1 (858) 800-3500<BR STYLE="font: 10pt Times New Roman, Times, Serif">
IR@modular-medical.com&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color:black"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="color:black; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>SOURCE:&nbsp;</B>Modular
Medical, Inc.</FONT></P>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>



<P STYLE="color: black; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>modular001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 0 "( P$1  (1 0,1 ?_$ )L   $% 0$!
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M95PC17=XW?EO+VJIQ''2C'.2^V>W'\I$Z.S4"84T <IQKH -N@ VC0 ;1I8
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9-K0\!$* Z74A%=X)%.)]&JYPVEU5RF?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>modd-20220209.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /685w7xRiXgOn8uAbHZMSa+PKcOdzpR0eelBvGZwHblajych5KUGvy3Hiv/W4SkC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:MODD="http://modular-medical.com/20220209" elementFormDefault="qualified" targetNamespace="http://modular-medical.com/20220209">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://modular-medical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20220209_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20220209_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>modd-20220209_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>modd-20220209_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20220209.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140252985938664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  09,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-49671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16772
    W. Bernardo Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>modular_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="modd-20220209.xsd" xlink:type="simple"/>
    <context id="From2022-02-09to2022-02-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-02-09to2022-02-09">0001074871</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-02-09to2022-02-09">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-02-09to2022-02-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-02-09to2022-02-09">2022-02-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-02-09to2022-02-09">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-02-09to2022-02-09">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-02-09to2022-02-09">000-49671</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-02-09to2022-02-09">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-02-09to2022-02-09">16772     W. Bernardo Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-02-09to2022-02-09">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-02-09to2022-02-09">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-02-09to2022-02-09">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-02-09to2022-02-09">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-02-09to2022-02-09">800-3500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-02-09to2022-02-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-02-09to2022-02-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-02-09to2022-02-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-02-09to2022-02-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-02-09to2022-02-09">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-02-09to2022-02-09">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-02-09to2022-02-09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-02-09to2022-02-09">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-02-09to2022-02-09">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *A;3E0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "H6TY4;@NZ8NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*'9&82;-I:.G#@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/
MGT"-#E+W$9]C'S"2Q70WNLXGJ<.:G8B"!$CZA$ZE<DKXJ7GHHU,T/>,1@M(?
MZH@@JFH%#DD910IF8!$6(FL;HZ6.J*B/%[S1"SY\QB[#C ;LT*&G!+SDP-IY
M8CB/70,WP PCC"Y]%] LQ%S]$YL[P"[),=DE-0Q#.=0Y-^W X>UI]Y+7+:Q/
MI+S&Z5>RDLX!U^PZ^;7>/.ZWK!65$$4E"GZ_YRLI'B2OWV?7'WXW8=<;>[#_
MV/@JV#;PZR[:+U!+ P04    " "H6TY4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M *A;3E02$B&55@0  ,P0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9C?;^(X$,>?=_\*BZ==J6T2EY\K0*) []"VE"MT*]WI'DQBP&IBL[93VO_^
MQH$FW%Z8<'TH<<A\\_',>,:FNU/ZQ6PXM^0MB:7IU3;6;K]YG@DW/&'F2FVY
MA&]62B?,PE"O/;/5G$6941)[U/>;7L*$K/6[V;V9[G=5:F,A^4P3DR8)T^\W
M/%:[7BVH?=QX%.N-=3>\?G?+UGS.[=-VIF'DY2J12+@T0DFB^:I7&P3?;FC#
M&61/_!!\9XZNB9O*4JD7-YA$O9KOB'C,0^LD&'R\\B&/8Z<$'#\/HK7\G<[P
M^/I#_3:;/$QFR0P?JOA91';3J[5K).(KEL;V4>U^YX<)98"ABDWVG^SVSS;\
M&@E38U5R, :"1,C])WL[..+(@+9/&-"# <VX]R_**$?,LGY7JQW1[FE0<Q?9
M5#-K@!/2165N-7PKP,[VA^J5ZZYG0<K=\,*#V<W>C)XPN^7+*^)W+@CU*?VW
MN0<$.0;-,6BF=XUAD+\&2V,U!.IO1/(ZE[S.).LG)$<J3"%]+%F\;WG9#''S
M]N5W!**>0]11E0$01!G%;<S6912X_8K%AB,<C9RC<9XS9EP+%9&QC CD2ZE?
M<*4L\IV+SY\^582^F:,U4<&QM,*^DUL1<S)-DV5Y.N(:ON]?UCO-5H#PM'*>
MUCD\CWPM7#*"SZ8L*744KG/_,'JZ&SR2^_%H,AS<79#)='B%\+5SOO8Y?$.(
MIF8QF<B(OY'O_+V,$%<"KP5^J]Y&W=;)L3KG8"W8&YE$P"96(F19X3T=5%RQ
MW;KTF]2O=QH(7N 7A<X_!W B0Z6W2F=L%V1N8140I<E0I>!0\*N*2H-=H3[]
M@4$>5>/@',A!%&ENS,7'!;F#Y\B#+"?#)8-FJT4_$_A[OB(W7$NF(T5&&IHA
MAEQ4[H#^+^2A&X%#%VHG2W%QN3F39"3X6F%P10\(\"K^*UP>[IE6KT*&Y0[%
M-8<##*WH# %>VG]%FREC83W_*;:G<Q!7[-" MC"VHEL$>)'/8CB 7=YI%%S@
M2[O1_HJA%-TAP$O[G0K!*[.-DEA[J!!I0W^X;O@^1E3TAP O[,]:6,LEN"9)
M4GFH<J:4"A>J:NY!T1("O)+/52Q"885<DWM(<"U87,J#JU3R%+T@P$OW3//+
M$-S#887M]V"P#8(-WL-J=2)^N%X5&2VZ ,7K]'_()L:D0%8%6"%;"5AT (J7
MZX6PL!%2*Q+0+\NO9,[#%/*MM+M7*+G\A/8[MRI\P=".]NAX:5YH%KD4F[\G
M2U6:8!4"L"4:821%6:=X"?[P"AF_A1LFU_SD'JU":#J8CP9_8$Q%/:=GU?-Q
MPO7:>>DW4+ ;5R6V3);'#Q>T.D53JJCF%"_&8W<$YA&9*EB(BCP93NR&@^^L
M2_J(0%SAE)WMU?;'@U)8_!TG%X!W=#9UY_Q[YMQC2,Q7(.1?M4!7[X_.^X%5
MV^RXNE06#K_9Y88S6)SN ?A^I93]&+@3</X#1O\?4$L#!!0    ( *A;3E2?
MH!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1
M&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMW
MDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<
M9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20
MIV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!
M)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B
M+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM
M(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS
M8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FS
MX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5
M[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7S
MJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41
MP+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS
M#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U
M(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,
M/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#
M!!0    ( *A;3E27BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,
M0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BD
MMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G
M<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^
M=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"
MR0_L?@!02P,$%     @ J%M.5*K$(A8S 0  (@(   \   !X;"]W;W)K8F]O
M:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y VY"F#8V)]]"ZU"*)*\>%C:^?VZH:
MTE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P
M9:P!Q+MTFF6SU%L,9KD8M;:<W@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<'
M)O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-
MY&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_
M4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;<L@F:NJF*9ZC#GA3
M#O9&3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#
M!!0    ( *A;3E0D'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z
M=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2
MO6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV
M-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^
M 5!+ P04    " "H6TY499!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S
M72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2
M%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;
M$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!
MZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKB
MRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'
MG2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"
M[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( *A;3E0'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MJ%M.5&X+NF+N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ J%M.5)E<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "H6TY4$A(A
ME58$  #,$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ J%M.5)^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="modular_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="modular_8k.htm">modular_8k.htm</File>
    <File>ex10_1.htm</File>
    <File>ex1_1.htm</File>
    <File>ex4_1.htm</File>
    <File>ex99_1.htm</File>
    <File>modd-20220209.xsd</File>
    <File>modd-20220209_lab.xml</File>
    <File>modd-20220209_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "modular_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "modular_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20220209_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20220209_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "modd-20220209.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "MODD",
   "nsuri": "http://modular-medical.com/20220209",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_8k.htm",
      "contextRef": "From2022-02-09to2022-02-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://modular-medical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_8k.htm",
      "contextRef": "From2022-02-09to2022-02-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001019056-22-000180-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001019056-22-000180-xbrl.zip
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MX3]O4;<.!VURP#OHUITX!5\J2KNAV_+H;F[+,PD#K?!( JXXG20,S=0<Z]%
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MU&)2,X$*,U%3 DF&:Q_HKE*ECU>Q=)/4)F,6K):V+0='P2T#)4<,8%*2S%4
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M"F6UP2[$9M,^9 GBY.ILEG%0/\41(-== [8\.YN<<- ZD(>/CX^C^='L*#K
M,_Q;6;V/SHA=!49#JY;XBT4C3GG$!2B5UJ>F-Z;Z+-YLP$G?=#HI.Q9V C2D
M"74"2!IA0VH/$K-ZUID*S!&.CC]).%7N$RC,0/X/6>6*1F"."_48K=PDDPF*
M)**O42H;M_&D?"9H?$:@)+4B +%[ ]?%L"A1#TM>G,//7R:XF]?3N@6!&%\M
M?;W=E']X;>4NXW:.OEGCHO^YG"SRI!H.?DXG6)T51Q?%^$L H-8:[<FC;[^]
M/QS\>A0]!3T/IFX9/:M 7^SJ>-\E8$(]R]*K,H[.3J/O[Y_<_W97QWJ*1:VH
MAA\/![]'_]S589[CE1 <XFX?^%5!G ?[(,X^B+-I$.>S& 0[=&]2I;6]Y5MA
MT_U=O[GJ/"OSLLB27"L^+C6Z;RRH7;[['SU"=*\$K-Z E@.O]P3<T>=Y65:[
M.NAW20Z>^DM,]Y\1W>LOE]%WWYR<G.SJ@%=; ?MSAFMH[MP\G3;W1*,?M_]]
M#*>MDOOXMOG\2LV\I4?WEE7;-J7C<ZP[_=_)%]Z WX>#K5J\G^1P/Y><I81'
M3"B$."TX%,+8$"_&)P'1V NMS+"1V$BC%!Q=D(\THM8)E2E1J7F)1F(X>C8<
M=",^-@A"+Z<QQI'P@W#R=)S-,\F#VN\P,,(M)<)HCX3*^!L..[']W>>/X_]Y
M@R)CSURZ-4AMF@UIB$H76GY)42KDGY#8*8<YJR4<L?)]&[?/F",6,*3J]3K[
M>ES>;LQ[Y5 EP<4R'@[TP[^GUTD^[0RFE=UCR(<4CVF6*(3*NL&H;SO[($@#
MCN'Y];[2*:B,DO DO#.I=+#4LA4++/!8Y$N983:5/\BB/#.-EBBJ2/A5 B*D
MZ6&K.E=HS">+RM93.#]O_7K?(/[3DV'WC^^6#'NWF,_SU-8_GL(?)_17-S^V
MWZ!/Y(?S(-E!E'BWQ7)MMH29"JA]0S]M-N?;&?Z#KW( 33_EY0A]*S=E3]8(
MI2I124PF%BN@Q/Y4B669_5OE4 I!Y;Z>!DS4@E'QFYT^=9C ))J#&CO=6AH0
MOR!%R %83W-Q%#B#1 $Q]U.B72*:6+*8\,OQ0F@8DMDHNUJ0EW.0?>#/RJHB
MR@6"CIN5%@2>*.).-P/;38-N#P7",209D8=UH_L2!32[MHTA#-@!#P0!U\%K
MP%2>7B%P@KZ))&>T2I2IH^]H-]]VQX].(4!0ZHC7S>#_:#$,JUN0*ATD)=.6
MDI6TEV3TO6ZG V.;P-U:4RV:!;1IV5N]4F(<66VEGSW""RDVFV%.#>MGI4IW
M7T:V<3"K,#NKBL#I=F& +-)&M*]G(KKG38XI>SJF!M=L,-($^*&69B0@8HL3
M3'N6_$LPR@I+#)-S($)). <M$'8]89^5$Z:.\G2H*C*!O)+ZG%C;S#F.HHLP
MS.-4.C*I#"6UD7 -X9C"6;@F:(N'U7UB8PKUS)JLUJY/[F0!Z&%W[OOX3@^\
M9JRL^SP"Y2-#-4]:D^LR'::V=?K(*YLU$=DYW0\,3HQL1Z9K](CM3E@ .ZTV
MF =,Y!*E2/JW3!9CA5G,X3-X,D:SC;,PY2M(RX^Z8_>V5#N*(!3(O:"=P^/[
M%IC/AX$L&H/YTQ(*E\V1=2C7LV.QYA,':,Q8[SBZ5GBR+G.B9IQS/TBY$*MD
M<G9HW=EL"/:34^H=*@#2SS7@"0Y6394!2CJ%A<+II*]4RW0\Z_!GF;'&[-/[
MV''%MH>Y:+V5XH+--E^/+1WW#1F^V[BT@RG*^<P2)S/H +."Q)6+, NC#LW"
M>1!O-,5?E2'S;686Q1,8XWQ99+W$*6@*RG!B^$/]<JY-LGG?[+-Y^VS>3A(+
M;>CMGMS5VY62!Q_]>9KG+?]GU=U-Y[&L^CRAE?!).?)9,1%";*DEZ3XGJ]2J
M1;U@:C4,2Q&LJ30WXM;27RA,H1*VF\&1^W<3EZ>\(P$9:(.'O:;>+0U/H#HT
M IIJP<:,J1R2!E32_%P+K;S&PEU[N]LR(G Q(KL!L<>C?0KF3,-6#]F5,58,
MI9.E8.6S6;  74O>PE>6"C^V(Y5Z-.''[CD/'N6PV_IIW2*LG8S#_2E"A _N
M=@I^XK0,"/C+Y.9)]+^<@N06"T*K%9E4[(70X6I9MJU3#*_3ZR@T'RLOAAR=
M;ID%2Y5;LTO%NEIT0_!A0^N4?2#O+I6@A*F1F>;9F \Y/ BAR,4X Q.N5O_5
M)SQ0_C"'U\ZR7,5.>T=[O+3Q*QP*"=N0V8]O)#<D3UP*G9MDN<I8'!'/BJQO
M0=UE#*$(U4:O6 HYM%Y=,Z(!87UA"6"*6'ZN1_M=B9U1JR(RGSN/$I*PJDH_
ME&,BQ^.Z^=H0D;F%ZU(3[1>S6_-75<>1'S25E;Y)X*.:/6LJA99@!>?@C-KQ
MGLV*18-7LBR&KQ0^YK@=7/D9\;G"G!>S_Q05 _]=-[F]H:;YYHY<*TR4C)CT
M>I5J$4];'20].%P)1D&3L?,DJXE*IR^*^51*E-%70[8K94AHDQ\DMH2<9=]0
M2P:>UI171&DP')#RRAJLU,;KM"QLX1H5M5O^23!#(X<BNJ, I'"!&JP0;U!5
M%MK%VF\[10\VQ?^QN)=, B :0YO08\[;3LR^?S>/@A6T.W:C/4NH[K$M9%CS
M/&^LU8_(A''3$\%S>D?")L+59@-&1JU0YP1+F8@QK3'S.3)5BHF.S]*DT"NC
MM)R$+9;^5CYA3PMU!PFZ8V.P=U04RJ?(DZ)?<6<^$(M'32SD,>N>%5E^)PU/
M61*XI42KD7Z1L##36'O1(I0L(@=08GWN+HY1<K!DN$5"-FWEMKJ2K&\G^K+K
M;)0)!0MEMU8]GX9GG^S,PH[1,)LW+N1&7V1X?Y3CP#3E1L92^L?$=.:N$'!3
M2/#4?[=)%_%W\!?[XMO/<F[N2*?VG#K-_IS\*X5;YK;Z=W:K6\7L-CFK1)7Q
MFOU/F'PC1^XJ#-\PDP<E$UU:WS8!(+H&HW19$B=N[1'[L2I'20VWE$_8]DW$
MN_BIQ :6:57!?0O> !-0UW!+4]:!9!K)H&+J^/!^4MZP6,^2?+HHQM+QCS1$
MM=!KROM83)_9?(&UAM-D+'0XE'8FLD/X' Y40@TQ8%TYZ6Y6 I^68G0?[8IH
MDF'@'-="8]]90:O$UGM35@FW2P!U564I0A#J9=VDLSH>#O)DA#EEYQ$Q9C>8
M\A0<L1Q4"J:#8^XR@<M-.@8>6TYL/#ZTL4@'[NS"")Z".K%$\XO=#$SVV*R\
M,*LRQ3-6$B/=*E5[B]<T2HKW[']-%H0GHW1EO9CY?,\(/RO1MZCU$2VB@'%6
MC1>SFEHMUF'(%TNT@ H"+ UN.N';,#.,>$<FG^)VE%S):5/SR+7',P_BKP]?
MY,#XK6C;3U=J%S^^4[-Y.*  ^G/"H()U>:'JK8M:7YFO>;C/U^SS-7]H]=46
MPP$7KX:#7R\N7YV_>Q?]^N+\[?GKY[%7KBY]$LA?I>X.'7R;H'3=+"@J+]%G
M$RG[7Z9))000<-M\,&U0VSJ-%L=NM[N][>W?> $]P9"3-X;CG\QK6!#]TU>T
M=R -F[_@ P9-X3K6C0&Q_DHEP4K6Q@-^B.*VD6(&F;S[:Q]\D;=^\^TGO)8.
MX(YLVUT6[>PU2ORK__KJ_L;B?=MK?WCZX\^OG_WR\O1M]//YLXNSTY=Q=/'J
M#,[?TQ__BDOY%WD5_V73_]WO9/^KGBX?KWQ/T"0[49-L(XMBK\6V_=I7R0S^
M?)[G:1&]%K?JK"RP+=X_RGJ_F!N]]A*!P(_[6EW_%1?SK_2JO\J>?%Z;!Y[^
M^M7%Z4OXSNNS_QU=OCU]]>[Y^5MXZ\_PTM_V-M"?Y57[/=E;,W\U_436S'[-
M/L%H"2^:1."V (?^DP3"33";PM(8BO- F^.EC=-M&-5^M(]J[Z/:?V14F[Y[
MO/XY6"OCPRO5M@E/BR+]""?D<?0<Z=##:.WH+5/M"MVT9R)^H>.^&TKGU].W
M8$1?@IR^O;QX?G%V>GD^'+P]_S^_G+^[C%Z]OKPX.__20_R#P!FW7E4E.-="
MFL:5L<-!F#2MV\8',1!"KAIYW*K1 :95_IY/./0A^67ZV^$7G_%GP;_VY;MN
M7?YK2?@3<\D$&\-H-:=7K?R&.PDXN?<#65[]!UU?!2%,16VT:GL5*-_BJ1%H
M-.% :^)5T/KJ<,LSIW^#APC0_D).82K"'"P#=)J7-UOE_EJY^*UJHL^;L_M^
M9<K.7+!(W&4RGSMB1]LT'DQASF7K;!H\P+75?U';X,'M5"HG1UMQ+>WB;FUD
MZ-!8X@&/=R"CCG@S'FWW[#R._GO5?W;52=K2NMW?UHY^CEV$G0MV9L26#QEU
MAT=_ X=,(+SB5AD(;/_A+?O_UQ>!![LE M*HQ]^\HB,8LIT\W/V1=E;PFUW?
M3[0P&8(9;)V*X[4@<3)L_K,W].&N;^C&!U3[_SK=SX),CUR6<*N&_HOO_Z.=
MVO_0C>PT<5+*3 89R^W<;CES>Q3U<WB0VV<AV CQN*8,[T>W']V&H_O<]!H;
MQCLD[C <.$3)#F$DE\-3KZIQ6112R""T24X_=<.9KZ6P[G710P#ALF%P5ZZ4
MNC@KD-@0$:9^6\BU7 4-PNA=Y[PJ_?<BR;6P(O!0B:P$:)J<P?\1519;%!7^
M[SKGX_=W%S^].KW\Y>UY]/IY].+URV?G;[?*6K[^4-3#O"BP>SA>2>=(2[C<
M>O1J&YKC\^N3U2/]Y$R'5^P"JWUJ>=;X@[):AG;!J859O6X[N5U?5J)#:[R3
MR[0K"T?Y_#_YRGVAI7L&M]6?9856KM>M:(1O]VB$/1IA8S2"\\';19[>TP_[
M1.@XL#CDGWMC<G_MG@M'U.AI+&??6*C=:BB>G2Q.3?[7G9HWA:W7$'X6H,7Y
M1R*.& Y.5D(M0MB*5=K@N[TVV&N#S;3!7A>LOO9/_F"%</\QP2/2HDZ4.\G#
MOVP;;B53O,VL>9,LB2<B ?V4ETC^]SCZV^_=^KJMN\VW#^U4J/^3//H9/KO.
ML:E]&AZ>-]3HH%X0%1_%7RPO>Z";"1&RSQ8-1E$22W_O<^4&24RW"CTR"V+,
MP[VJ]Y2<VLS&=O[ZZ>MGOZ&:^_K%Y<\O?_S_4$L#!!0    ( *A;3E3_,,?>
MP94  ,\V P )    97@Q7S$N:'1M[+UI<^/&EC;X71'Z#QA/3X<4 >E*M7A_
M':%:[*Z8NK:GJMR.CHZ.#I $);A(@ 9 J7A__9PU\V0"X%)DW9+CJM^9ZQ))
M)'(]>9;G/.?[_WCW]]<_'!]]_Q\OKU[ ?Q/\O^_?O7KW^N4/W_^-_PO?_DV^
M_O[9+R_^*WG[[K]>O_P_7TRKLOTVN;Q8M,F[8IXWR<_Y7?*FFF=ERA^DR=N\
M+J9?P(/X_[[_O\[.DA^+?#;Y-GFSG.5GOV;7>7)V]L/W+U[]9W+U^M5//_^?
M+UZ__/'=%_J&>59?%^596RW@/8\6[7>)?#*JVK::?YL\7K1?\..F3V=-\8\<
M'L#?CZIZDM?<PK-9-GZ?/('N-M6LF+@OM3'^_M)_?U=,VAL<X<7_\\4/_UZ.
MFL5WW_\-7O:#_*\9S]^" =%H?PU'\6UR@?\/.]7F']JS;%9<PX=U<7T#'VT_
ME]__^,O/[_J&>T%S\>R'EQ]NBE'1)I?GE]__[1GT%1^ __PZU*W#O5WG:."-
MV[Y&EYFGC!?>SMDX+]N\WF(J_O[+B]]>7[TY/OK[RQ>OGE^]3I-7/S\_7SLK
M']''C^S<?_\O_-__)&]OLCIOCH^J:?*\FL^K,GG;5N/WA^[D/W_I]IF6__V?
MXZ/?L[K.RK;Y!#/QUYS0_<["][_]\-O/+UZ^^?W-JW>O?O[I^.CJIS<O7_[]
MY<_OOO_;;S]\VC-!0NY \]XK/NFCHISDV-S%^=.BW#0CLLW2XZ-'%X\>R=!Y
MS;;_WW_M_1A/^Z8>_+)8Y.5-#HW5R;]G\\5W(/#.DU?E^/QS]BIKDC?Y D0P
M_#QKB]N<1'%[DR=-?IO7V>QS=NXW^&%]5Q=PQ.&**+-Y/DD*N"'&-_D$%([D
M57*3UWE;?<X^?OTT>597V03NK3K/V\_9%6SQOZKZ?9KHOU!YNWCR<'UL\<;7
MV:2 AK)RDOP$TSW+YWGY[5];!>F],?]8-FTQ745[ZW+SE?'W"LY<5H,VF4^*
M<39+27:E208]N<TF63*NZD55@Q !)>X$)<B_SR9_+JOO0*];9.7JWVOZZS1-
M%G6UJ!KL<;,<_9&/VZ2M2.3 .9_S$HRK<E)@2PW^L\V*$HX^'O:BA#L+?M[D
MLQD^MJJ6]  ^7L'_U,G2"(V@'U:::&<2%BI5(%2H-T63N >*\CJYNH;C#7NB
M/3ZRC;J/_?"F59W<W51S[EN=)]F86NB(VJ!WX5>^M:Q,LFMXR776P@BGR4EQ
M>GS$US<IT TIT$%3K%.[(8H\=\O0X,<XKZ1N-ZANI\F_79Q?7%PFBZQ.;K/9
M,D\6,)74=KR6\-#Q$2GI[@VX "=%<9K<B=*:)GDVOM$_D_Q#7H^+)AO!].+L
M5&4N;4=J?Y*U.&#Y/72B+L;THW\3A<5WZ_CHKFAO8/?AIL&?3'%&5WD6K;KJ
MT=K9\^0=? GSLX"-AX]D\VH)W^LT\>31D/11W! CZ,RR'M]D#6R7T8K&%U^5
MB=UAM/)-WN* H9_5 K8\?(&_+VK:=DVT[?@N.Z@V<%@) !-W?"3[+5ZXHFF6
MM+[+16464";(S21.2IU/\[J&:81IY2.-1Z.[9+(4Y[)R";V>/TNC5D4 A _2
MR\;5;,8+/5LE(+5F^<2^ZFT^7N(!#U_C6X;1@IR!Q<?QY9/C(]@$,- 2159*
M[^5?W&2WM+2LD7./8//>%K/\&GKB]P'(+]BS>C"RZ[P<K^ _(D329 +'G.01
M')-1#L]PL\]GL'O*Z^.C%_ ]R<VFA08*>/<*52+\#?QX#@>HS7!+R6["F56/
MR+.^<Y%T!!B\MKW+\](*#1J/MQF@43N"-CF!WN+/FN5XG#=-5:=]ZWEU;5[#
MY[#OM-T5=LIA[D HP:AAH*-E2]\>'P7'L:VN<Q+]-!$%;D[883!=ASY+'??5
M?D=))Q=& 9L%APF#P:F8%C/6=.'NPU4MVE5"THYV6/[GLJAIR;S0<MLXN8+K
M%#Z]_.;QXQ17'P0-=&L27A#NYV 'CUM[V?#I6"Q'LZ+!;52#;.+U@2L([G^^
MDW&V<[IHPSL,?^QOA4FU:%E:1GW$YEY^@-4KKWD:YK#6/6J#?&SZ!S?H==&T
MHF6\A<N2)B(Y@9&R+,FF('V323Y%E>$43]*/>"[>GETF)S^#P?7X\>.S1U]>
M?/GU(VBO*,>SY80.5H9+,"OFT$*]0A6%+HAE(Z=\"=<9327/.TT 3#.\=IZM
M^/B/\-#(ZDQ4I9G(M4W[TIVU<SA8BX+%*#9]?#0T+M?#!,5,MP=\^<HV@ &0
M^/C5C.17-Y+A2<+N'Q^QQ""10T.90"-PK_D5U/V*A[T6=>L.I7QVFQ4SDOZL
MD?'9IHM9%K._1RIRYWE6PE;$MOL7018*CT=+@J:%,TJ[&S665L<_,(G07SY1
M[@R9+1>.+1#PY*9/GCQZ<I(Y+8JV>'=\_6_6\4%'EPV?Z' ?\,BIX:(L4)P?
M']6VJ69H)^0LU!N1%V56CN'II!%U@C_''TZJ\9)W#'Y2D#SAMB?8AXDJ-SR-
MH%L/S^,(KQJKY<,'=)G#)9;C++L=<1J('E@STNYIS4JZW=S1@'MIE(,J"CW.
M06J/V05AY<!+_3C!N\_+ C\?/'U^8"?%%#?)J3$=[!5)NF()DV7V5[@_ IG4
MNR%&X8:@877GTTD),P'PIQMH"7=E3_N/+ZZ<:BG[[56@P].-P5U&\V TJO/;
M@D[^P.:!IOD;./79A"TKF  CDN->'!\]^?(1#I.EO!^I71KYR=K-?TJJ0$FG
MUF\6T?M$2/8W0+HF"KU90U/JYU>D 4OEM9WHDT2Q]!D\G<='_G@&LLCO)2>7
MY,.!D[-V Z"V!#O6K7VPLXZ/H$<H$TDK3)V9;.6ZF2:=&>K@^DV>#.QQW,KX
M&QX1" 3L-,ID$"&3O!G7Q8C'.W08.EJ7"11BB/ [V'=_+G$;@#;$\4(*NYHX
MYL;(YY<FNAD&,!]I !-4L'=7SUZ_3)Z_?/WZUZL7+U[]_-/_^>+B"_K[[:]7
MS_5O>:<)=^X4$GSW!O[_%]I*-S@Q$$A]]P(CS&_P?["7$E3M3L4"9NP,#GCV
M_HSM@6]AI>^R5>/FA&;IRYY)PIG[*\^"#3#WQY8/J\8?R+?Y"8QNE?LDC-'R
MFZ!4$JD2>!W$MX8'>9Z]SU%!0EU^[&RBKLE =[6U4-EZ]2*!E0*49LNVVE*E
M5$OB5ZM(PVLJD#;\4_PVO-O=0_U*,]F=+&0#+QK>"W #3V[9P\0BW]V4T#E0
M4]"0*M"YV#]K?'UG,_RWU^6S97M3U; 6=.E,4+ 78()BB*1.QMF2IQEO)O?5
MA!U?_>HNF1(DZ[/% M8$>RN>LE=HZ];)CS#4Y'?Q. Y/\_%1,,_D8QSH:[0(
MU-*TKN9\%^']2UJ9:&HPKF8)?:/Y1BD?JAW395VB68BZNK=$@H?$,,&&J\X\
MG]YCY];E>??[:38O9JMO-PF_]5%2Q _QH'_[X6V&*_ZK>"[2Y 6;6.Q?^35;
MD;* 'M+PA&*(^CSYA56,4=84C;?X_%$ PSQ5OXQ:V<ZS!$MFM6&U:C>[WZMI
M&IW#@T9%=EC$K0+;8*KM&L:V_QM(6YH\\OZ2*XJG3.(.=&IE$>P6YXD=^E::
M3-5C/..5+ZLV^:,JRG:VXNB&^K;DJ/HCR I@N9R/0%K "_K\9_U.9W(YJ[_!
M=LIH^.-JMIR7QT>B*O^\]C4L^G0O3U2;[@^E&,_'.WK1?$0[T0V4/?W0;1"N
MI?@%Q5CT?ET[,_9S_K7SU?[;-BN=P%FY*6 JW&/PGVI,5A3(R.W:P&B$[RK&
M4"[I,^G8N3_[]_*LC/8Z*R*OG*G:7<M4+E81<O"[<5Y#;PN<YH9_$;D&W6K,
M,S!CY*X&W05:)*'705'@<3V74&04B_=Q\#@BGF++EQ??7EPDV?G\W'S]''VM
M>">FZJ9H<I2&R6C9%&2N33*X""O8*W?B>X#;N%=?(3]9R^>-+;^2_^ XY80\
M^7CTT6F'!Q!L^1;4CI/+B]/@=8W1F/I?Q3YYOY/Q\PF'8B+?G:I8<232]Y*6
M3-XRL??30NXG"JMT(BE!A,(Y^>_U]A\?9OMW[^MH%\OUJDLP0F<^QG5 1#13
M%K#%?)Y/"HYR>&_J=(F*/D:"5GIR6$FC X'^OE%6OH>;_28'RQ>54OQ'@RM%
MSX,J[S?V+,](__^/"A77DP:O ]A<I_*629W=.8<,&=91X!C.S#6H#TWK=P7_
M&IW7P6;2";%!UO$XB+(&EV*/7(A"L7^KZL%H[/$1;_'Y9XKV;+?7)ONK)7W[
M2[UZ[)&A0\RA91^:'.7N*^APA58):W;]UA0_A&&,O&E-"!+D+)]P;ZJY]H-(
M <7WX5/X<AIM(>_O"U[9WM35\IJ=4M-L7,QXD/+LBYR4&# \CX_>U; $KK43
M$3TOWCUW02?=.[+AG,(3OG(7%]6C[^#2H1G[%O?-6]S15?E=\I\(DX"O_^4\
M6':R=)J^2]ZM%C ;5W4V*L;?)3_#)N2I_+G""7H4.'/T*<I^>/"$/7C"MK+0
M'_TS+/0WH4%M31XCDT0"L5UNW4W.'N<G[\R=13:AM;LR;4X42 T6E1/_56*%
M+GG06/5L#FV$'_2RV\\&_Z5DAV/H'$S7Q5? GEQ@B"3MQ!=E&JT3SGU'\>:J
M:<]</,8'V,D,7Q<+C8.64;O>(T9F@#:K-Z#QR!5K C/IVGALU\>:G-#N03W?
MOU'V5>"F4R_=*:-M:/Y6*?E^X<\Y&B2H7HH&UZ2"MML2?^*,#!<;70, ,8B5
M)X.(%8\6,7@5UW(_2,6?50US>=C*.9R*@LRP-?-;"JK)^SII.117)>VW=,C@
M7RO<%*A5FSWA?6[LOF_K96[BLGC<_6R#[D.[!70TVBCT.WI0?P+&!O[&@DQ&
MTMZ$1U<0<JS,$8:%WF?ZF_P[$A @DU8[T+B'T Z%:0(C 4/JW]ES%)Y#A&E8
MN.V$5':+Z<M&%?RVW&Y^X\/9F?-HWR)$05J6^4=-X+J"3J>ZEVG*=YEP>FYX
MUI-@TDDR?))9/T]^UTCY (+G+H,M."UJ4(*'@[DG=S<,AQ.$0+,E1J9';$#W
MX8L>;$ 7$\.G\4X'L*7\P1$E&P:4L@9OIN3XR,R)D1AQ^$*OA4&YYE_G(S(8
M0KLM&BM"NN)-Y++'?A3LQ?V(S;?MO@L.NPBB0^V[5STAJ8$M**<_6 )O__4$
M?<@D0Y<#XQE+MI]TY@U:D_9"@7H&IA=H4SG"=^NJQ,]F*W::P(S1'(P91*<[
M;#M\0_B5@\._=.]!,9<E/V78+(F5JS*;K3#H@F-_D[=UD=^B+&Y68'K/G1GZ
M\L5/5V\\ZB7_,,X7[HV@1.$66.0U=QXMY3?NLDK>GKV#*ZEJL?,4WU5<DY%N
M);J\^^,^+)1-[$>Q+ B=O:ZSQ4WR" ^L($5@J5=NR_'.P) 0;\:&MSY&'M;I
M7&DLIX(=T9'L[ DK2L*R9&C[H7<R%5!:#'1- SR7W^D><JBA2'I:<C34$Q3[
M%SKNB%Z\/G:47%"XS<R>/=@4I.IQ&:.3'&&CHQQ$/FY7D4>Z6:#WXYRV  X"
M+>4T=.*.WY?5'6SVZ]Q$M*MR!CVP$]<W2<D^<[3=M#"2<T!^='=&T<1BJH/;
M(^0Y[17)>_$;N['QJXP<-2Z 91-X-#XE+5J=V>8(!,!U:ZV]\O,ZZ-U>XT5Z
M_. PVLEA]/C!8?3@,#I$A!.$P1Z^B"NG UYY!1$[/XA\\O?T27$JTAS#H2K:
M&8VE-I2)Y'L=DQ0BU&_(R5[-)G1SP,"+L68'<;0>)'2"F[SKY4#&@U<_)-__
M[15Q&S@3?!<,%\IQMJ<:T,IJFV@S+#)_RDNZ-EX4S7A6-<L:>@4R"CKI-2-,
M%>3IQ7L"QW5;3);P4 \**KA2R;KHZX_3^89?GVJ68G&:1*_%5V'@]5W>X"O/
ML*'?,[KP4%%<HN[)]PI.E4R/3-EINF>O%$'L_M4XBU3!O-Z8 )US"VNBQ=8J
M NSN:MQN]BB@AK&5D9'J53O#E#C=HN.B'B_GJ.)B0)^O;L9AD ?E#AXE53'M
M>"3(+,.).CZZJ>Y0.TE5]R&(M%6(K?-U)5HOMM>O^8:*K_1Z>,V.CWIUV0%5
M-K:'K"+QV<+CFR7G2\IOW0V6:&2@25:!O>9MN(3@&0TLH$UHP7FJEBVCS'4!
M5TZ-&U5E!L;=).]MR,#X]6@Z</KCQR<WIR=/;19#:,N?)B=H[&)FF6;R$'[$
MMPL7" KR0DW3:1&34+QZY9(M-0_:.1Y(-G B8RK(.OJF&?:U]F?Z.93-5J[6
MP+>ZCY?4Q#;@V&6-@^7 L6Q: F'!0:3'U!FD\V=P#+J^,$0PGL>:.\39%? <
M*?*PIF,K;3D7884F<T.>\'!/+2HTJ''BBO(6VJUJ/;EFAL@=SB#6&A-*DSE'
ML[,R[GIF.JXQ9.>80#%#B1@965$MR7O35;X!M;7UX[YSD^A^5E8!!,BY5J7!
M3P.;W4Z!NHIR8R3ZS:I)/FOR.Y[9.'7F4V!$N<>[BS)E:G *W/$1OBA(/DS^
M._F?;R\N6"OY;\2$_<_?_GN!_TE.7F:(L"C)T7_:#2X%Z,;[-VRG\EE-RLA,
MBCA*0J5/=QHPWBG!E$Y$%1\UNHH+DZG9XR- W@A57RSB"33DJM8V(T7['DXI
MWXK'1P/78KBQR)<J#T[Q ?7#+#H/G/1=81=/(S>[9HJ3MVL=V(9]->05M^&9
M"!#8ZY4ULJ\G7<0)8@D+AE>WN(^=.+W7L*SQGO;AN^&(2F&"PX/ZA\"_D85E
M(5HUK.\MWFPX]QC/@$WBW<%!YJ!/$AV,Z9C'JZ!I?&S)!!W#SKHT=I5)E,AL
M9]@!0_LY[57)8#]'*:4II;-2QHU0/O@MJCJ)3!.\8YR39U11@G@Q+Y8UY3SY
MS!V$*18MY>-(LGI[4^<P+]B5H;4X3ZX(P2&6T+28R?Y?X\UD;")'@Z(@280"
MT(#75NG$;D+4?E,HJ0A5."(E(DA<JB;W@(0XZ$M%-?'C&*T$ >=?QB,UFF=@
M_'$8)1(3/5G*CT^07Z&6D.#EEX^AY9-'^XXDV6H@.R69/GGPO>[D>WWRX'M]
M\+U^;LCSR\UID9Q*2<ATTF/1X<696A.%*"-=" @=Y$NB;=PZN(Z'')-)GK?&
MAF4G+5ZO4Y%-33;+>]  J&+!?3IC+T=6@V7/B!@?E5,!6E8>OB__[L5?9R;+
MGGQMY":&V3>Q0$$;P#\J:(0<6R0_Q<ME_88V'$A]0O<4#(Y\A/IO[R?43T@8
M\Z5B6^@$YH8"HX/.YD[X[_.EB'RUQ29^-053UU#.^,0?(CPKQZ)!;4K@90=$
M-8:=4TL*!_Z[(;:[6U'6)O"O6;5@;!\Z&V!?+&><8"6Y:LO-N<)^@6E5J^5L
M$BYK\K&KNB8/O!O5)7^,F(*N'WYG[H*.L4.!R0A=V1_MR-X6+!/ZL9W.'3JR
M4;/.6&&4<Q^)G-B?'0;TF0$,_FAGH:2@0QE^LU),:"@V0  $K1A,5-@(?1%"
MI2@=CL(%=\C=!Q9#DZ>#FRT(R2"PF17CEBB QA5L\+%DO>FV2WM6V[O<[W>2
M6+YOXHYE9_*;*[+5(W8G6&C-X7&$3JTB=K?CG$D9I=5[6BG;W/\I&PFY-&M)
M<YYF19W<%C#=BK)T@Z!L''-9VLS"@L$;I! S3 V/03$ILII@OZWSG=EXICJH
M UE0@?JO2>W$47I3S2;$W$J K03/><MO'6?-33)%5'S4)W93QIU*@CZILY>M
M#0<#RB??>>*WWA5D1SH3KH6T6[QZLEZI!\PNRPR6N,TM85< UQG$KVV%X4R-
M >SH!-$TC"-2UQS:0EDP1HP:+@&G2[$=#QNL6)!A3E'-!AWM^.,%QS1$=T*O
MCYVXHKRM9K?YA(,&S7(^SSAQ%#8!Q6V"<4\08Q?OY$-M5CNI&"(J/5S2X[9-
M=B)O2&JJF[K8V1@B:\U4-PPWQ842>@8_<4:3"C9A[YX*6%@B/8FF%:0X$4]E
MPWN2N\_[,MB)&D'90WOKR3C0]<!%F*WZI]]=I1A#ZMFBM/WJ":E3/=O?831]
M!.MZ62#HM,PE7&8 =.NGB$^C[04*&N2&!9%!YZ]R-!NY);QRVH#.008WXYP3
M TV,))=QJ<8M.3U$>YLU5<GQ!]?&!*\F7CMJPVW3FB#)T+FZ('.B2JYQ,[+_
MSQ%V(!@V&_M,I5 IL5Y?:?A>.V.G>UVU/V8U0FG^ ]8E^8]E/<M7R>O7OP99
M)%<H?JO:(U'N;M!O" L&9X[Y@M?*X&&V21/92!/A@P#S;%FKKU6E"(%VG'NM
MJ/7E*4,?<,+084M888$*L6AFHN,F<(>%UBCEQH0!X5V\9$\?O&0[><F>/GC)
M'KQD^PN]Z[WM"ZN *_$0ZKQ6S;6('/H-AH% 'SPQ=*XI23=0#9N;8I$R(5&"
MOHEE3:FG305W*6O^@L0_/G(T)55]G97%/^A[)EZM*Z((F11H#\Y6[!!P?T7A
MA1B%X_J^LK!!@N& GKW2UQ$:[!9680*?Y1^*A@LM,!#KNJHFB4NF\%&?6>8,
M!9*_3M/[ P1I,RG&#A@3LMWBJ,THW7RCD>-G%(UP95 HB'QI4=V)%U%(VEJ"
MH(VS&CEQ2EHK-X\9X>')341*]RC'SB,#S7(LU$0!">=Z(R_4U41WJ=#,3PG!
M(Q1+9&KEU!'6AUR2)IKW>,+A58)O@F^9^12-6+B@KC4#)<ZQL;R#@0\UR@.-
MF&P\B IGDA;;<]MA5@T\K4:CR3N"1N#^<]0[88ZB9T$3MQ"-B2:0 ^)%.Q0'
MWV(4J=D)O*WF*6N'N'23I2?GT_@XC4&WD&-3D2/!7<:CB#/DL_#4GB0S@J.;
M#2SB-59BH2/ MM:HD'"O7QL8+BS9."=,A9*X\)![%._P3! GW'ERA1A2,:Z$
MEM_5@1AGBZ(E)1NL=)R"U D(W&DL3W"J<\1!<:H1R2!_R(U"SBL.\Z+'VC ;
MTL'FUROOX72)=NPBX^$C]OH,IAX]?$[1)JYRZ <J9+W"*(VD49H04(,4:F3-
MT1@P6+_0]3$,'(&[<U#;K@G"NZ!,'"1UHRVQ<F,%X32>905L!X-LA/_OMB(Y
MQ;4B4G%EI&C0-JV?.U GEO-1G9'+?R'<R81X(V#KM5:,R,DD()2'AYEQEX^/
MWA>4E9FU3860V9"M8-V-X43MGTM8"+)[D5BR,J**5J,K:4E11F4&[D9T/G@)
M"C^EUUE!2ZE)"@!.R@QO&]UJ[E5>_O%AA<$25YMQ0^&J<R##B#!>]N,CDG7D
M](3#C-Y-;4BTZ8;]/#+4L3NGE,$W)5]IU&T"HTMQ#C!]9]AK=$I7TH@%F&-:
MEH<G^FH^[!-'OS!M?^/*SB:(_7/FGIBD/,34###U3(VI,7=MIAP>1A='XH!"
M$_O7_)).T8QGRBG]3'$='9^E^M:"76-P\+0/P,*:Y7;XJ!I@-"L(M:V_)2I3
MU*D7DI2<.,7A[SJ%5S*%G+VN6L1W8GL'C%S.O^"RZM(0;&( *@&PA#+7'*Y$
MTGX[6P5F_;9Z3SY_$@/D0D=7^;)N.69  K/)\_<"K:,'<OEYXG\J/OD^A0)^
M%.Q>NC&R]YB-[04^[N2"$,9T4L^6"SP;!1R!B7MH @*VFBWUSZE6=H&NS% 4
MXI_9K+JNR/?C9D@&;\>=ZO,<KPGTB)6583P;L!;J658OW CF=5K07AG#CD+;
MO7&MTHE8+%!+]?$C3)PL*#4@F\#U*_;Y;6Z^("F;4[!"!D6!7I +]?V.1-SL
M92F@]GP5TM +PFD-@LSI8A;URCZM,("%J&:-0Q?Z3SV3($=@] 5=R'1]U^DP
M:)][&\,>K?UR@F6 B#<1CP?=2Z<Q\)'^0[>H43(4)N73:_'TYLG)XU,I'":R
MF-)D<\[JN950*NZN:3ZKN/TY[/(< 9YD% 3/,.4?1P")79<>_0/Z/B8&#^Q=
MN#<G^;CF#<GQR%C''YZ6>^W.*P[(Q+M.4<&=#1<]W_T5*7^J&:-5:'1?*<X%
M$@BACVBE+5!VTYU*_W J&>84E'P[PIZI84EAFMXC(%+_K80)<H72Y\R]AXI@
M?8LY?_+,N%JLM&'W[^AYT4O@7W@)G84),M(%5##K7-S\6NR0.\X:\=\J_XE2
M62Q@CEK<_21CRREGL821)^@Q41FP;C'F"61-"@X*J#;-*=^;<J3D+@AJG?D7
MN5L41\#+-B:V:^4E,:2%#(81B]U%0,W,D*BW54TP'R?,/E14-OI(2<J8ZHXN
MV*\WAFB2NI%4RPGY@#QF1R1)=]=Q-HS<*@SVQ.@\X4%2T0UH9'=<YC!5- YZ
MA'V0LXZ@&:CBU53(A><6?X/=ZH0Y.,?>C)G-G]T&07J-7RXQ<[;NY/%1IY=5
M/=!*VFUFDRZID5YY21SG(?/&3 #GE79:'10;?J?G\\6L6IE -'R%FT0B\'R8
M&RH00$9S7#)JS02#O41 +>00;P,%4^<G6$.Z*MJ;HIZ0 V 5+&JD?LNZDL^A
M=V'[-^?&Y4VW>.GPB=AY-Z5]>SZ<A)Z53X*%9T.-F7C9TM!?2R=(;;8]:6P_
M)'G%F6-I8+LE/:9;JA9;;&X<'[&]D4JFL9B0/5Z[;0.LZ:Z'FA+5Q/O#1OLB
M6Z%J7*U@_X*\O.;"C7KEB*#'W%J1[VK#!6EX=D%Z?&78"[LF/L:YC87GH(LM
M[('K7.QM(9P.#'&WFM:_M6[Y>DWOP?43<W&7N-F7#W&SG>)F7S[$S1[B9OM;
M%W_LARX_@%S>6M/ >Y%<I/@KM GREKW3;=$R2_L4S#_0JA=<09/#1UR[#1U]
M*[Z2>YI(N 5Y1B('\A [/]G/F296$W?N;71/JW\;GD?_-MZFWN^,!@LZL)L>
MY[9639H20:C*:"Z4JHJ/\VBB'U^@*S!K7&$<J1Q9SFN/J<'.@_1"='Y[M7'9
M2!:1N'NKQB%^^6-A_78M]U1!*! ,9->)HQSND1LX8Q(UY%!9?QL=ISD])Y3T
M\CR%,M(P0&GL4O%/-[UQAP.O"UHC=GYY&_PS)SV8L'OMP'A_L-"\J==)9UL@
M/PXVFA)BC9"N 99/*%9="==M,O5HRPE4OY\KPK)#6,>:C>!*HG]R^9B(/NOD
M\BFF^[7J_%-[NKVKQ'=FO6H1I?6)1E":&Q@XRBA.[1,^/.M$M/"F67;'82U'
MDP@=PS%S8[I;3QGCY9@2W1=-0!J!OW%5<UO#V.&GU\?[N0.^7JE#_W7)?>R5
MH-%Z[Y[ >KX;RMUC7;"7SQ'0C[L".<6=_X(0I>BN120 U_VJ(]M.8K_$+ZED
M%J;DS!3Y8F<J=&S=6-&CS:O#//S\PZ*H,Q-,Y-^[%X&X[(=1$)I60*0OGU-U
M$&I]!S;6'3BFP\V,$LX0F9)PL[R99K1"W$33L0=1L]A8Z[-1#L@9_#&T2L='
M@[Q*4;5$=.-CG%@*($I&=FTKQ5'V[^63)^AV'4ZE?F=S!@QM52>*V,& F_W(
MM.0;]HMA[C4H]I [9U<*G-#CX"F_48MB-2;K"Z6<)V^'T@6V13[_5E)(@T(P
MS=9(?8?-)X%AP.<L-!B'*L&/"*[OZ&M!#/UT=?6KE3^I\5\P7ZEA8/5X>"TO
MTY_HPON#D.B&/ATU("'(1>.]+S7"-((O#^B583M,JZIE?+N],W (J<L*(&X1
MQJ?S4\C=%>^B]J/36V"Y;7:+D*GX+ +.*VA]80=>@MXH?)S)$N>EM"BL**4K
MU=/H1 $I]=":GT4_=^1[+-'3/\/K<*[C3^G:/LLIB@P/62RZI' ,9&WX)(4.
M\ZI>:6_UT1_=HTBJ+/O*P1'L6<?AZ].2.P(CZGU^4_K"!A+ ('\MW"6I0?_#
MN1%QK?L[N#P^\N5673@^(I,LNK/:*(/""4BY 'AQ#*0MU&$Z]NS:]+!UO!_K
M1A(K/BI@0^E=2HWT4'QG>NZDL##W>*&N/#XL_C[6RU)>@=AZLF'L%#C,5(^J
MW,')6_4!U+/>*Z%U'&A:XG>':5W+IM*=55B%_FE5V6DGM:H#W7\@4<'KN>N*
MF#!_HMQ,*%[I=FHJ,]A*J@B<)Y2/G]G:ACSCB"VI:<Z3$^%E)(@<J#\YH_8H
MLUD:/,4>>;B7"Z$4FERQDG)W_)N":'0PWLZWSPBN/J9TH5M80C9,M,KT4U;;
MWF*E9#6.CS9O\I[5H* 619V06D[W]P"X2$.-ANXF0K>RGN+AS()TC<&)C+E#
MX&-"+@2^3%DM&525!)C1AP0-%H+R5C;#H]H.4+55>&J/4D,[,2<#5R[]DP^G
M5 Z<@=/2)RS\ML(;FM9:T1VC%54YK)>+=DPE:AK46TK\-T@*"\CVB![&>/,F
M(8M,T4-13-'I5VERLJ(>Q9UQ4:Q)/B\#=!5AW+'&-A48T)H12=1[?T5.\PD=
M? J!D+70>)&$_17H\S]D,[-T@KTZH9M0Z>D5@$VSRW'S/Y;EV"6!\ZJ0.P$?
M(VPI@Q] )N53[5]4^MG_#!U'"$00=86_GL#IJ .*#%!":U<>D \KT01Y1!AM
M"/I:#R^EC;98YZ#TWJ)0BGMI0F[3XR.V0T"P79<]1V%-S'N;7>Q10A+7HI,%
M,Y"!?F;N@*V/!=Q*S.: 1]RQ/>!RIEY4S[(%JVML/'#/KXM;@39RI)9$RZC"
M^*CP'GC8-XC*;A]!+=C8/;MU(J^1+*L3'&$1%%PIF(3!I7+Q.U9M208DMT4U
M"_P'WO_I33;8^"F99:FY?U.$2UVSE)92I%3SGF%2W-@U)M*5^!L\4]<H$/A4
MPKY$8I0YDCF/!2R(4.1445H!-I,XM(.)" *K#E7L4UU"!KP>[EJ4CIQ6Z,D2
M\_*VJ"OM+DNG4.5PHC'$S, ^DO7GZ94<4CI0R-0P%O_#X>*97SW$,W>*9W[U
M$,]\B&?N'VR8[15L>.O89MR=W>4W(%$NBK4U,!O*+2\/R J0,FDVFVLW@@T6
ME^)*KDCNR)A0&^NEUW>L8^^,@[DA#;,Q?EW0\.7NDNA6H*)J?H67]%$ZB:NL
MQJ'52B*#8-5@M22L8X;%LSXLL&8G45;GH%;<_+G,$,P_G6'\UME-XVR6S2GM
MQS5:BX_+98C#%;N4_!^\Q_ =-(ILQ$#]Q9))=_!#5LBH2[!\,T(6$_:%7Q=>
MEPZ?SW>K(I!Y2>ZV6A*!AJ_%..V0F0@SSF&6H&PGLEA@%6J8*_RZN<GS-MF.
MQ<*[V[;!4O7&[$^N3GVZV<JJZTQNQ=H=9X:)P4#KZY!)L ,XQTSM!82?X5&:
MDG)7UV O3Y(YJ,.K,%"K[<F[+-;)O5=&#VO(C@;< *Q7.DL33N&STS#9D:!<
MGC9"^.(VM41V[O-3W">S3'"[DG.W2@AK)9Q2S&Q.'S;..H)M**DQ+F>0YAOS
M!3G -T&]$C1L5]0]2&&"_2J^G$IR.2><)8./^8=ZGV&(9/CB(&'Q7D>@Y_M&
MH)GUOJR<8XPC7;4&L-H@/3:.+^_D].HE&N\GAK,>K(PY\-AAM=Y?I7<77R==
M)Y6EQW"UX"*_7U5+Y@0[M(SOD6-\.CNIF[&^>?IHYJWN=&1H)3(-.IC+,W+6
MB!<GB%"0_T3E(EE\LY6DA@]UV%AL,MSM1O=QR]X=9KP19AB4<HUNYZ-<Z^T2
MIY;+?@[<6R.A_^IQ<R6QQ%_UU>9;[\K:)F,@Q!<Q76F0D.2\GESX=F>/11JY
M+%22CQ"TCITF#<":_4KW#T,(;Q8YE/);ER#+_BL7_<_"//U^?X>H$<1[I;CS
MNNOV0.^&YZ=4WP:_1D>4!EF5M#C<NHX8VJ$>#&&V\0PXT.\VF@VZIUSKY+%H
MMAMK,C!46H+^L8;#).5GF7<<?'XU[>JEI"B66:G*A:8!QXX=S/Z-]OKP/O1N
M7'E5+!L"QT^O,S_RH'2@Z7U^_NA<V@SN.E!"@FZO__50R.#X:+<=E.RZ@7;P
MM7S]X&O9R=?R]8.OY5_3UW)0K;K<L^@'HR/0V=MPJ6H/RG;,B[W\EONS9<-U
M5C,W(6%]R'2O"0A(WH$&++>QK0FL@G6$P9_;7/EOJ' =Q0#+B=- -UE"HPID
MWRX+QZ5VDL<'6SL^0&=W.4;OOA54"RQH=:I=7U^^9X\U[[8<]T+40?8YQ/J@
MN;6TFEP9!DC(,,5KC&*,[-:!O\:2%AA04>$ESQ'#X(EIXC-ZD=>!(Y#>-S%6
M*)-7X@SC5U]PWX97$?ZCZ(K41;V-\DFJHNI*QT=#RE*Z5EN*XUZ]ZI*^BGP'
MC5%\QTC&P?%9Q#I9+-?'$?@D'\_? S.P/X%/$O'WI*YL^LHD>M0N3A71'W=W
MG\%X<RNCBI@J\Y$2O2&FCG0A_<#/TR1G)@0:*$Q*E95]N\9])+EW7761<1W#
MB ^GM+DGC$89ZGLR\J+QJ#@&912GI&[&YXSF@V0M$JST1Q_9$R:E%FIVHMN8
M9$S8(,TJQX-KC)PA;EJ(D0 ?&@A=CJK)*M5H)8EV"6*>)TXR'\Y5M;'6F2@4
M]Y@097'8_ QT,="13H<H^P22DQC:MB2FK\/S]SM7GO6>;OG _,[Q$ WPZ24>
M@.: ;_0G>][1/90INU#@LV/2'X= %8IL/C,1$1U(J$$FND*@Y1\U./<5"F\$
M<VK%S\(!UBUU,6$;6LS")]4)ASI:^6&/5C%BRJ"D:+CWVH?[YYZ[]&-6H,.G
MMYE!L2=9BS@Y8:,JE:';4/O2&88<AIEQX"EKB[(8VJLDN-O2P->W%>8L:UQ)
M=GF6IXH!IUNCSHZ/IG6VQ+0MO-%P&T_Q7@ZQ:'1KX@50+.?^8@S0:18>XMP3
M.LV&6H4@8(50+2J.C9U**P6P&?R620IPX4I#RD;('(/2PE*^G&:%N!-29$XC
MY(H%Q&G8[]1Q?Q#.,@3'$9+=HN.\+.O.<H@%8F'%C &+"OYW%;(1[,1H_<V#
M=V4G[\HW#]Z5?TWORF'5LGJO"\]&5=S-DOIKQ7 0JTL\U%+BFZRLZJXNHM[M
M;961DXV(O]Q7!',D)_T82Q^1/&7@)%5VJ#%H3;Q.+/PI& 3WEZNLA!E@,R9J
MUHM8H1)D#3)9"GWNS>.0<:EC+^-!9=("#2MPP,BAF3UQ4]<(/R'K,D#SK+/L
MAT,^KDE)*$RI$Z+7"KBE;,3$O,M([1[R 'AE!*^TM1X \OQ[$YTL:VM84\!B
MR+;NA!")4BJBP-:8K9)_;3*I=S&AMXNX#)G9/:'+O@%5-?.,N33?_E@+OX>,
M]E0[,\5)O2$"6B$:(OSQ',DH8DM:D$BI-\S1)@]SOZ$C7E,( Z7KQE_58O[G
MNK1N9[-4@*W0,@B*?6I#SB\D2=#<HNY6&'A]ET-8=G+CMW(C2\)1I1F<R,E*
M2N:.''1MPH[?H4CXO3: FKWN@^.CV%"/",%!%#OJZ0#90PDFFW,5G_,SLM!1
MBF$_J*4+8.MC2(\[-\"8'N^F82IT84]=1W[NN<\EW]]5Q.8GB;D+T_"]H42Y
MM)R;DFH:.UIBU3B;4:ZAR[CC-&X.4BQ0/BT(7=HQ;[QE@&>!H"2)4+-Q 6P'
MUS(@K2VG9QW;GI,]=-*D%U8FDX^=#WPZ[%T/98$)@COY@YWH=XSK$VL"YE8,
M?YP01SE[SN?"H)L&37[F8.XH)^%E%6A0E.T2Y19;QX,@G#INA_/D]QN_U^A-
M&#,:?I.$OGCEM3QXQ\?#[:71=B=BAVB_&ZJ'N6O/;_V.(WCC+I81T3N9?DXK
M$% 2<U_=LFW\8_;C:/3K!]U;X. 3C-KP8W%B9'\0,RA[-1C%'"#/<MA$*R2K
M!2O4=S([KH.L%(-,(C*3J2+,3!E>YW9T#8\Q*;:52-<L*SFHYD(O)!)PFE(O
M@#:*YS4 +R=^-(R$]-&H+;&+BE U-6JH];C@/4M_,G\)_3W%O#5ARL%=P;G>
M\@3Y=MCB8:U]P4N J%Z1HY@%3*%E['A<4T='P-_^LC#7W:E,V R!,RWTAX9,
M=14EKJV478C T7GBM^$>D-MVDK/%DD\"PG#X*7-.:LY?7T_X!KWFH\.-=W[3
M<)&T\(CP&7!U_*AJWJUW:#ZKLIHT[!<4R:GJ;NU5%G=3YTG'#("6L*!S(GAQ
M\J^WK3#@*RS,^!'-DU0MC=Z)15Q]KEW?C1RZQ?P9"F"@N*=A#UJZE\'YE;DS
MLIG^AG&@[NT63!_UQ ONA#>]@$B70@OKL*&:J*#HJ(NRT(Z%!-\I^W2$_K4)
M.2!E>SJ.9S@?=[@$_*UCD=>B40NF.9E51&VCWU9>NBT0_$IDOC&G+-F.[(*]
MC;8M'T)STPX1&RA>EX_D+& P(4Y:9;$2$I0MZVZ[M=]2N.[B(KV\>/"1[N0C
MO;QX<)(^.$GW-XK;O8SBJ\;%PP9+<C!-'$*'#;.Y?@EWTVPF*4G+G+-IZ*?T
MR_=YOD@R+&C/FG5+TJREN2*<&:D^L9D1J$W"90F=--JF F80Q8L55PJ4;N5R
M/F(,A;<  SW&,2$M:^2<)/T'<Z =I94.2M6Y6+4F'1$'0AX^ITTA_9+1/%5O
MO]]%8);[.=?!AF>-Q$%A5%?M>"$:^EX $>JB,IF<Y+UB5@1V706M*?<L7?;R
M2H5#.OZG@?N._0189H-3Y/UO.IWN>PW9:4HQB8L,UM$-Z$BUG /"[8&Z<G+Y
M]<4IG)\5,H6T>1THK*&=JME"HO9Q,^QI1B.*JP?U,89QG3M?OK[CS9"<&!R_
MD($FKUYIU3^J@.AK'&J>C)!548IG<A.QNF"1K!:69P;O/%LNNDE+I+ID;9OA
M^R1;.+3^&S#_.!WK2GNB)'&OL=7?%O[7:D!\YE-S<KM_IAR[6,D*Z@-J^:!Y
MDV")9HF/[^'(<=G8%LT7 QTV-$>&AG"Y"+P2+!ECB$DIN=EJ>Z<YAL P1+,I
M'V*;'&''FA(4A@B '&H2F GFI3"UU3@&Y<-RHY@ 1&!:8H6;)T?BOD.Y_GFV
MYMU^5SV2%GJ64$=0J_"O#="H. :)EHE>V=O&6&5+?A002;_I^A^[M*YA5S_7
M>FVX@#\<(KK=#Q(?..+.1I94N##]WU(=#9^QHO&.<7D2^Z"G1"]X;72[1#D;
MF(G*'24!WP^%8E$<E:WO?;NL1[R[9-VE#(^4P;%X7W(AH&:Y))K36JNW4"YK
MY2)H']MKD#:VVZ'845&/V?B2*3G*VSL\<9NBIQ2F\>/H* S2;Z3EG!HY[85W
MNA4]1J+,SF4E!$$,!:6,#TX%$>;F[ON%MXF(QI!85:/HM!3*?!P>RGNL'*_V
M5HXM-4*0NJ!KCD<53)/KCJ9G%MI-+VUT\12FD3]0XD139 Y6A(?^T3C>.2YU
MH_JE;XZ<6KZ]Q-,?#B?P2[9TF#N_/C-):.0_TN]TGX+0_SA<,4*U@NA^Y<1M
M.D<%?S1<99H6G/<6+  SVDE0@ 78G&(<_21?I*F/LV63!Z 7\S3VRZ-J)MLU
MF[ ?4A[B:QU,8D1[>E9%6*ABX7 8ZGS68(2<!&^PQV&02*%%$O]LC'!2Q3*Q
M/D"C$LV@%RZUDV/S\L&QN9MC\_+!L?G@V-Q?T&;9/ZGL*SE'EBXVCHJ,P#$H
M_XJ!&0[) J+Y@]<L*:O.8SJ3J*(PREHB>:SF.3^8.N\FLHGH9QA$P@N87 '\
M$0HPN1PE-4"_P3C9]4H@_0C99ZR-?,MJ,0=;.:+95&,.#AH@O?8%UJ>:X_"Y
M"/Q_7KU+0T?9-)=>N)2#_)9^JH\P!)(KSLP7P@^,<,F6E0],.20N9YA4)$5&
M'LH<XY)L2(!6S,4$L78SAJQKCZG4Y$F31L!>I%.+=!OE-+LN02E;L?N*6$/0
MOU [CY>X\I:+1"H'A$5=N@C@DTK0C1E-&9681F?SF&H-[DI808X'-F1@Z:D*
MUS2C.*U0_>_D J+!2[U%],Z G,5M8/A6322:;*-MBT"<=M&&T,\9EN]-/J[
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MC'0E'J))7PE0H=.J.*6)[VH:]D*CLX5_.2D#9:5Q>I7EZ$%93S+D8*7,+RR
M4R7M*$CN9F,.MHBC*HTZKUDG(1]2=V]LJG;J8W-/+AZY?0#O0GIH'JK\H($;
M\1%]\,W%E_:7GL5<*![OH?/Q_?O#XIJZH0[B=T)KS-?^$^8 M&/ FJ*8K[N?
MT06$U)A*S"DA=*X?5S6-'L.B>2_%G N!(V1S#L!D_%)&$U$=&&&%,[1>I74B
MD4]*5%>FB:.$3')8XJ>21R>UC$4_42ZT(#;QL>K9=R3CB!FT4.H>B8-P@*C
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MTD3#US'.!W2[FY-6>WCLG.(1<P9W ">HT$MJ52O_#O*4HT"E8_2L:E]IT25
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M?C YFU75>P7+,S*?\*+Y.&LH90K&C4H_&G(MUOQUIE^N2'JVE3[@^QWQ<+4
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M/"%OL1!([WY#4D8Q&R8"F#:FH34!V;DRYNI<^D(.A!X?C>&7*Z$\YTM<OI>
M.)H/%4?Y<<18$Y[M72HG[]BX*7=*U7763&"H;0V+F_*_YU59@68@WFR: *K;
M/LT*PC:S$Y%K7?)-[*JI>8\WWL2-^ #$%HS39+>\%:'7>8.,1P1RYN)3KKP+
M#]; 3<2#A1XNJC-*]+K>]*@XPTF+QS.,0.N.T0QED]NB8?8F ZAE?=^/Z?CH
M!.Q)V@7<I#<8<>N1X3T6WP:B_4[[+0BW0,K^ZQ>(TP#MCV'^9U+9BZRUG$+A
MFP>9[F^11&%K7H0=+)(MK,D'\V17F5JX$@('DZEI+,>NE)NW\5\I+X\KP%"T
MQ@<GV2+DU1RJX( G@@G8:4>P"YKH0<5 <1@:_(*,%*6<D ?02[1<!;]5 KT0
MHFBV_CACMPG5<F(+>2#38Y03W/BZ]E4RF)!+GXN34:1B+9'CND$8-9L\VY)R
MXPK/1NQPQ%#!TE6KSSK:)%D1DC&&@#]R-]>>0J,V9>D^Q<GZS(?HT#1PCY%>
M9(^C]/UO/SP/2DG&.1&".$M^\7F[W__MMQ\X9=@F\_9E66D<)O1QH5L_OV6W
M&<,?6V9VYD;E3J3BV1O:-[E-\6&@MWCB9HM$<G&)XZ.^@IK??N8R.MEILE\^
MGK]  P*>7C^F0<YZ-@=.M/%0+&?:B^R(R'RZ',ZF!4D<D&C+,#%;#X9*V2">
M.,ZQCJ\T\#5$J#EZ5Z?F>$SCG#QY_-@P?[VAJ@CQ!'Q,[SG1 9H[6,F-W4C
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M$14W&<AGJB:#%YF].W%->3!!NOE/OF,2HA(7HUIL;\@/G%LV*6F KK*8(TF
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M6V\.!=SJ)DG<'FG6;9+.?MY]EVP6@.?)#K5$'UT\N')W<N4^NGAPY3ZX<@\
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MF?2D:-(E0F@_,58^*DVSDZ6)]RF&(3V((>@(S4-XK?%M9N8,[71F8W?V5V2
MBA(C:IN]]YVY$!K-SO;ML>@HT.IHU8Q]BG=K+O<@DM%>U]GB1O*UQ!"UA%YI
MF"$:7MV:@\I)VYPC+O>JLSLJ4[^;$72^-?N\0'2$M51K0'X*I]7A1<CMGA(D
M%"#>:1#J+)ORSCFTK,>XU&.-3(VW^:Q:<$97S_'&K0*SOJ%YX;BLRNFL0+X
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M%;*MB/#>@__6@;5)>GEXKA;SQ(<<[DNN4/60\+:TA*SN0X^!LK6YK)G.P]2
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M#3V!=1N4,:$L?-4I@&=6;>@6*(1K+B,E#H08[!@H!P3RQM339:;&X0T'>,@
MO:;*4JE7H;2K?I9Q4,X*AN+#"2TWTSOW;/#O<H-F*\X")3!P:JY\V?''L5!K
M_<FV'$<ZDP=]6#=^R!9@C-P7ILI0*IX[KADF%:Z7<LK05#)[;I-2__:&G#0>
M)G$G-(Q8C(!,P11E%F;-X43UN](Q8B!BJOS,T\/Y"-BNL7S81B%?L^-AW4DE
ML[@!MU=NP/G<@-LK-^#2N0%K]/75:;[]#$%;YPK$BV:)9UVPCCI#U95J#P+X
MRX(T4YZ$B1A4&+/ 9R$2[>D" =*DTLH**=P.1F0@YTEU4[JL89V*\>U+TBNY
M78"7.)-CQVML36[1OBI/-#C8ZN9>9YHF7?BA[V. 3<>@MZG/MU-\*K2_B7GE
M2_#S5H#'_"P,BX]"-3I:2:FJ'S=*/85_0@U*P1WX2+O$EPR:L.1N8 L:[B N
MAG/'0J6>+HJ$_E1Q!\&'B[/6T7L=;X04!KEG?#74.].CZ[G-%QQ^CG&7R$<7
M[Q=Q1%_4^!X]L?7^[2X:6AB0#[I/Y4*9Z6A^QRI3*\4T%_6O=F27KLH0\1S+
M4L/02D.SS\%00E>\+J-"[&4NDU4[#5,YW%7H2O/=3\B(1""L,.WTI80(UBFD
M0'4O3*2.T 5&7?\.7(R#07P#_2K D_8=Y5:Y,'!F.GX7!F>XJV(%6(D[D,\"
M#]@3L0V)Z30)#ZV2]V@$55M0R\/%::A/NN.$0/DHMZ!T[O3UDD%@AFAQXZJO
MI;$=L$=H\139ZWRN9L;*01V(K5K-L&));"*DDL05K-5* 48,'W=ZVZG:@,+>
M4&\4=92S/)U4#MG. J !0+8YA"&'(*5QB?!BO.GFD$=NVF5X>P"G4DC&EKTH
MPJH .,"M)Z0%W56Z>.A5NL\0E]G1@SY=#O%P; *]LPKH3B44Y8K>RO/B-9 3
MT\GB-U5R" *0QP-U:S#N*&Q%3#!.2BBUV(V++F$JML_\6Q *44%Y6#J9ICH=
MS"E/)07%)9MRC\'J13ZVLF8I.FP1DV"B -WZ\5 :(>&0JBEDHX/@.C2%JL[K
M74'^9WWRA9 J4@$SCO5XA.AI^5+H C1%_.FXW0TI;$9L@E#7XM_BB=0,4AQ8
MU!@"8:38%^QU(1PPPO%*#6B='+PTS@0CHB-0KUX"3A)&P38;%9(M*?]E^6(0
M$)M@] 5[.+@1X!22][:K7L=\!E$_<9$-A$]U0AA^O&K#Z")X<Z60;!U0-4S)
M5]$GM/^(H2!("PAD=K2+*H5<>#82,7(RD/O.4WI"38-@Z1'8T^5#5O79@#"+
M-G*1(_-IM8-Z.CU2W^JY=@\/]-''\Z\8L4?8,2EP?+0=1>Q61]5['/0R>/)'
M5RWQ379(QQL_^!DMC[1U 3&'G(BG>"9V5IZ)^3P3.RO/Q-)Y)AXWJ4%!XQ':
M(WL>3>XJWN)! N_>U,O1LQB6H4A;49Z%\PSHBT[:(OY6'6XB?D9R#Z219IX/
MJ-G7[+G81(A!J<?(%:DO!?H,F4AT4%MHDE?8_Y<QH> ES"D,(!&<'D4IPVHM
M? 2N'1>3,.<Z$*RM(%#CCU(Y1/63LZ/G.2LP@J^J^6M MI#&CI(9G=WYFL/#
M(@_?E].?7_?.<B?Y3>ZX57U\]C7GAG<>J=W7;TOTPR/+K'PB!Z>P(;[\US^V
M_W'/24W;Z']!/ID\CG(;WT%!G*>WZC)/?):.7L@"GIQ^^G&\]U6<''XZ.M@[
M]L31EX/6LUC$&B:?JX)>T&R-8=2%)Y"Q=NPAU:*02GN8+)+]N]^*4GGX2$I-
MYBUC,C^DVGOUIU/[_K2']KX'M=;&)F]Q?.4LAXI[!M+Z#B&S,G%)@?&;9]$/
MFD4 9!RH=-3?GC<LQ[0>3\_.#K_\<7AT<OA59;&>MEPCH-[,D5]+?/\S_9]?
M>__L$<48E_X01*>IX FS-!CT%CD>RNUW"IRN=;8PCW*1XW$"1YJVXUNG'P!%
MBC@"MW04W ;=10Z*G"NK$PX]EKFU9W%A:Z]TLX&NO<S"S((3H5UJ]_!3OU[Y
MJ>?S4[]>^:F7T4]=$36:=KR^'?QQ^.G'\6&S<53M^;1%FA?Y?3UWM!B5#M,I
MGD^Y/>[W0G!WQ-OW_]0O=]1/LT_##<;-J4NS;N60MI9O2-M/-B+Y1^)NA >L
M>=5#<Q%3^_ #G\)0+#Y1XH\\QKHO[WG%\ 6#6Q"(5E+81V_ 9!4%0%:4?C#'
MMWY2E3T4CLSQ+;E.DUT^^X$X4\E,TYQ#/VQ39+;U1KUF+W:9S)_R_-6MB)=$
MT[WH83R;5:Y!?<TL)JODF*8STS]N<;)C4:F/+'06QP!$2H71A2)K,Z3CXX.G
M'RJ4J>W+IT0?:%5,.;,[MF4Z-DLRC&=S>I^G>)=D&+_&*G^/,\LEN#S279)A
M_!J+O+3B79)AK%;Y)0QCM<HO81AJE5]E4)CPT.B\">Q,"5J\>7&ABIE\ZZL(
MPZ-%&!X26Q!'A=C"KQ^W/(X[5QOC$5?4Q$  ^-1#6GS&PID_'HA/X1D@5RVR
MW\/!((C$*:/P',11%"?BK[C6%9BZ 4)_*/;'2;307G^&@P%T_&=+? [:[7B1
M?9_$R:4?B0/9=>)'5XOL^L!/AG+%_XH'5WZ2+;+G/WUH9Q] 09.%]GNX+^V"
M)(L01?2X=;903JL3/^KT@Q3*3 ]O1P-YOR9/.@CYHT\T!P5GYJ)LLMV53;:R
MR9Z335:K4;8<]LA]1G&4IF.I03X#W,5/2BAK-@S+S$LTV\Z_Q%%P\21:].U*
MBZZTZ#/2HG^]O)?M=V!SB"XWLGZP\=,G0JT#!\3\J4?X!!KS^ZDX.#TY?"2E
M.5%EOENIS)7*?"+ 3K[1ZSO@R#MQ'ZB;P]M^V ZS9F/OU],^]QG%^><X&4(Q
M#CHB?XPLX)&GL>S>K]342DTMO"I"2-51NX;9V'IL-)SR].KI8ZQ?]]0YN@_[
MI)80B>PG(/DF6D.-1Q? /,%)VOSGQW.;^>4XR&2W_<#OTD>?;);UXKT5"[)G
MU/"=.!G%Q,=R01([&[<'84><]GJR&\+J!\L<^5JDD&N6V/9K^?F=UMN9CMC&
M9FM[AD-VWFQ<>&)[\US4>DNQF*<[/@#U"BH-]IBW(>Z19$\)!1$P%#\Q.Q?]
MQ5>XX?!!Q#OZ*<;]*? 3<9*T7IVD+8&3N*BUEOXQ<- &>)H!;+,=@/0,F546
M \ 1U.YVXBAB$@J-;1:KS=V^$^<'UA$0:Q8E"N</:\H8>1+DEB)2]!2YZ3MT
M,%(X&)[XC\W6YN86H+B+:R@'S3>FSY#=8AD9&W#*8.#78(MU$=E;=@\;>WL+
MFVXVN&T5)];6F6$](;!U0AZM$ A!*;-$: R #86@I0 V3U3CYS>T,\5Y$B!:
MVD6SX0P*_Y,'8W?DY>@11SB&JTV-?*FAPYV\?C==7U$0&;YR$IPE-\-A)$4.
MPLJ2D,F,<L2;@;K6^-KRD+\^CH 8P!*T9DLV8O0L2ABS/N>P8 PFO., A*<$
MH=MEYB$Z5Q>_BP\_/BIN:*A%\N 7_?@&ZO+I_P$I#_APY!8J[A XF)J*!4!\
MHQP$=!2/HPZ<0V2G&DJI(LAL24MM B$&I #\C8;Z]>4R_V\LUR$*;E+#4Y8)
M^)C<@S>Q6-M>STV6*0JTC"*&G*Z8!_#?R*FPMD&<7.@(Z= B9/,I$E;WILYI
MF=&H#Y&PJ=F0$V2Z2KGG: I=,P7Y(VUWKV2S,K[D%++7%5;B"BMQBLR>"FWN
M;P!(%-<:,7&%E?C,%K 4*ZG96"$F+DK+K1 31RO$Q%\4,=$^NS4?VN4#/'S$
MR2X$KW!.T[C^-^<C];!9[&"Z;=_I_ 9.#WRG(.1YYG?JC>?@OZ];!9_> T@H
M<J.;$"1ZO;D*$JV"1(L/$I7L]SK"1-O/.SGHT4(_X&P0/T;L,'_UE=U"RO]R
MALXB_FWMH9X91JI$N?".E6IW0F$?SS_YV2\DA]+;?-IH%"V\EI!R-B.H)[@B
M,7#0!;(Z( "QXX:NEY?\7>=((-V.XZN-9!Q%\AUR(4<(102))F!7(02F\@8"
M*B!NI1A;Z@\"C".X;G(WJA"FY'C#YMGSAC_[.DQ@^9"G>.#+QD3=-1O8G^A+
MW8AA$? :^Y$X9^ZN5UT.65WDVB%R\!*7+?I),P"/8189.3H[5J""'0G1ELH!
MT# 5I0V2HR'5ML5%!A[J%1#JC&</O=:NVQQY[C.D_(&(#W'^\3YDS%T50U![
MV&60)%):0X?K\/#=@#O8"B@)[#_&RRSHTI(3F;KNI=F ]8Z(SA2_1&Q_N/RE
M(_#;R$68!)>AW/:^XF.74PIN@^'($ (ZGU!$B;G6F@T3-#$TMCL[#HVM*%%?
M4XS0K941NC)"GQR_]>$&Z'[]QF!-&O<1TBJMMNMR;Z@,2H:2-"'Z@CI9J0I]
M2,#ULW_ZZ6]$Q?CC^\GQQ_\'4$L#!!0    ( *A;3E3J]Z>6D&    H= @ )
M    97@T7S$N:'1M[7UY;]OHM??_ O0=^ YZ"PN0/7:663+M +*M3'P;V[FV
M,]/!17%!B93%"46J)&5'_?3OV9Z5I"3;2N*T+M VEB@^VWG.?G[G+V^N3M\&
MEU>_OQW^]9M)GE6O@H/]>15<);.X#,[BV^ BGX59GS_H!Y=QD4R^^;G;^<N;
MX>#X/C\,\#]_N3JY>CN\^\__\BW]$,?_%B> _S@\/_[]/A.!G[Z[Z^]^"F9A
M<9UDKX+]GX(J_ECMAFER#7\6R?6TPOF]XS?_O]W=X'42I]&KX&*1QKOOPNLX
MV-W]^2_')[^J0?E5NU4^AZ&?S2OU\MU17E7Y[%7P'#^[3:)JBG/;_Z]OG)_C
MG'?+Y%\Q?(D/CO(BB@M^W6$:CC\$+V Y99XFD?Y2O9F_/U#??_/SG[-1.?_I
M+]_"^W^6_[66\*VS!ES@)]J^U^=G5\[Z)N$L29>OUKW6W@N8!;SI\.?AW]^<
M')Y<=3LO]@[^\NTA+ O?;HYH>[,?QUD5%UN>OCJ1VL0?-GFFC_T&:J///OFR
M7I]?G'8[YZ^#WP87%X.SJZ_P9$[/C]^_'5QT.Z?#XY.CP=M^<')VM/>E%F)/
M3M',5[6=0@C=SM5Y\.[]Q=&;P>4P.#H_/3T_@R'.C_[V>796[=TV+AD,LNZH
M?@N+(LRJX"S?>Q7\G_6?;:YTW23.%K-17 3Y)+B<A@6\$OYUE,]F>19<5OGX
MPY>;V7%8Q3B;D[)<A-D8/O]?F,$_^L&S_6?/@IT_I]$_%_E/]Z1#(COUYFX'
MQ[)H[,\%O;NWS>7ZK/6/15DEDZ5\F&113*_<>YEDG_^.;S:Y_4TF=YI'BS0L
M@#7&43(.4V"-V7BO'X3!.)_-PVP9Y,5UF,$OHF !+RZ":AH':7A+I'<6WX11
M&.S@9ULXX2,>LN%H^]W.-"[BT1)N?P%K3>!-U32L^L"@BN ZSZ,@S*+@)DP7
MX2B-8?)9F<!LPRK)822<7Q&/XP0V&9\K%Y-),D[B;+S$9=Q.D_$T@/L4R""@
M:V7Y;1I'UW'4=ZX43(1?=IV4P(5@5Z9YBMN"OX17P6R2J@SF<3%+J@J^#LL2
MSJC<VAZ]H>&:MR@I SCYI$IQUN5B]$<\KH(JI^7#9&=E4,85[E@U#49QFM_V
M\=OYHAA/PS(.)D4^HV?E'( **OI[^#$NQ@D\\:Y(QG&P$Y9!%$^2#)9'K^GA
M4UF09$$\F<"8,)40-WH95#!]W).*U@5<"OX=3F NS!VVMBLG65(E8:IF&HZ2
M-*F6K9RB'XP659#EE4SFX.#5RQ^#^=X,*!^'^3TO/M"<^SAGWH)YPM04X#O[
M#9O@$DJP8__5ZW8FBS1=!O,PB6#@;!?H(BY+(M:RD94WCF =:ACAM9_!@0.-
M!?,BOP&"CX@.X2"VM;$B];H=EC<->[D'>S..YS2+'$8M;I%2U,1Y.OU@',Z3
M"M@5\A$FQ00W%BA6R558TCM%B>X^)-DX741)=@UD!30E/RC;?Y& I(!QD!X_
MPM?9-9Q7!;\I)R@["[B]<S"G8MH[OK=]GLOV-JSY@L))IVDP#6]B(JI9#)PU
MN[:O)<SY$@X8Z>S@^[W@RMXA_G7"I ZT-(K52I&GS<(DJT+:](1I%MXX0ZH*
MX?WC10$7 E:;1L G,C O\P^[L/YBR8_A&_ WQ_$\+Y,JA\^O"J OQ0L48\OR
M&0P1;T6@'U\=-6R3VB5GG3@U,'R;&"\LT*8C]XX$AW$6(ZL'WG!^F\7%GXL2
M1RG9@,5GXE0>)@$!)Q,&FNAAHT3>C$-DYK15P"]1$?$X*TTCUF<UN";A,K@N
M8J*S/AX*RYDQTBM-N41-%C0:.5GB1_-YNL1SUUP8B3ZJO;N"\U["+8OEZ(I8
M>+6U06]:-B@O8#;N=.%K)(V@3ADL/,TV@BF(^]C'ZX[?A",XEP7J?OBQ$H,H
ME?%;V"N@)U(,D8AB)4B,M,2/(YAQD0!+1K*77>7)]VEU^#;<(&(OZITE2IE1
M2?QO7"U"VC\43_("4 '@SA=+[Q(E*(9B[[A6\)(M,](F#HJ"FZZQ35D[28\T
M'") N-;!>]2^;N$6 \>PZ2H*6<W )3DJ]Y8F?KD8E>,"-"<XG%:!&J#2E*&<
MJF[C.+.U"/K\?#Z/LVD,[RZ"/X>S^4_P[9Y2-4MDR"!<8#D@86_TX93Q#6AP
M*>N=N/*X  84SN*(E# 6+#L);90>3E_P"[H((K,OX<W,[^&/UWB++W</@IW7
M";"4C&VJY\^?[S[[;O^['Y[UMK9W]AQ A*I)-&T@[A*LI64Q(-[+.?"I1=EV
MWGN.@6'[ M$+^!-,ZI^+F.RR W8)DE?W+L[-[RR?I>N6?&;<DG^Y&AR^'09'
MP[=OWPV.CT_.?OGK-_O?T-^7[P9'ZF\9TW*5LJMA0Z?RU07\5SNSZ\X!SPFK
M++"K8_1'7^#_X"S%;UK?BCGLV.X(6.J'W5$,S <V+4QOPV7I^N2^:]@DW+FO
M>1=L'_(G=!\_P&(]V(.9W/M.OO]Y^/?AQ=')Y3"P79KOU7W<^W1^JQ87PI=P
M(&QI8CMA[V%G<1JC>IZ,B9DI*],^C>"RR8I%7@GB/4J0KY:B3'0[QE#H ^57
MTQQLO#0!.]SR IB_V[3NG4FOUW=-$U2U0 E5VDN$TL[H*(%KZX)LJAF[^'"S
MB2K6)"F'J-^BFIV!E5B 9!^A@I>"0 15;.=V&I/V<Y.$P20<E[".%'Y(VFN1
MPQZB 9#B[[41!H=#VC^*3M S13_J.^9!6%7A>"J&&FK,9?"@R_5QFHP24%&M
M0X2#V9(XU7Z(,UI)HV$ON@,?C9:?M$TDA%'C5Z^Q#WDO^ U(!K8&M<.=@QZ8
M/R&2$AP0*L(IV-_X%[Y;'XJ,Y4VK;],&:_:S\ /HPN&2-) J9Q^2MJQ0-P["
M6;Z +T%* XT(M7M^%^U?44Z)2'RNY0+,"KVJV2*MDGF:&#K-M-=8431;\Z!
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MEJ RXL\A#@N0V\0(=L034,:HZ08[S^XM<K-(A*J[+G$X]%@9,1S(N388!"Q
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M*O@Q:,7__?X,5-M?40J_/1F^]F$-"?88K +T<ZA(0SM.S&*VD.Y2@K+KM'1
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M\ X&-3M?5= PUQ097[<\Y?Q%#],N_&.7U%_JN$2K4.UH+<C4T0*TCXJX"W9
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M];#)!L-]KB>D6!5D\"(Z -WZ4%P[D@4%)W238T24\JST(&BKB=L&Q[.:6+!
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M #PO1VG5;/AGJ'34.YWDBFP;I2HJ==5*L^E;#)]5/D:N8ET/ZZ&4(# "@85
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M?R/0,S^5K>EMKMN2@@8R=&G3H4^G=YZ,0\'"(K# .9R7<$#J7]\0D0'9WGT
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M&24G#9E#8]VSGA3A Y'2Y0>Z"L$^D$)IH^2B07MHN!\4RXA:#5G2W($<:J'
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MDJC6F4%@>B?=&,I,BN"]W$,5E"U*QNDSA=$1N_G,VML-;'T,GBV'TLWNVT!
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M%KK!4B[IY+V91RN$@/?0)6F8SB-=%40&@5R@YI!1>V2QBBNY96CC ?->A8=
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M)2&HZR&# /!&T4$HC* 9.J8-Q++S'"/RHL_&(ARE?.[_&M8MB#\$@X"+IP9
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M     &5X,3!?,2YH=&U02P$"% ,4    " "H6TY4_S#'WL&5  #/-@, "0
M            @ %K1@  97@Q7S$N:'1M4$L! A0#%     @ J%M.5.KWIY:0
M8   "AT"  D              ( !4]P  &5X-%\Q+FAT;5!+ 0(4 Q0    (
M *A;3E1JY4_L^@T  &XP   *              "  0H] 0!E>#DY7S$N:'1M
M4$L! A0#%     @ J%M.5+27;]!$ P  "@P  !$              ( !+$L!
M &UO9&0M,C R,C R,#DN>'-D4$L! A0#%     @ J%M.5'X'8E/_"@  ;(<
M !4              ( !GTX! &UO9&0M,C R,C R,#E?;&%B+GAM;%!+ 0(4
M Q0    ( *A;3E2N_NLN60<  ,]8   5              "  =%9 0!M;V1D
M+3(P,C(P,C Y7W!R92YX;6Q02P$"% ,4    " "H6TY4'"Z-+;07  #<GP
M#@              @ %=80$ ;6]D=6QA<E\X:RYH=&U02P4&      @ " #?
) 0  /7D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
